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Summary 
The increase in antimicrobial resistance against standard antibiotics and established therapies 
is a major concern for global health. The development of new antibiotics with new mechanisms 
of action is crucial in providing effective means of therapy for infected patients in the future. 
Antimicrobial peptides serve as a rich and as yet unexhausted source of potential new 
antibiotics. The three-dimensional character of peptides and peptidomimetics allows them to 
exploit a larger surface area on a biological target than traditional small organic molecules, 
potentially resulting in a strong and specific binding. This makes them ideal inhibitors of 
biological function. A novel class of β-hairpin peptidomimetics with high antimicrobial activity 
against the opportunistic pathogen Pseudomonas aeruginosa was recently discovered. The 
cyclic β-hairpin molecule L27-11 contains a 12 amino acid loop sequence (TWLKKRRWKKAK) 
connected to a DPro-LPro template. It was proved, that L27-11 acts through a stereoselective 
interaction with the outer membrane protein LptD, a large β-barrel protein incorporated in the 
outer membrane of Gram-negative bacteria. LptD is part of the lipopolysaccharide (LPS) 
transport machinery, and is responsible for the final step in the transport of LPS from the inner 
membrane to the bacterial surface. Although important progress has been made in recent 
years in understanding the LPS transport and insertion process into the outer membrane, the 
binding site of L27-11 is still unknown. 
The aim of the project described in the first part of this thesis was to expand the structure-
activity relationship (SAR) profile of the closely related lead compound LB-01. N-methylation 
of backbone NH groups was chosen as a simple chemical modification to study the correlation 
between stable folded β-hairpins and antimicrobial activity. N-methylated analogues of LB-01 
were synthesized and tested for their activity by determining their minimal inhibitory 
concentration (MIC). In-depth structural analysis was performed by solution NMR. Not only the 
previously suggested folding of the β-hairpin proved to be crucial for high antimicrobial activity, 
but several outward-facing NH groups sensitive to N-methylation could also be identified. 
These non-hydrogen bonding positions on both sides of the hairpin, likely make direct contact 
with a β-rich sequence in LptD through antiparallel strand-strand interaction. Further, the LB-
01 scaffold was established as a non-toxic, cell penetrating peptide for delivery into 
mammalian cells. 
 
In the second part of this thesis, the mechanism of action of the antimicrobial peptide thanatin 
was studied in detail in E. coli. Thanatin was first isolated from the hemipteran insect Podisus 
maculiventris in 1996. The peptide consists of 21 amino acids (GSKKPVPIIYCNRRTG 
KCQRM) with a disulfide bond between the two cysteines, forming a β-hairpin fold with a 
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flexible N-terminal sequence. Thanatin exhibits antimicrobial activity against a wide range of 
Gram-positive and Gram-negative bacteria and fungi. However, the all D-enantiomer of 
thanatin showed a complete loss of activity in E. coli and other Gram-negative bacteria, 
suggesting a stereospecific target in those organisms. A series of assays was performed to 
study the effect of thanatin on the membrane integrity in E. coli. Sytox® Green uptake, β-
lactamase, and β-galactosidase release assays all ruled out a permeabilization of the cell 
membrane. Electron microscopy and confocal fluorescence microscopy was performed to 
learn more about changes in cell morphology as a direct effect of thanatin. Additionally, a 
fluorescence-labelled thanatin probe was used to study its localization inside the cell. The 
effect of thanatin on the macromolecular synthesis pathways of DNA, RNA, proteins, and the 
cell wall was studied by monitoring the incorporation of radioactive precursors. Only the 
incorporation of N-acetylglucosamine was upregulated, whereas the other pathways remained 
unaffected. A thanatin probe containing a biotin tag and a diazirine group suitable for 
photoaffinity labelling was used to identify potential interaction partners. Several crosslinked 
proteins could be identified by Western blotting of polyacrylamide gels in 1 and 2 dimensions 
and subsequent biotin detection. In a collaboration with the Wollscheid group at ETH Zurich, 
the crosslinking of LptD was confirmed by protein mass spectrometry, as well as the 
identification of LptA as a high-confidence interaction partner. These proteins play a crucial 
part in the LPS transport machinery, making it very likely that a perturbation of the LPS pathway 
is the cause of the antimicrobial activity of thanatin in Gram-negative bacteria. The periplasmic, 
LPS binding protein LptA was recombinantly expressed and binding affinity between the 
fluorescence-labelled thanatin analogue and LptA-His6 was studied by fluorescence 
polarization. A Kd value of 12 ± 3 nM for this interaction was calculated and a competition 
experiment with native thanatin and D-thanatin confirmed the specific interaction with LptA-
His6. A key point mutation (Q62L) in LptA was identified, rendering E. coli bacteria that contain 
this mutation completely resistant against thanatin. These studies provide an important 
advance in revealing the mechanism of action of thanatin and propose the LPS pathway as a 
new major drug target in E. coli and other Gram-negative species. 
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Zusammenfassung 
Die zunehmenden Resistenzen von Mikroorganismen gegenüber herkömmlichen Antibiotika 
und etablierten Therapien, stellen eine grosse Gefahr für die globale Gesundheit dar. Die 
Entwicklung von neuen Antibiotika mit neuen Wirkungsmechanismen ist entscheidend, um 
auch in Zukunft infizierte Patienten effektiv behandeln zu können. Eine bei weitem noch nicht 
erschöpfte Quelle an potentiellen Antibiotika stellt die Klasse der antimikrobiellen Peptide dar. 
Die dreidimensionale Struktur von Peptiden und Peptidmimetika würde es erlauben, mit einer 
grösseren Interaktionsfläche auf einer biologischen Zielstruktur zu interagieren, als es 
traditionelle kleine organische Verbindungen in der Lage sind. Solch eine starke und 
spezifische Bindung macht Peptide und Peptidmimetika zu idealen Inhibitoren biologischer 
Vorgänge. Eine neuartige Klasse von β-Haarnadel Peptidmimetika mit hoher antimikrobieller 
Aktivität gegenüber dem opportunistischen Krankheitserreger Pseudomonas aeruginosa 
wurde kürzlich entdeckt. Das zyklische β-Haarnadel Molekül L27-11 besteht aus einer 
Schlaufe von 12 Aminosäuren (TWLKKRRWKKAK), die dabei mit einem DPro-LPro Templat 
verknüpft wird. Es konnte nachgewiesen werden, dass L27-11 stereoselektiv mit LptD, einem 
Protein der äusseren Membran in Gram-negativen Bakterien, interagiert. LptD ist Teil der 
Lipopolysaccharid (LPS) Transport Maschinerie, welche LPS von der inneren Membran zur 
Oberfläche eines Bakteriums transportiert. Obwohl in den letzten Jahren enorme Fortschritte 
im Verständnis des LPS Transports und des Einfügungsprozesses in die äussere Membran 
gemacht wurden, ist die Bindungsstelle von L27-11 an LptD weiterhin unbekannt. Das Ziel der 
Arbeit, welche im ersten Teil beschrieben wird, war es die Struktur-Wirkungsbeziehung (SAR) 
der mit L27-11 eng verwandten Leitstruktur LB-01 zu erweitern. Die N-Methylierung von NH 
Gruppen am Rückgrat des Peptids wurde als einfache chemische Modifizierung gewählt, um 
die Beziehung zwischen stabil gefalteten β-Haarnadel Strukturen und antimikrobieller Aktivität 
zu studieren. N-Methylierte Analoga von LB-01 wurden synthetisiert und mittels Bestimmung 
ihrer minimalen Hemm-Konzentration (MIC) auf ihre antimikrobielle Aktivität getestet. Die 
strukturelle, dreidimensionale Analyse wurde eingehend durch Kernspinresonanz (NMR) 
durchgeführt. Es zeigte sich dabei, dass nicht nur, wie bereits früher angenommen wurde, die 
stabil gefaltete β-Haarnadel Struktur für die antimikrobielle Aktivität entscheidend ist sondern 
auch mehrere nach aussen zeigende NH Gruppen, welche empfindlich auf N-Methylierung 
reagieren. Diese nicht-bindenden Wasserstoffbrücken Positionen auf beiden Seiten der β-
Haarnadel interagieren vermutlich direkt durch antiparallele Strang-Strang Interaktion mit einer 
β-reichen Sequenz in LptD. Weiter wurde das LB-01 Gerüst als nicht-toxisches, 
zellpenetrierendes Peptid etabliert, für den potentiellen, gezielten Wirkstofftransport in 
Säugerzellen. 
Zusammenfassung 
4 
Im zweiten Teil dieser Arbeit wurde der Wirkungsmechanismus des antimikrobiellen Peptids 
Thanatin in E. coli grundlegend untersucht. Thanatin wurde 1996 erstmals aus dem Insekt 
Podisus maculiventris der Ordnung Hemiptera isoliert. Es handelt sich dabei um ein Peptid 
bestehend aus 21 Aminosäuren (GSKKPVPIIYCNRRTGKCQRM) mit einer Disulfidbrücke 
zwischen den beiden Cysteinen, welche eine β-Haarnadel mit einer flexiblen N-terminalen 
Sequenz formt. Thanatin zeigte antimikrobielle Aktivität gegenüber einer Reihe von Gram-
positiven und Gram-negativen Bakterien, sowie auch gegenüber von Pilzen. Das D-
Enantiomer von Thanatin jedoch zeigte nur in E. coli sowie anderen Gram-negativen Bakterien 
einen kompletten Wirkungsverlust, was auf eine stereospezifische Zielstruktur hindeutete. Es 
wurden mehrere Messungen durchgeführt um die Wirkung von Thanatin auf die 
Membranintegrität von E. coli zu untersuchen. Die Sytox® Grün Aufnahme, sowie β-Laktamase 
und β-Galaktosidase Freigabe-Untersuchungen schlossen alle eine generelle 
Permeabilisierung der Zellmembran aus. Untersuchungen mittels Elektronenmikroskopie und 
konfokaler Fluoreszenzmikroskopie wurden durchgeführt, um mehr über morphologische 
Veränderungen als direkte Auswirkung von Thanatin zu erfahren. Zusätzlich wurde ein 
fluoreszenzmarkiertes Analoga synthetisiert um dessen Ansammlung innerhalb der Zelle zu 
studieren. Der Effekt von Thanatin auf die makromolekularen Synthesewege von DNS, RNS, 
Proteinen und der Zellwand wurde mittels Einlagerung von radioaktiven Vorläufern untersucht. 
Nur die Einlagerung von N-Acetylglucosamin in die Zellwand war erhöht, wobei die anderen 
Synthesewege sich unverändert zeigten. Eine Thanatin Probe, welche eine Biotin Markierung 
und eine funktionelle Diazirin Gruppe enthält, wurde zur Nutzung der Photoaffinitäts-
markierung synthetisiert, um damit potentielle Interaktionspartner zu identifizieren. Dabei 
wurden mittels Westernblot von 1- und 2-dimensionalen Polyacrylamid-Gelen und 
anschliessender Biotin Detektion, mehrere quervernetzte Proteine identifiziert. Durch eine 
Kollaboration mit der Wollscheid Gruppe an der ETH Zürich wurde die Quervernetzung von 
LptD mittels Protein-Massenspektrometrie bestätigt, sowie ebenfalls mit hoher 
Wahrscheinlichkeit die Identifizierung von LptA als direkter Interaktionspartner. Das 
periplasmatische, LPS-bindende Protein LptA wurde rekombinant exprimiert und eine 
Schlüsselmutation in LptA (Q62L) wurde identifiziert, welche E. coli Bakterien komplett 
resistent gegenüber Thanatin werden lässt. Affinitätsstudien zwischen dem fluoreszenz-
markierten Thanatin-Analoga und LptA-His6 wurden mittels Fluoreszenzpolarisationsmessung 
durchgeführt. Dabei wurde ein Kd Wert von 12 ± 3 nM für diese Interaktion berechnet. Ein 
Kompetitionsexperiment mit dem ursprünglichen Thanatin und D-Thanatin bestätigten die 
spezifische Interaktion mit LptA-His6. Zusammenfassend liefern diese Studien einen wichtigen 
Fortschritt im Verständnis des Wirkungsmechanismus von Thanatin in E. coli und anderen 
Gram-negativen Bakterien und erklären den LPS Transportweg zu einer bedeutenden 
Zielstruktur für die Arzneimitteltherapie. 
Introduction 
5 
1 Introduction 
1.1 Antimicrobial Peptides 
Antimicrobial peptides (AMPs) are part of the innate immune system in many different 
organisms. They serve as a first line of defense in the fight against invading microorganisms 
and viruses and are therefore also often referred to as host-defense peptides. Most AMPs are 
genetically encoded with a signal sequence and have a length of less than 100 amino acids. 
They usually bear multiple cationic charges and hydrophobic residues in an overall 
amphipathic structure that allows electrostatic attachment to the negatively charged surface of 
the membrane of invading pathogens. Many AMPs are then capable of disrupting membranes 
by forming pore-like structures, finally leading to cell lysis. They are released directly at 
infection sites by effector cells due to their unselective mechanism of action and the normally 
micromolar concentration that is needed for activity.[1] Lysis of mammalian cells (e.g. red blood 
cells) can cause toxicity issues under higher concentration, as well as when AMPs are 
administered systemically.[2] However, some AMPs also have mechanisms of action that do 
not involve membranolysis. Certain peptides have been shown to translocate across the cell 
membrane without disruption and bind to nucleic acids (buforin II[3], tachyplesin[4]), inhibit cell-
wall synthesis (mersacidin[5]), inhibit protein synthesis (pleurocidin[6], indolicidin[7]) or protein 
folding (pyrrhocoricin[8]). Hundreds of AMPs have been identified thus far and characterized 
on the basis of their amino acid composition, secondary structures, and origins. AMPs can 
adopt a variety of secondary structures, such as α-helices, extended coils, and β-sheets, which 
often include the formation of disulfide bonds (Figure 1).[9] 
 
Figure 1 Different secondary structure elements found in AMPs: α-helix (LL-37), β-sheet (protegrin-1), extended 
coil (indolicidin). (Adapted from Nguyen et al.)[10] 
 
In addition to their defensive role, AMPs also seem to play an important role in 
immunomodulatory activities, acting as cytokines at infection sites and signalling receptors. 
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They have been shown to modulate the host response of endotoxins such as LPS 
(lipopolysaccharides) and lipoteichoic acid from invading bacteria. Chemotactic recruiting of 
monocytes, lymphocytes, and neutrophils, promotion of histamine release from mast cells, 
inhibition of tissue proteases, and stimulation of wound healing are further processes in which 
AMPs are involved (Figure 2).[11] 
 
Figure 2 The two main biological roles of AMPs acting as host-defense peptides in mammals. (Reprinted from 
Hancock and Sahl)[12] 
 
AMPs serve as a promising group of drug-leads in fighting a wide range of microorganisms 
and may not face the rapid emergence of resistance when compared with classical antibiotics, 
as bacteria are less likely to adapt to the physical disruption of cell membranes.[13] However, 
the use of peptides as drugs has traditionally been limited. This is due to their usually poor 
pharmacological properties, which include low metabolic stability towards proteases, low 
bioavailability, rapid clearance, and general toxicity issues.[14] Hence, intense efforts have been 
undertaken to improve the pharmacological properties of peptides. Medicinal chemists have 
developed an array of strategies to confront this problem, such as incorporating non-
proteinogenic amino acids, cyclisation, peptide bond isosteres[15], peptoids[16], and retro-
inverso peptides[17] to reduce protease cleavage, leading to a longer in vivo half-life. 
Additionally, conformationally constrained peptides can minimize binding to off-target 
receptors and increase binding affinity towards a desired receptor.[18] 
 
  
Introduction 
7 
1.2 Antibiotic Resistance in Bacteria 
A global report on surveillance of antimicrobial resistance carried out by the Wold Health 
Organisation in 2014 states that resistance to bacteria has reached alarming levels in many 
parts of the world, and that few of the available treatment options remain effective for common 
infections. A post-antibiotic era, in which common infections and minor injuries can kill, might 
be a real possibility for the 21st century.[19] Resistance arises as a consequence of mutations 
in microorganisms through a selection pressure from antibiotic use that provides a competitive 
advantage for mutated strains. Sub-lethal antibiotic dosage enhances the stepwise selection 
of resistance. Resistance genes are borne on chromosomal and, increasingly, on transmissible 
genetic elements (e.g. plasmids). This spread is facilitated by inter-species gene transmission, 
poor sanitation and hygiene in communities and hospitals, and the increasing frequency of 
global disease transmission.[20] Recently, a plasmid-mediated polymyxin resistance 
mechanism (MCR-1), was reported for the first time in China. E. coli strain SHP45, isolated 
from food animals, showed a colistin (polymyxin E) resistance that was transferable to other 
Gram-negative species, with a high subsequent risk of spreading around the world.[21] Colistin 
is a last-resort antibiotic, only intended for difficult-to-treat infections, making this resistance 
emergence especially dangerous. Resistance mechanisms include the proteolytic degradation 
of AMPs, the expression of antibiotic efficacy reducing enzymes (e.g. β-lactamases that cleave 
and inactivate β-lactam-based antibiotics), the upregulation of efflux pumps, which actively 
transport antibiotics out of the cell, and changes in antibiotic targets through mutation and 
modification. Bacteria can also be intrinsically resistant to certain antibiotics. This is often the 
case for Gram-negative bacteria, which exhibit an additional outer membrane (cf. Introduction 
1.4), hindering agents in crossing the outer membrane.[22] Six species of pathogen that 
currently cause the majority of infections in hospitals and effectively “escape” the effects of 
antibiotics are the so called “ESKAPE” pathogens, selected by the Infectious Diseases Society 
of America (IDSA). These include representatives from Enterococcus faecium, Staphylo-
coccus aureus, Klebsiella pneumoniae, Acinetobacter baumanii, Pseudomonas aeruginosa, 
and Enterobacter species.[23] There is clearly a need for new antibiotics with new mechanisms 
of action to combat antimicrobial resistance. Further requirements are a paradigm shift in the 
prescription of antibiotics, patient compliance, and prevention of spreading pathogenic 
microorganisms by screening, isolation, and containment of infected patients, as well as a 
reduction of the careless use of antibiotics in intensive animal farming.[24] 
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1.3 β-Hairpin Protein Epitope Mimetics 
A primary reason for interest in peptides and proteins is that they bind with high specificity to 
their in vivo targets, resulting in exceptionally high potencies and relatively few off-target side 
effects. This high degree of selectivity of interaction is the product of millions of years of 
evolutionary selection for complementary shapes and sizes from among a huge array of 
structural and functional diversity. Thus, peptides have been fine-tuned to specifically interact 
with biological targets, evolving into potent endogenous hormones, growth factors, 
neurotransmitters, and signalling molecules, as well as immunologic and defense agents.[14] 
Protein epitope mimetics (PEMs) are specifically designed to mimic surface regions of 
proteins. Their three-dimensional character allows them to modulate protein-protein or protein-
nucleic acid interactions where small organic molecules would fail. By exploiting a larger 
surface area on a protein target, they achieve a strong and specific binding, making them ideal 
inhibitors of biological function. A strategy in designing such modulators is to transplant a 
selected motif crucial for binding onto a stabilizing template. The template helps to orient the 
side-chain residues in the same direction as the native peptide, by rigidifying its three-
dimensional structure. The most important secondary structure elements found in protein 
epitopes in nature are the β-hairpin and the α-helix. The β-hairpin (two antiparallel β-strands 
connected by a loop sequence) is an especially interesting scaffold, since it is used by many 
proteins for biomolecular recognition (e.g. antibodies or T-cell receptors), and it is readily 
amenable to mimetic design.[25] A β-turn occurs where the peptide strand reverses direction 
and consists of four amino acid residues designated i to i+3, in which the distance between 
Cαi and Cαi+3 is ≤ 7 Å. Several different types of β-turns exist[26], depending on the dihedral 
angles Ψ and Φ of the i+1 and i+2 residues. Most normally abundant are type I and type II, 
and their mirror images I’ and II’ (Figure 3).[27] 
 
 
Figure 3 In a β-turn, the distance between Cαi and Cαi+3 must be no longer than 7 Å. Dihedral torsion angles Ψ 
and Φ describe orientation along the backbone and define the β-turn type. (Adapted from Whitby et al.)[27]  
β-turns Φi+1 Ψi+1 Φi+2 Ψi+2 
I -60 -30 -90 0 
I’ 60 30 90 0 
II -60 120 80 0 
II’ 60 -120 -80 0 
III -60 -30 -60 -30 
III’ 60 30 60 30 
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In the case of the defensin, arenicin, tachyplesin, and protegrin families, the stability of the 
three-dimensional structure is enhanced by disulfide bridges, which hold the β-strands 
together (cf. Introduction 1.1).[12] A stem template, such as the dipeptide DPro-LPro, holds the 
two strands in the correct H-bonding pattern, favouring a stable β-turn at the tip (Figure 4). 
Linear precursors of the loop can be synthesized by standard solid phase peptide synthesis, 
cyclized in solution, deprotected, and finally purified by HPLC – making the process amenable 
for combinatorial synthesis. These newly synthesized libraries of peptidomimetics may then 
be tested for biological activity.[28] 
 
Figure 4 A β-hairpin loop identified in a crystal structure of an antibody complementarity-determining region (CDR) 
(left) can be transplanted onto a DPro-LPro template (bottom right), resulting in a cyclic β-hairpin peptidomimetic 
(center). The template rigidifies and so nucleates the folded β-sheet. An NMR overlay of the CDR loop mimetic 
(blue) and the same loop in the crystal structure is shown on the top right. (Reprinted from Robinson et al.)[28] 
 
With this approach, our group discovered new classes of β-hairpin peptidomimetics with 
different confirmed targets. L27-11 targets the LPS transport machinery in P. aeruginosa and 
will be described in detail in the following chapters. JB-95 exhibits high activity against E. coli, 
and its mechanism of action was revealed by Matthias Urfer.[29] PEM POL6326 (Balixafortide), 
which was developed by Polyphor AG, is derived from polyphemusin II, an 18-amino acid 
peptide isolated from the American horseshoe crab (Limulus polyphemus). POL6326 has been 
shown to inhibit CXCR4, a chemokine receptor of the G protein-coupled receptors (GPCRs) 
family. CXCR4 plays an important role in the mobilization of stem cells from the bone marrow 
into the circulating blood. POL6326 is currently in clinical trial phase Ib for stem cells 
transplantation and for a combination treatment in oncology.[30] A further PEM developed by 
Polyphor AG is POL6014, also currently in phase Ib, derived from the sunflower trypsin 
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inhibitor (SFTI)[31]. POL6014 is a selective inhibitor of the human serine protease neutrophil 
elastase (hNE) in immune cells, implicated in tissue degradation and inflammation in lung 
disease. The drug is intended for the treatment of cystic fibrosis and other severe lung 
diseases.[32] 
 
1.4 Outer Membrane Proteins in Gram-negative Bacteria 
Most bacteria can be categorized in two major groups (Gram-positive and Gram-negative), 
differentiated by their cell wall composition. Gram-positive bacteria exhibit a membrane with a 
thick peptidoglycan layer, whereas the Gram-negative bacteria are composed of an outer and 
inner membrane. LPS is incorporated in the outer leaflet of the outer membrane, covering the 
surface of the Gram-negative bacteria. The two membranes are separated by the periplasmic 
space (Figure 5).[33] The Gram-staining is a technique used to identify them under a 
microscope in a quick preliminary diagnostic procedure.[34] 
 
Figure 5 Comparison between a Gram-positive and a Gram-negative cell wall. In Gram-positive bacteria, there is 
a thick peptidoglycan layer, with proteins and teichoic acid incorporated. In Gram-negative bacteria, there is an 
additional asymmetric bilayer, separated by the periplasmic space. The outer leaflet is covered by LPS molecules. 
(Reprinted from Molecular Biology of the Cell (5th ed.))[33] 
 
Membrane proteins are incorporated in both membranes, serving as signalling receptors, 
transporters, ion channels, and cellular anchors, regulating numerous processes in the cell. 
Integral membrane proteins of the inner membrane all have an α-helical fold, consisting of one 
or more α-helices, whereas in the outer membrane, proteins have a β-barrel fold consisting of 
several antiparallel β-strands. These so-called outer membrane proteins (OMPs) are folded 
and inserted by a multicomponent complex called the β-barrel assembly machinery (BAM 
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complex), consisting of the five subunits BamA-E. The crystal structure of the full BAM complex 
has recently been solved, providing a better understanding of the transport, folding, and 
insertion process of OMPs into the outer membrane in Gram-negative bacteria (Figure 6). 
OMPs are synthesized in the cytoplasm with a signal sequence that directs them to the Sec 
translocon, which in turn transports them over the inner membrane to the periplasmic space. 
Chaperones SurA and Skp then escort OMPs to the BAM complex, which folds and 
incorporates them into the outer membrane. 16-Stranded β-barrel BamA is the central 
component, with a periplasmic domain consisting of five polypeptide transport-associated 
(POTRA) domains. BamB-BamE are lipoproteins, and are assumed to have a stabilizing 
function.[35] 
 
Figure 6 The folding and insertion process of β-barrel OMPs in Gram-negative bacteria (left). (Reprinted from 
Bakelar et al.)[35]. Structural representation of the full BAM complex in E. coli, consisting of BamA (red), BamB 
(green), BamC (blue), BamD (magenta), and BamE (cyan) (right) (Protein Data Bank (PDB) 5D0O). (Reprinted 
from Gu et al.)[36] 
 
1.5 The LPS Transport Machinery 
LPS in Gram-negative bacteria consist of three parts: lipid A, core-oligosaccharide, and the O-
antigen (or O-oligosaccharide). The hydrophobic lipid A domain anchors the LPS molecules 
into the outer bacterial membrane. Lipid A is evolutionary conserved, and mainly responsible 
for the toxicity and immunogenic response of Gram-negative bacteria in a host. The core-
oligosaccharide is attached to Lipid A, and contains several sugars as well as non-
carbohydrate modifications, such as phosphates, amino acids, and phosphoethanolamines. 
The O-antigen is the most variable region, and contains a repetitive and often branched 
carbohydrate sequence crucial in protection and surface recognition.[37] LPS is assembled at 
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the inner leaflet of the inner membrane and then extracted and transported to the surface by 
the LPS transport machinery. Seven Lpt (lipopolysaccharide transport) proteins (LptA-G) have 
been identified in E. coli, forming a transport cascade across the entire cell wall (Figure 7). 
LPS is extracted from the inner membrane by an ATP hydrolysis driven ABC transporter 
composed of LptB, LptF, LptG, and probably LptC. LptA serves as a soluble, periplasmic 
chaperone that transports LPS to LptD/E for insertion into the outer membrane. LptD is a large 
β-barrel protein, complexed with the lipoprotein LptE, which acts as a “plug” inside the β-barrel. 
Although the fundamental process of LPS transport is still under investigation, all Lpt proteins 
are essential for the correct biogenesis of the bacterial cell wall and the survival of the 
bacteria.[38] 
 
Figure 7 In Gram-negative bacteria, seven LPS transport proteins (LptA-G) transport LPS from the inner membrane 
over the periplasm to the bacterial surface. The insertion process into the outer leaflet of the outer membrane is 
guided by the large β-barrel protein LptD in complex with LptE. (Reprinted from Vetterli et al.)[39] 
 
Important advances in understanding the structural basis of the LptD/E complex and LPS 
insertion have been made in recent years, with the reporting of the full length LptD/E crystal 
structures in Shigella flexneri (PDB 4Q35, Figure 8)[40] and Klebsiella pneumoniae (PDB 
5IV9)[41], and lacking the N-terminal jelly roll domain in LptD: Salmonella typhimurium (PDB 
4N4R)[42] and P. aeruginosa core complex (PDB 5IVA)[41]. The Lipid A moiety of LPS is 
funnelled through the hydrophobic β-jellyroll domain of LptA and LptC as well as the N-terminal 
domain of LptD (LptD_NT), and finally enters the LptD β-barrel with the carbohydrate 
headgroups making contact with the hydrophilic lumen of the LptD/E complex. The membrane-
engulfed part of LptD is composed of twenty-six antiparallel β-strands (termed β1–β26), 
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making it the largest single-protein β-barrel observed to date. It is believed that strands β1 and 
β26 are able to dissociate from each other to create an exit gate for LPS molecules necessary 
for the insertion in the outer leaflet (Figure 9).[40] 
 
Figure 8 Structural representation of the LptD/E complex in Shigella flexneri, viewed in different orientation. Hairpin 
strands β1 and β2 are highlighted in cyan, LptE in purple. (Reprinted from Qiao et al.)[40] 
 
Figure 9 Proposed model for LPS insertion into the outer membrane: The hydrophobic moiety of LPS is believed 
to enter directly into the lipid bilayer, whereas the hydrophilic head groups make contact with the luminal LptE. LPS 
is then inserted through a lateral opening of the strands β1 and β26 in the β-barrel. (Reprinted from Qiao et al.)[40]  
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1.6 From Protegrin-1 to L27-11 
Cationic AMP protegrin-1 was first isolated from porcine leukocytes, and consists of 18 amino 
acids highly enriched in arginine and cysteine, with a β-hairpin structure stabilized by two 
disulfide bridges. Its broad antimicrobial activity is exhibited in low micromolar 
concentrations.[43] Protegrin-1 served as a lead structure in the development of new 
peptidomimetics in our group, with higher activity and less hemolytic toxicity – a critical side 
effect that reduces its potential as a systemic antibiotic. Iterative cycles of library synthesis and 
screening led to the discovery of a new series of β-hairpin peptidomimetics. These 
peptidomimetics contain a sequence similarity to its ancestor; however, the loop is stabilized 
by the introduction of a DPro-LPro template at the stem, which substitutes for the disulfide 
bridges to hold the two β-strands in place (Scheme 1).[44] 
 
Scheme 1 Protegrin-1 served as a lead structure in the development of new peptidomimetics such as L27-11. A 
DPro-LPro template (red) was introduced to stabilize the β-hairpin fold of the sequence and to substitute for the two 
disulfide bridges in protegrin-1. 
 
L27-11 is a fully synthetic cyclic β-hairpin that was recently discovered in our group. With a 
minimal inhibitory concentration[45] (MIC) of 0.008 µg/ml against Pseudomonas aeruginosa, it 
is a highly potent antimicrobial peptide. Surprisingly, L27-11 only exhibits antimicrobial activity 
against Pseudomonas spp., indicating a specific mechanism of action. Indeed, it was found 
that L27-11 possesses no membranolytic activity, and a delayed bactericidal effect compared 
to protegrin-1. The enantiomeric form of L27-11 proved to be completely inactive against P. 
aeruginosa, suggesting a chiral target. A genetic screen for resistance determinants and a 
photoaffinity labelling experiment revealed outer membrane protein LptD as the target of L27-
11 and inhibition of LPS transport as the assumed mechanism of action.[46,47] Related 
compounds have been synthesized for clinical application with improved ADME properties 
(absorption, distribution, metabolism, elimination). By substituting Lys and Arg residues for 2,4-
diaminobutyric acid (Dab), protease cleavage sites were removed and plasma half-life was 
prolonged, with minimal effect on antimicrobial activity.[28] The structurally related clinical 
candidate drug POL7080 (Murepavadin), developed by Polyphor AG, successfully completed 
clinical trial phase I studies in 2013 and is currently under phase II evaluation for P. aeruginosa 
pneumonia infections.[48] 
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To study the contribution of a specific residue to the total activity of L27-11, an alanine scan 
was recently performed in our group by Schmidt et al.[49] In an alanine scan, each residue along 
the backbone of the β-hairpin loop is systematically substituted by an alanine. Most 
substitutions led to a 3-10 fold loss in activity. However, the substitutions of either Trp2 or Trp8 
resulted in a complete loss of antimicrobial activity. NMR analysis showed no significant 
change in backbone conformation for mutant Trp2Ala compared to the native L27-11, whereas 
mutant Trp8Ala adopted a more flexible structure. Further substitutions of Trp2 and Trp8 to 
other aromatic residues (Phe and Tyr) were studied, and results showed that those 
substitutions lead to an about six fold drop in activity at position 2, and are even less tolerated 
at position 8. Summarizing, positions Trp2 and Trp8 are crucial for high antimicrobial activity 
in L27-11 (Figure 10).[49] 
 
 
Figure 10 Peptidomimetic L27-11, with crucial positions Trp2 and Trp8 highlighted in red. The antimicrobial activity 
against P. aeruginosa ATCC27853 was determined in MH-I (Müller-Hinton broth) with addition of 0.02% BSA 
(bovine serum albumin). (Adapted from Schmidt et al.)[49] 
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1.7 LB-01 and NMR Studies 
LB-01 (Figure 11) is a more suitable scaffold for studying NMR structures than L27-11. LB-01 
differs from L27-11 in five positions (Table 1). Four lysines are substituted by ornithine and 
Dab to facilitate proton assignments. Otherwise, signal overlap would highly complicate 
assignments and structure calculations. Another difference is the Arg6 substitution by DLys to 
give additional beta turn II’ stability at the tip region. Despite these substitutions, LB-01 exhibits 
approximately the same high antimicrobial activity (MIC of 0.01 μg/ml) against P. aeruginosa 
as L27-11. The LB-01 scaffold was previously described by Schmidt et al.[49], emphasizing the 
importance of the β-hairpin fold in antimicrobial activity. LB-01 exists as a single rotamer 
(> 98%) in aqueous solution, with all peptide bonds trans. Analysis of coupling constants 
revealed 3JHNHα values ≥ 8.5 Hz and mostly positive chemical shift deviation Δδ = δobserved - 
δrandom)[50] for several residues, consistent with backbone conformations in β-sheet 
structures.[51] Characteristic long range cross-strand NOEs indicate a regular β-hairpin 
structure with a type II’ β-turn in the tip region. It was also shown that the substitution of the 
DPro-LPro template by LPro-DPro results in a disordered, non β-hairpin-like structure, leading 
to a complete loss of antimicrobial activity.[49] 
 
Figure 11 LB-01 scaffold with highlighted amino acids (red/blue) that differ from parent compound L27-11. 
Table 1 Comparison of peptidomimetics L27-11 and its analogue LB-01. 
 1 2 3 4 5 6 7 8 9 10 11 12 template 
L27-11 T W L K K R R W K K A K DP P 
LB-01 T W L Dab Orn DK R W Orn Dab A K DP P 
  
Introduction 
17 
1.8 N-Methylation 
N-methylation is a modification that often occurs in Nature, and which regulates many 
biological functions. It is most prominent in epigenetics, where different degrees of DNA 
methylation regulate gene expression. DNA methylation occurs on the nucleosides adenine 
(N6 position) and cytosine (C5 position) through DNA methyltransferases. N-methylation on the 
side-chains of lysine and arginine in histone proteins leads to a change in chromatin structure 
and gene activity regulation. This so-called “histone code”[52] allows for a specific recognition 
by other proteins, leading to different gene expression patterns. However, N-methylation is not 
limited to histones and DNA modifications. There are many examples of naturally occurring N-
methylated linear and cyclic peptides with interesting biological functions. They are mostly 
synthesized by non-ribosomal peptide synthetases (NRPSs), allowing the incorporation of 
different non-proteinogenic amino acids, leading to a high variety of molecules. A selection is 
described in the following (Figure 12): Enniatins, a group of cyclic depsipeptides[53] (the peptide 
bond is isosterically replaced by an ester group) was found in Fusarium fungi. They are able 
to target membranes by incorporating themselves into the cell membrane, acting as 
ionophores, subsequently causing membrane disruption. Enniatins have been shown to exhibit 
cytotoxic activity against human cancer cell lines.[54] Enniatin B has been found to inhibit the 
multidrug efflux pump Pdr5p in Saccharomyces cerevisiae, making it an interesting candidate 
for cancer therapy.[55] Hemiasterlins are a small group of cytotoxic N-methylated tripeptides 
derived from marine sponges. They are able to target microtubules, resulting in mitotic arrest 
of cells by preventing tubulin polymerization. Potent analogues of this drug have been 
synthesized and are currently evaluated as anti-cancer therapeutics. HTI-286, a synthetic 
analogue of hemiasterlin, is a potent inhibitor of proliferation (mean IC50 = 2.5 ± 2.1 nM in 18 
human tumor cell lines), that also exhibits low interaction with multidrug resistance protein (P-
glycoprotein).[56] Echinomycin, an antibiotic found in Streptomyces echinatus, targets DNA by 
intercalating between DNA bases, forming a complex that inhibits transcription by RNA 
polymerase.[57] Cyclosporin is a potent inhibitor of calcineurin, and a clinically widely used drug. 
Calcineurin is a Ca2+- and calmodulin dependent protein phosphatase, and plays an important 
role in T-cell activation.[58] Its inhibition leads to an immunosuppressive effect, making 
cyclosporin especially important in preventing graft rejection in organ transplantation.[59,60] 
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Figure 12 Selection of naturally occurring N-methylated peptides that act on different targets in the human body. 
(Adapted from Chatterjee et al.)[60] 
 
Introducing an N-methyl group at the amide NH position of the peptide backbone has a direct 
effect on its flexibility. The additional steric hindrance influences the cis-trans equilibrium along 
the backbone, generally favouring a cis conformation of the adjacent residue. The rotational 
barrier of the cis-trans equilibrium is higher in energy, resulting in rotameric isomers (rotamers). 
Further, the removal of the amide hydrogen prevents the formation of hydrogen bonds. N-
methylation therefore affects the ability to adopt secondary structure elements like helices and 
β-sheets in larger peptides. This obviously also strongly depends on the specific amino acid 
sequence and size and orientation of the residues.[61] N-methylation is a minimalistic approach 
to overcome obstacles in drug development, and has successfully been applied to improve 
bioavailability and metabolic stability of somatostatin analogues[62], G-protein ligands[63], and 
reduction of hemolytic activity in gramicidin S[64] towards human red blood cells. N-methylation 
was also applied to increase selectivity of ligands towards different integrin and melanocortin 
receptor subtypes.[65] 
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1.9 Cell-Penetrating Peptides 
The cell membrane protects living cells from the outside environment, and, among many other 
tasks, regulates the permeation of compounds into the cell. Ions and small organic molecules 
are able to cross the lipid bilayer of cell membranes through specific transporter proteins, 
whereas larger and hydrophilic compounds usually cannot enter the cell interior unhindered.[33] 
In 1988, it was found that the 86 amino acid long TAT protein (trans-activator of transcription), 
derived from the human immunodeficiency virus (HIV-1), was efficiently taken up by cells from 
the surrounding media.[66] The transduction of large cargo molecules coupled to a short TAT 
peptide sequence was later demonstrated, substantially increasing the possibilities of drug 
delivery.[67] Hundreds of so-called cell-penetrating peptides (CPPs) have since been 
discovered, usually with a length of 5-35 amino acids, with a high abundance in basic residues 
such as arginine and lysine and/or an overall amphipathic structure. The guanidine headgroup 
of arginine was identified as a critical structural component responsible for the biological 
activity of polyarginines (containing six or more arginines), entering cells far more effectively 
than polymers of equal length composed of other residues.[68] However, the mechanism of cell 
entry by CPPs has not fully been understood. It is likely a combination of several mechanisms, 
ranging from energy-independent direct translocation to the active take-up by the endocytic 
pathway through phagocytosis and pinocytosis, including receptor mediated endocytosis 
(Figure 13).[69] 
 
Figure 13 Mechanisms for CPP internalization: CPPs and CPP–cargo conjugates (e.g. nucleic acids, proteins, 
imaging agents, therapeutics), can penetrate cells using different endocytotic pathways: in particular pinocytosis, 
which includes macropinocytosis and clathrin-mediated, caveolae and clathrin- or caveolae-independent 
endocytosis or phagocytosis. Alternatively, CPPs can cross the membrane by energy-independent direct 
translocation. (Reprinted from Rizzuti et al.)[70]  
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1.10 Thanatin – an Insect Antimicrobial Peptide 
Thanatin was first isolated from the hemipteran insect Podisus maculiventris (spined soldier 
bug) by Fehlbaum et al.[71] in 1996. The peptide consists of 21 amino acids 
(GSKKPVPIIYCNRRTGKCQRM) with a disulfide bond between Cys11 and Cys18 showing a 
sequence homology to the brevinin[72] family of antimicrobial defense peptides. Thanatin 
showed activity against a wide range of Gram-positive and Gram-negative bacteria and fungi 
(Table 2). A main factor distinguishing thanatin from other defense peptides of the innate 
immune system is its non-hemolytic activity towards red blood cells, indicating a mechanism 
of action that does not involve membrane permeabilization. Indeed, the cell membrane in E. 
coli was found to be intact upon thanatin addition by measuring potassium ion potential as well 
as respiratory activity (i.e. oxygen consumption) during the first hour. In order to investigate 
whether the activity derives from an interaction with a stereospecific cellular target, an all-D-
enantiomer of thanatin was tested. Although activity on fungi and on certain representatives 
from Gram-positive bacteria did not change, a dramatic loss of activity on Gram-negative 
bacteria was observed with the enantiomer. This result points towards different mechanisms 
of action, dependent on the organism. Truncated isoforms of thanatin were tested for their 
MIC, revealing that a truncation of three to five N-terminal amino acids led to a fully active 
peptide in the case of K18M and a 50% reduction in activity for peptide V16M for both Gram-
positive A. viridans / M. luteus and Gram-negative E. coli D31 / D22. A truncation of three 
amino acids from the C-terminus (G18C) led to a 25% active peptide in the Gram-positive test 
organisms and a complete loss of activity in E. coli (Table 3). High antifungal activity required 
the complete sequence. Four regions within the thanatin scaffold were therefore described 
essential for high antimicrobial activity: i) the C-terminal loop, ii) the C-terminal three amino 
acid extension, iii) a stretch of seven N-terminal, mostly hydrophobic residues and iv) three N-
terminal residues necessary for high antifungal activity but dispensable for antibacterial 
activity.[71] 
The first NMR solution structure of thanatin was published by Mandard et al.[73] in 1998, 
indicating a well-defined β-hairpin structure held together by the disulfide bond. The N-terminal 
region ranging from Gly1 to Pro7 consists of an extended, poorly defined region with high 
flexibility (Figure 14). The hydrogen bonding pattern of the molecule constitutes of regular 
hydrogen bonds characteristic for β-sheet structures between residues Asn12/Lys17, 
Tyr10/Gln19 and Ile8/Met21. At the tip region, there are two distorted CO(i) – NH(i+3) hydrogen 
bonds between Arg13 and Gly16 and between Asn12 and Thr15. The PDB file for thanatin is 
accessible under the code 8TFV.[73] An additional NMR study was performed by Imamura et 
al.[74] in 2008, in which Cys11 and Cys18 were substituted by serine or tert-butyl groups, 
disrupting the disulfide bond. The β-hairpin structure proved essential for antimicrobial activity 
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against Gram-negative E. coli, whereas activity on Gram-positive M. luteus was not affected 
by the change.[74] 
A primary effect of E. coli cells treated with thanatin was an arrest of motility within seconds of 
its addition, followed by agglutination into larger clumps. This effect was attributed to a binding 
of the cationic thanatin to the negatively charged surface of bacteria, resulting in a reduction 
of the electrostatic repulsion between cells, leading to agglutination. This agglutination effect 
induced by thanatin was recently reproduced by Robert et al.[75], using artificial phospholipid 
vesicles. The influence of different cations and pH on antimicrobial activity was studied, 
indicating that thanatin is sensitive to the presence of higher concentration of cations, but 
insensitive to changes in pH in the range of pH 5-8.[76] Wu et al.[77] introduced S-thanatin, an 
analogue of thanatin, in which Thr15 was substituted by a serine, which exhibited improved 
antimicrobial properties and the ability to bind and neutralise LPS. Additional studies were 
conducted by Wu et al.[78] on the efficacy of S-thanatin in preventing septic shock in infected 
mice. Imamura et al.[79] cloned a synthetic thanatin gene into rice in 2010, generating a 
transgenic rice plant resistant to the blast fungus Magnaporthe oryzae. The potential of 
creating crops resistant to phytopathogenic fungi and bacteria was further reinforced by work 
in the model organism Arabidopsis thaliana.[80] However, despite all the advances since its 
discovery, a comprehensive mechanism of action of thanatin and a cellular target structure 
remains to be identified. 
 
Table 2 Antimicrobial activity of thanatin and its enantiomer D-thanatin on certain Gram-positive, Gram-negative 
bacteria and fungi (values in μM MIC units). MIC values are expressed as intervals from the highest concentration 
tested at which bacteria were growing and the lowest concentration that caused 100% growth inhibition. ‡ : No 
activity was detected at the highest concentration tested (40 µM). (Reprinted from Fehlbaum et al.)[71] 
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Table 3 Antimicrobial activities of truncated isoforms of thanatin, expressed as percentages of native thanatin. 
(Reprinted from Fehlbaum et al.)[71] 
 
 
 
 
Figure 14 Superposition of 18 selected structures of thanatin fitted on the backbone atoms of residues 9-20. 
(Reprinted from Mandard et al.)[73] 
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2 Project Outline 
2.1 LB-01 
Intense efforts have been made in our group in the development of β-hairpin peptidomimetics 
with high activity against P. aeruginosa. As described above, outer membrane protein LptD 
has been identified as a target of lead structure L27-11. Recent NMR studies revealed a 3D 
solution structure of the β-hairpin conformation of L27-11 and LB-01, adding important 
structural information of how the peptide could interact and bind to LptD. The formation of a 
stable β-hairpin conformation seems to be important for high antimicrobial activity. An alanine 
scan of L27-11 identified the two opposing tryptophans as the most crucial residues for 
antimicrobial activity.[49] At the start of this project, no publication existed of a crystal structure 
of LptD alone or together with an inhibitor, which would give a better insight into the binding 
site of LptD. N-methylation of amide NH groups was chosen as an approach to add further 
information in building a detailed structure-activity relationship (SAR) profile of L27-11/LB-01. 
The aim of this project was to develop a reliable strategy for the synthesis of N-methylated 
analogues of LB-01. These new analogues would then need to be tested for their antimicrobial 
activity on P. aeruginosa. Solution structure NMR analysis would need to be applied to 
correlate 3D structure to antimicrobial activity. Further, the LB-01 scaffold makes a good 
candidate for a cell-penetrating peptide, and a study of its localisation and uptake into cells 
should give more insight into possible applications in drug delivery of this class of molecules. 
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2.2 Thanatin 
Thanatin was chosen as a naturally occurring, insect derived peptide that targets a wide range 
of Gram-positive and Gram-negative bacteria and fungi. Since the antimicrobial activity is likely 
correlated with a stereoselective interaction with an unknown target in Gram-negative bacteria, 
the decision was made to study its mechanism of action in E. coli. The effect on the membrane 
integrity was investigated through a variety of assays; such as Sytox® Green uptake, β-
lactamase, and β-galactosidase release in E. coli. Effects on the macromolecular pathways of 
DNA-, RNA-, Protein-, and cell wall biosynthesis were studied by radiolabelling methods. 
Further, a suitable photo-reactive analogue was designed to identify potential interaction 
partners through photoaffinity labelling. Electron microscopy studies were performed in order 
to reveal macroscopic changes in the cellular organelles and the overall shape of the bacteria. 
An analogue suitable for fluorescence confocal microscopy was designed in order to give 
additional information on the potential binding on the surface and cellular uptake of the 
molecule. Mass spectrometry and proteomic studies were applied to confirm the interaction 
partners found in the photoaffinity labelling experiments. With the identified proteins LptA and 
LptD, as well as the accumulated information from the other assays, a perturbation of the LPS 
transport pathway seemed very likely. Recombinant LptA was produced, and the binding 
interaction was studied by fluorescence polarization. A co-crystal structure of thanatin with the 
protein target LptA should give structural proof of the interaction and identification of key 
residues in LptA required for activity. This would open the field for SAR optimization and 
development of a high affinity drug with activity against a wide range of Gram-negative 
bacteria. 
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3 Results and Discussion 
3.1 LB-01 
3.1.1 LB-01 N-Methyl Scan 
To investigate the influence of N-methylation of the amide backbone on structure and activity 
of β-hairpin peptidomimetics, the modifications were applied on the well-structured LB-01 as a 
reference compound. Twelve analogues of the LB-01 scaffold were synthesized according to 
the method of Srinivas et al.[46], with each amide position along the backbone N-methylated 
(Figure 15). N-methyl groups were either introduced by incorporating commercially available 
amino acid building blocks or by on-resin methylation following the Kessler protocol[81]. In the 
special case of the highly hindered amide position Thr1NMe, the dipeptide Fmoc-Pro-N-Me-
Thr(OtBu)-OH was synthesized separately and then incorporated into the sequence by 
standard Fmoc chemistry[82]. 
 
 
Figure 15 LB-01 scaffold with highlighted amide NH positions (blue) that have been individually methylated to give 
rise to 12 N-methyl analogues. 
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3.1.2 On-Resin Methylation 
Regioselective methods for N-methylation of amino acids and peptides on solid support have 
been developed by Fukuyama et al.[83] and Miller and Scanlan[84]. The improved on-resin N-
methylation method developed by Kessler et al.[81] is completely side-chain tolerant and 
regioselective for any amino acid: The free amine is temporarily protected by a nosyl group (2-
nitrobenzenesulfonyl) and methylated under Mitsunobu conditions with methanol as the methyl 
donor. The nosyl group was then removed by treatment with mercaptoethanol and DBU (1,8-
diazabicyclo[5.4.0]undec-7-ene) as a base, revealing the free N-methyl amine (Scheme 2). 
Generally high yields of > 90% were achieved in a reaction time of approximately 3 h for three 
steps in total.  
 
 
Scheme 2 a) o-NBSCl, sym-collidine, DMF, 40 min b) PPh3, DIAD, MeOH, THF, 50 min. c) Mercaptoethanol, DBU, 
DMF 20 min. 
 
This versatile strategy could be successfully used in the synthesis of all LB-01 N-methyl 
analogues except in the case of Thr1NMe, where steric hindrance in the sequence led to an 
unsuccessful coupling of the subsequent amino acid, as described in the next chapter. 
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3.1.3 Low Reactivity of N-Methyl Amines 
One problem encountered when introducing N-methyl groups in a sequence was a decreased 
coupling efficiency on the following amino acid. Exemplified here by the highly hindered 
position at Thr1, three factors contribute to the low reactivity of the N-methyl amine: The N-
methyl group itself, which substantially reduces the nucleophilicity of the amine, the beta 
branched side-chain of threonine, with a bulky tert-butyl protecting group, and the proline, with 
its five membered ring in close proximity to the carbonyl C (Scheme 3). 
 
 
Scheme 3 Low reactivity of N-methyl amines, when a proline is coupled onto an N-methyl threonine on solid 
support. 
 
Several unsuccessful attempts were made in this difficult coupling reaction. Coupling under 
standard conditions with HATU/HOAt[85] only led to a conversion of less than 5% determined 
by HPLC. Increasing equivalents of reagents, an extended reaction time, plus heating of the 
mixture to 50°C did not improve the extent of the conversion. The third generation coupling 
reagent COMU[86] showed a slightly better coupling efficiency under standard conditions, 
though still far from ideal. Microwave heating of the reaction mixture only led to a premature 
resin cleavage and was therefore not applicable for 2-chlorotrityl chloride supported resin 
(Table 4). 
 
Table 4 Unsuccessful coupling of Fmoc-Pro-OH onto N-methyl Thr under different conditions. 
Coupling reagents Conditions Product yield 
HATU/HOAt/DIPEA 
double coupling, 4 eq., 2h < 5% 
overnight, 10 eq., 50°C < 5% 
COMU/DIPEA 
3 eq. < 10% 
microwave 50°C, 5 min premature resin cleavage 
 
 
The decision was thus made to synthesize an N-methylated dipeptide separately and 
incorporate it into the sequence through standard Fmoc chemistry. 
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3.1.4 Synthesis of Dipeptide Fmoc-Pro-N-Me-Thr(OtBu)-OH 
Commercially available Z-Thr(tBu)-OH was N-methylated and esterified to its methyl ester in 
a single step by treatment with iodomethane and silver oxide.[87] The carboxybenzyl group 
(Cbz) was then removed by catalytic hydrogenation and the crude free amine subjected to a 
peptide coupling reaction with Fmoc-Pro-OH and COMU as a coupling reagent. Saponification 
of the methyl ester proved to be difficult under strong basic conditions with NaOH and LiOH, 
as it led to the undesired deprotection of the Fmoc group. The ester was then finally cleaved 
by nonbasic lithium iodide in refluxing EtOAc with complete regioselectivity in good overall 
yield of 59% over three steps (Scheme 4).[88] The dipeptide served as a building block in the 
synthesis of the LB-01-Thr1NMe analogue. 
 
 
Scheme 4 a) MeI, Ag2O, DMF, 16 h, 94%. b) Pd/C, H2, THF, 30 min, then Fmoc-Pro-OH, COMU, DIPEA, DMF, 
2 h, 72% over two steps. c) LiI, EtOAc reflux, 16 h, 87%. 
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3.1.5 Analysis of LB-01 N-Methyl Analogues 
All LB-01 N-methyl analogues were subjected to high resolution mass spectroscopy and 
reversed-phase HPLC analysis. The occurrence of multiple charged ionic species in ESI mode 
(electron spray ionization) is typical for peptides with several basic residues (i.e. Lys, Orn, Dab, 
and Arg). The most abundant species were usually [M+2H]2+, [M+3H]3+ and [M+4H]4+. All 
measured m/z values matched the calculated values with sufficient accuracy. HPLC retention 
times were in the range of 10-13 min, run with a linear gradient of 10 to 60% MeCN/H2O with 
additional 0.1% TFA (Table 5). UV traces (226 nm, 254 nm, 278 nm) showed a purity of > 95% 
by integration of the 226 nm trace after preparative HPLC purification (Figure 16). 
 
Table 5 Calculated mass and experimental m/z values of LB-01 N-methyl analogues measured by high resolution 
ESI. Retention times (tR) were determined by HPLC chromatography. (Adapted from Vetterli et al.)[39] 
Peptide Exact mass (calc.) m/z (HR-ESI) 
Retention time tR 
[min] 
Thr1NMe 1706.02565 
854.01996 [M+2H]2+ 
569.68292 [M+3H]3+ 
427.51393 [M+4H]4+ 
11.4 
Trp2NMe 1706.02565 
854.02035 [M+2H]2+ 
569.68258 [M+3H]3+ 
427.51382 [M+4H]4+ 
10.8 
Leu3NMe 1706.02565 
854.01884 [M+2H]2+ 
569.68228 [M+3H]3+ 
427.51364 [M+4H]4+ 
12.6 
Dab4NMe 1706.02565 
854.01946 [M+2H]2+ 
569.68196 [M+3H]3+ 
427.51310 [M+4H]4+ 
10.9 
Orn5NMe 1706.02565 
854.02013 [M+2H]2+ 
569.68328 [M+3H]3+ 
427.51416 [M+4H]4+ 
12.0 
DLys6NMe 1706.02565 
854.01956 [M+2H]2+ 
569.68207 [M+3H]3+ 
427.51349 [M+4H]4+ 
10.6 
Arg7NMe 1706.02565 
854.01911 [M+2H]2+ 
569.68236 [M+3H]3+ 
427.51394 [M+4H]4+ 
11.7 
Trp8NMe 1706.02565 
854.01905 [M+2H]2+ 
569.68204 [M+3H]3+ 
427.51330 [M+4H]4+ 
11.4 
Orn9NMe 1706.02565 
854.02048 [M+2H]2+ 
569.68328 [M+3H]3+ 
427.51441 [M+4H]4+ 
12.1 
Dab10NMe 1706.02565 
854.01930 [M+2H]2+ 
569.68200 [M+3H]3+ 
427.51286 [M+4H]4+ 
11.3 
Ala11NMe 1706.02565 
854.01880 [M+2H]2+ 
569.68178 [M+3H]3+ 
427.51305 [M+4H]4+ 
11.0 
Lys12NMe 1706.02565 
854.01921 [M+2H]2+ 
569.68255 [M+3H]3+ 
427.51400 [M+4H]4+ 
12.9 
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Figure 16 Analytical HPLC chromatograms of LB-01 N-methyl analogues, run with a linear gradient of 10 to 60% 
MeCN/H2O with addition of 0.1% TFA on a C18 reverse-phase column. Wavelengths: 226 nm (blue), 254 nm 
(magenta), 278 nm (red). (Adapted from Vetterli et al. suppl. data)[39] 
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3.1.6 Antimicrobial Activity of LB-01 N-Methyl Analogues 
MIC values were measured for all twelve mono-N-methyl LB-01 analogues by a microdilution 
assay in Mueller-Hinton-I broth (MH-I). The bacterial strains used were P. aeruginosa (PA) 
ATCC27853 and PAO1, and Gram-positive Staphylococcus aureus ATCC29213. All 
analogues were essentially inactive towards S. aureus, which is not surprising assuming the 
same mechanism of action as the parent structure LB-01/L27-11. MIC values are generally 
two-fold higher for P. aeruginosa PAO1 compared to the ATCC27853 strain. Overall, there 
was a large variation of MIC values. N-methylation at positions Trp2, Leu3, Ala11 and Lys12 
lead to a complete loss in activity and a major loss at positions Orn9 and Dab10. Analogues 
Dab4NMe and Orn5NMe and DLys6NMe retained approximately the same activity as LB-
01/L27-11 or showed even slightly higher activity. Considering the role of the NH group in 
intramolecular hydrogen bonding of analogue Orn5NMe, retention of activity was unexpected. 
Moderate activities were measured for positions Thr1, Arg7 and Trp8. N-methylation at the 
highly hindered position Thr1 was expected to disrupt the β-hairpin completely but this 
analogue retained moderate activity (cf. Structural Studies by NMR 3.1.7). From a global view 
on the scaffold, it seems that modifications near the stem are less tolerated than in the tip 
region (residues 5-8). 
 
Figure 17 Antimicrobial activity of the N-methyl scan library of LB-01 tested in MH-I with addition of 0.02% BSA. 
High antimicrobial activity is depicted in green, medium in blue and low activity in red. (Reprinted from Vetterli et 
al.)[39]  
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It is likely, that N-methylation of amide backbone groups in LB-01 that make important 
hydrogen-bonding interactions with LptD, will cause major loss of antimicrobial activity. Certain 
outward-facing NH groups in LB-01 are sensitive to N-methylation such as Trp2, Orn9, and 
Ala11. N-methylation at those positions leads to a severe loss in activity, highlighting the 
importance of those H-bonding positions. The also outward-facing NH groups at positions 
Dab4 and DLys6 retain antimicrobial activity upon N-methylation and are therefore unlikely to 
directly form H-bonds towards LptD. Figure 18 shows a possible binding interaction of LB-01 
with two unspecified β-strands from LptD on both sides of the hairpin.[39] 
 
Figure 18 Possible H-bonding interactions of the β-hairpin LB-01 with neighboring β-strands of the target protein 
LptD. (Reprinted from Vetterli et al.)[39] 
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3.1.7 Structural Studies by NMR 
The following NMR studies were carried out in collaboration with Dr. Kerstin Möhle. 1D 1H and 
2D [1H, 1H] NMR spectra of each N-methyl analogue were measured in H2O/D2O 9:1, pH 2-3. 
The differences in the shape and dispersion of amide proton resonances with respect to the 
reference compound LB-01 indicate that the structural behaviour in solution can be strongly 
influenced by single replacement of an amide proton by a methyl group (Figure 19). The 1H 
spectra of the N-methylated analogues also displayed the occurrence of major and minor 
isoforms in solution, which can be related to a cis-trans isomerism at the N-methylation site or 
at the Lys12-DPro13 peptide bond. The majority of LB-01 N-methyl analogues exist as 
rotamers with > 90% all-trans peptide bonds along the backbone. However, cis-rotamers with 
higher percentages at the N-methylation site were calculated for Leu3NMe and Trp8NMe, with 
25% and 50% of the cis-rotamer respectively. In the case of analogue Orn9NMe and 
Dab10NMe, in addition to the cis-rotamer at the N-methylation site (each 25%), cis-conformers 
were detected for the Lys12-DPro13 peptide bond (12% and 8% respectively). For Trp8NMe, 
two slowly interconverting isoforms coexist in solution with a ratio of 1:1 arising from cis-trans 
isomerization at the Arg7-Trp8Me peptide bond (Table 6). NMR resonance assignments were 
completed for all major forms of the analogues (Appendix 6.2) except for Trp8NMe, which 
shows significant signal overlap of both major forms. The three representative solution 
structures of analogue Orn5NMe, Ala11NMe, and Thr1NMe are discussed in detail in the 
following sections. Analogues Orn5NMe and Thr1NMe have peptide NH bonds oriented 
inwards across the hairpin structure (Figure 17), and so it is of interest to determine whether 
the regular hairpin structure is retained in these cases. The Thr1NMe substitution, in particular, 
is at a critical position next to the DPro-LPro template. In addition, the Ala11NMe analogue is 
of great interest, since the peptide NH at this residue should be oriented outward in a regular 
hairpin structure, and yet the analogue completely loses antimicrobial activity. 
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Figure 19 1H spectra (amide-aromatic region) of N-methyl analogues compared to reference compound LB-01. 
 
 
Table 6 cis-trans peptide bond rotamers in LB-01 N-methyl analogues, calculated from NMR data. (Adapted from 
Vetterli et al.)[39] 
Peptide cis rotamer [%] Peptide bond 
LB-01 < 5 - 
Thr1NMe 7 LPro-Thr1NMe 
Trp2NMe 7 Thr1-Trp2NMe 
Leu3NMe 25 Trp2-Leu3NMe 
Dab4NMe 5 Leu3-Dab4NMe 
Orn5NMe < 5 - 
DLys6NMe < 5 - 
Arg7NMe < 5 - 
Trp8NMe 50 Arg7-Trp8NMe 
Orn9NMe 
25 
12 
Trp8-Orn9NMe, 
Lys12-DPro13 
Dab10NMe 
25 
8 
Orn9-Dab10NMe, 
Lys12-DPro13 
Ala11NMe 8 Dab10-Ala11NMe 
Lys12NMe 10 Ala11-Lys12NMe 
  
Results and Discussion 
35 
Solution structure of Orn5NMe. The Orn5NMe analogue was one of the most active 
compounds in this study. The chemical shifts of amide resonances show a good dispersion in 
the range of 1 ppm (slightly less than in LB-01)[49] (Figure 19), suggesting that the peptide is 
predominantly well-structured in solution. As a qualitative indicator for the formation of 
secondary structures in solution, secondary chemical shifts – namely the deviations of 
observed Hα chemical shifts from tabulated random coil values (Δδ = δobserved - δrandom)[50] – 
were determined. These chemical shift deviations (CSDs) are typically negative (upfield shifts) 
within segments of four or more contiguous residues indicating α-helical conformations and 
positive (downfield shifts) in β-sheet conformations. The comparison of the CSDs displays 
similar trends as in LB-01, with positive Δδ Hα’s between Thr1-Dab4 and Trp8-Lys12 (except 
for Ala11), indicating the occurrence of extended conformations in these regions (Figure 23). 
Characteristic cross-strand nuclear Overhauser effects (NOEs), consistent with a β-hairpin 
conformation were observed close to the template, in particular, the backbone Hα-Hα NOE 
between Trp2 and Ala11, and the backbone side-chain HN-Hβ NOEs between Lys12-Thr1 and 
Dab10-Leu3. In the tip region between Dab4 and Orn9, only few long-range NOEs were 
observed, indicating that this region is more flexible and/or interconverts between 
conformations. NOE connectivities occurred between side-chain protons of Trp2 and Trp8, 
indicating a π-stacking of aromatic side-chains on the same side of the peptide on the one 
hand, and between Trp2 and Orn9 side-chain protons, as they were observed and expected 
in a regular β-hairpin fold, on the other hand. The structure calculations performed with the 
program CYANA[89] gave a bundle of 20 low energy conformations, which revealed a backbone 
root mean square deviation (rmsd) of 1.3 Å, suggesting a flexible backbone (Table 7). A 
restricted clustering of the structures by superposition of the backbone atoms close to the 
template (Dab10-Pro14, Thr1-Leu3) shows a rmsd of 0.8 Å, and clearly indicates the β-hairpin 
shaped fold of residues close to the template (Figure 20). The 3JHNHα coupling constants of 
most of the amide protons were in the range of 6-8 Hz correlating with fast conformational 
exchange, except for the N-terminal residues 1, 2, and 4, which exhibit values > 8 Hz – 
suggestive of predominantly extended conformation in this region.[90] The temperature 
coefficients of chemical shifts of amides Thr1, Ala11, and Lys12 were < 4 ppb/K which may be 
due to intermolecular hydrogen bonding (between Thr1 and Lys12), or solvent-shielding effects 
in the case of Ala11, whereas all other amides show significantly higher Δδ/ΔT shifts, reflecting 
the exposed nature of these protons (Figure 24).[91] Further, the lower exchange rates of Thr1 
and Lys12 agree with the low Δδ/ΔT observations. 
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Figure 20 Backbone trace of 20 selected NMR structures of Orn5NMe superimposed to the backbone atoms of 
Dab10-Pro14, Thr1-Leu3 (left) and a single representative NMR structure with side-chains in ball-and-stick (right). 
Hydrogen and carbonyl-oxygen are omitted to simplify the view. The N-methyl group was highlighted in magenta. 
 
Solution structure of Ala11NMe. The replacement of the amide proton by a methyl group at 
position 11, results in a complete loss of antimicrobial activity (cf. Figure 17). The comparison 
of the 1D 1H spectra of Ala11NMe and LB-01 show high similarity in the dispersion of the NH 
resonances (over a region of 1.2 ppm). The shifts of the amide proton signals (Figure 19) 
suggest a similar structure in aqueous solution. The comparison of the Hα CSDs (Figure 23) 
show the same or slightly stronger tendency of positive values between Trp2-Orn5 and Trp8-
Lys12. The resonance assignment of the 2D NOESY/ROESY spectra provides a consistent 
network of medium and long range NOEs. From the NOE distance restraints, a close bundle 
of average solution structures was calculated with a backbone rmsd of 0.4 Å (Table 7). The 
analogue adopts a well-defined β-hairpin structure in aqueous solution (Figure 21). 
Characteristic backbone cross-strand NOEs were observed, in particular HN-HN between 
Thr1-Lys12, Hα-Hα NOEs between Trp2-Ala11, and HN-Hα between Leu3-Orn9. Further, 
numerous cross-strand backbone side-chain and side-chain side-chain NOEs between Trp2-
Ala11, Trp2-Orn9, Leu3-Trp8, Leu3-Dab10, and Orn5-Trp8 support the stable β-hairpin fold of 
Ala11NMe. The conformation of the tip region at DLys6 and Arg7 is characterized by two strong 
sequential backbone NOEs HN-HN between Arg7-Trp8 and Hα-HN between DLys6-Trp8, 
suggesting the formation of a β-turn. The NMR structure exhibits a type II’ β-turn with backbone 
torsion angles (Φi+1, Ψi+1) of (81.2 ± 9.5, -89.7 ± 17.4) and (Φi+2, Ψi+2) of (-108.8 ± 18.3, -8.2 ± 
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3.5). The low temperature coefficients of NH chemical shifts (-Δδ/ΔT > 5) at hydrogen bonding 
positions 1, 5, 8, and 10, as well as slower H/D exchange rates of residue 1, 3, 12, and 8 
support the β-hairpin conformation (Figure 24). Finally the 3JHNHα coupling constants display 
values > 8 Hz for the majority of β-strand hosted residues, indicating extended backbone 
conformation. Interestingly, despite the stable β-hairpin fold in aqueous solution, the 
peptidomimetic is completely inactive. This leads to the conclusion that the amide group at 
position 11 is involved in the binding to the target protein. In the β-hairpin register, the group 
points outward and is basically not involved in the intramolecular hydrogen bonding 
interactions. However, it can form hydrogen bonds with the protein target (e.g. β-barrel or β-
jelly-roll proteins) to stabilize the peptide-LptD complex. 
 
Figure 21 Backbone trace of 20 selected NMR structures of Ala11NMe superimposed to all backbone atoms (left) 
and a ribbon representation of a single representative NMR structure with side-chains in ball-and-stick (right). 
Hydrogen and Carbonyl-Oxygen are omitted to simplify the view. The N-methyl group was highlighted in magenta. 
 
Solution structure of Thr1NMe. Residues at position 1 normally occupy a hydrogen-bonding 
position, which is formed cross-strand between the amide and carbonyl group of Thr1 and 
Lys12 (cf. Figure 18). Due to the replacement of the amide proton here by a methyl group, the 
intramolecular hydrogen bond cannot be formed. The 1D 1H spectrum shows well dispersed 
NH doublets in the amide proton region, with a remarkable downfield shift of an amide proton 
resonance (9.2 ppm) assigned to Trp2 (Figure 19). The Hα CSDs of Thr1NMe exhibit 
significant differences in comparison to LB-01 (Figure 23). Most striking is the fact that there 
is no continuous segment of at least three residues with positive or negative Hα CSDs in the 
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sequence, indicating the absence of regular secondary structure elements. In contrast to 
Ala11NMe, most of the observed NOEs in the NOESY spectrum were intraresidual or 
sequential. Only weak medium and long range NOEs could be observed, indicating that the 
cyclic peptide adopts non-regular secondary structures or is more flexible in aqueous solution. 
Furthermore, the observed NOEs indicate proton-proton connectivities, that are not typical for 
a regular β-hairpin nucleated by the DPro-LPro template. In particular HN-HN NOEs between 
Leu3-Orn9, Hα-Hα NOEs between Trp2-Dab10, and HN-Hα NOEs between Leu3-Dab10, 
Orn2-Trp2 were observed. Those backbone NOEs suggest a shifted residue pairing with Trp2 
and Dab10 on a non-hydrogen bonding position. Based on the NOE distance restraints, the 
calculated average NMR structures have a backbone rmsd of 1.5 Å (Figure 22 and Table 7). 
Despite the spatial orientation of the side-chains that cannot be correlated with a regular β-
hairpin structure, two pairs of residues in the middle of the fold – namely Trp2-Dab10 and 
Leu3-Orn9 – get closer in contact, resulting in the “eight-shaped” overall fold of Thr1NMe. The 
side-chains of the neighbouring residues Ala11 and Lys12 are pointed to the same side, 
forming a backbone bulge close to the template. The coupling constants 3JHNHα of most of the 
amide protons lie in the range of 6-8 Hz, suggestive of rapidly interconverting conformers that 
coexist in solution (Figure 24). The low temperature coefficients of Orn9 and Ala11, with values 
of 1.8 and 3.2 ppb/K respectively are consistent with the calculated NMR structures. The Orn9 
NH appears to be shielded from the solvent by the aliphatic Leu3 side-chain on top and the 
Trp2 side-chain on the other site. The amide proton of the Ala11 residue is pointed to Thr1 
carbonyl allowing hydrogen bond formation. 
 
Figure 22 Backbone trace of 20 selected NMR structures of Thr1NMe superimposed to all backbone atoms (left) 
and a single representative NMR structure with side-chains in ball-and-stick representation (right). Hydrogen and 
carbonyl-oxygen are omitted to simplify the view. The N-methyl group was highlighted magenta. 
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Figure 23 Hα chemical shift deviations (CSDs) from tabulated random coil values[50]. The bars were not displayed 
for N-methylated residues, because Hα shifts are strongly influenced by N-methylation. 
 
 
Table 7 Experimental distance restraints and statistics for the final 20 NMR structures calculated for Thr1NMe, 
Orn5NMe and Ala11NMe. 
 Thr1NMe Orn5NMe Ala11NMe 
Number of NOE upper-distance 
limits: 
 
Intraresidue: 
Sequential: 
Medium- and long-range: 
 
160 
 
73 
61 
26 
 
250 
 
141 
62 
47 
 
188 
 
79 
53 
56 
Residual target function value (Å2): 0.12 ± 0.04 0.26 ± 0.15 0.69 ± 0.11 
Mean rmsd values (Å) 
All backbone atoms: 
All heavy atoms: 
 
1.47 ± 0.45 
3.06 ± 0.86 
 
1.30 ± 0.34 
2.54 ± 0.60 
 
0.45 ± 0.13 
0.96 ± 0.19 
Residual NOE violations 
Number > 0.2 Å: 
Maximum (Å): 
 
0 
0.17 
 
6 
0.36 
 
2 
0.38 
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Figure 24 Coupling constants 3JHNHα temperature coefficients Δδ/ΔT of amide NH resonances, and relative peptide 
NH exchange rates (open circle = fast, half-filled = slower, filled = slowest) for residues 1-12 of Thr1NMe, Orn5NMe 
and Ala11NMe (nd – determination not possible due to significant resonance overlap). 
 
 
3.1.8 Circular Dichroism 
The far-UV CD spectra of all N-methylated analogues are shown in Figure 25, grouped into 
three diagrams according to signal intensity and the shape of the graph with respect to LB-01. 
As judged from the signal intensities at 215 nm, the peptidomimetics Ala11NMe, Arg7NMe, 
and DLys6NMe (group 1) showed similar graphs as LB-01, indicating that the β-hairpin fold 
remains stable in these analogues. Slightly reduced signal intensities were observed for 
Orn5NMe, Dab4NMe, Trp2NMe, and Lys12NMe (group 2), which suggests that the β-hairpin 
content is lower than that of group 1 compounds. Much lower signal intensities were observed 
for Orn9NMe and Dab10NMe, whereas Thr1NMe, Leu3NMe, and Trp8NMe exhibited a 
distinctly reduced and shifted negative band (group 3). In the latter compounds, the β-hairpin 
fold appears to be no longer populated in aqueous solution. The results are in good agreement 
with the one-dimensional NMR spectra (Appendix 6.2) and the NMR structure determinations 
of selected analogues described above. 
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Figure 25 Far-UV CD spectra of N-methylated analogues, comparing β-hairpin propensity to the reference 
compound LB-01 (thick black line). Molar ellipticity in deg*cm2/dmol. 
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3.1.9 Additional Modifications at Positions Dab4 and Orn5 
Due to the high activity observed with N-methyl analogues Dab4NMe and Orn5NMe, the 
positions 4 and 5 were chosen as interesting sites for further modifications. An ethyl group and 
an aromatic benzyl group were introduced respectively by the Kessler method described 
above, with ethanol (Et) and benzyl alcohol (Bz) as the donor groups. The introduction of an 
ethyl group retained activity, whereas the introduction of a benzyl group led to a drop in activity, 
especially in the case of Dab4NBn. Peptoids were introduced to study the influence of chirality 
at positions 4 and 5. In a peptoid, the amino acid side-chain is directly attached to the nitrogen 
of the peptide bond, instead of the α-carbon as in regular peptides. The solid phase synthesis 
of peptoids was first described by Simon et al.[16] in 1992 as part of the drug discovery of 
protease stable peptidomimetics. Peptoid analogues of LB-01 were synthesized according to 
the refined method of Zuckermann[92]. Exemplified here for the synthesis of NDab4 (Scheme 
5), the peptoid was installed in two steps; acylation and SN2 displacement. In the acylation 
step, bromoacetic acid was activated by diisopropyl-carbodiimide (DIC) and reacted with the 
free amine of the previous residue. In the following SN2 reaction, the amine displaced the 
bromide to form the N-substituted residue. The subsequent amino acid was coupled under 
standard conditions onto the sterically hindered amine with HATU/HOAt. The NDab4 peptoid 
showed lower activity compared to Dab4NMe, whereas the NOrn5 peptoid retained its activity, 
indicating that the chirality of the ornithine side-chain is not essential for activity. A double and 
a triple N-methylated analogue was synthesized and subjected to MIC testing. For those two 
analogues, the MIC was determined by a new protocol in MH-II instead of MH-I, which leads 
to an approximately 8-fold higher MIC value in general. Whereas the activity for the double 
methylated 4,5-NMe analogue remained high, a significant drop in activity was observed for 
the triple methylated 4,5,6-NMe analogue. A third N-methylation at position 6 therefore seems 
to be detrimental to high activity. The purity of all analogues was confirmed by UPLC analysis 
(Figure 26) and the identity by HR-ESI (Table 8). MIC values of all analogues were determined 
on P. aeruginosa ATCC27853 and PAO1 and are also summarized in Table 8. 
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Scheme 5 a) Bromoacetic acid, DIC, DMF, 1 h. b) N-Boc-ethylenediamine, DMF, overnight. c) HATU/HOAt, DIPEA, 
Fmoc-Orn(Boc)-OH, DMF, 2 h. 
 
 
Figure 26 UPLC chromatograms at 226 nm wavelength, run with a linear gradient of 10 to 40% MeCN/H2O with 
additional 0.1% TFA on a C18 reverse-phase column. 
  
Results and Discussion 
44 
Table 8 Antimicrobial activity of different LB-01 analogues modified at position 4 and 5 tested on P. aeruginosa 
(PA) ATCC27853 and PAO1 and calculated mass and experimental m/z values measured by high resolution ESI. 
The two analogues, indicated by a star (*), were tested in MH-II with addition of 0.002% Tween80, all others in MH-
I with addition of 0.02% BSA. 
Analogue 
PA ATCC27853 
[µg/ml] 
PA PAO1 
[µg/ml] 
Exact mass 
(calc.) 
m/z 
(HR-ESI) 
Dab4NEt 0.008 0.009 
574.3549 
[M+3H]3+ 
574.3555 
[M+3H]3+ 
Orn5NEt 0.012 0.009 
574.3549 
[M+3H]3+ 
574.3544 
[M+3H]3+ 
Dab4NBn 1.5 0.5 
446.5221 
[M+4H]4+ 
446.5227 
[M+4H]4+ 
Orn5NBn 0.05 0.015 
446.5221 
[M+4H]4+ 
446.5231 
[M+4H]4+ 
NDab4 (peptoid) 0.15 1.5 
424.0103 
[M+4H]4+ 
424.0106 
[M+4H]4+ 
NOrn5 (peptoid) 0.005 0.02 
424.0103 
[M+4H]4+ 
424.0093 
[M+4H]4+ 
4,5-NMe* 0.05 0.06 
431.0176 
[M+4H]4+ 
431.0180 
[M+4H]4+ 
4,5,6-NMe* 1 12 
434.5215 
[M+4H]4+ 
434.5217 
[M+4H]4+ 
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3.1.10 Cellular Uptake 
Since LB-01 shares many characteristics with known CPPs, namely its size, net positive 
charge of +7, and a non-lytic mechanism of action, it makes an interesting candidate to study 
its delivery and uptake into mammalian cells. The eukaryotic model cell line HeLa was used to 
study the cellular uptake of fluorescence-labelled LB-01. Two labelled LB-01 analogues were 
synthesized: LB-01-FL with a fluorescein coupled to azidolysine and LB-01-AF647 with an 
Alexa Fluor® 647 red dye, coupled to a glutamic acid PEG3-azide linker (Figure 27). Both 
fluorophores were coupled via Click Chemistry (cf. Experimental Part 4.4). at position 1 of the 
scaffold, which has been used before in studies of antibacterial analogues for the introduction 
of different linkers.[46] The purity of the two compounds was confirmed by UPLC (Figure 28) 
and its identity by HR-ESI (Table 9). Commercially available Tat-FITC (Anaspec) served as a 
positive control in the experiment. The FITC (fluorescein isothiocyanate) fluorophore exhibits 
the same spectral properties as regular fluorescein, facilitating the comparison and 
quantification between the two probes. The Tat sequence 47-57 (YGRKKRRQRRR) in Tat-
FITC is a well-studied CPP with a high transduction rate.[93] 
 
 
Figure 27 Fluorescence-labelled LB-01 analogues LB-01-AF647 and LB-01-FL as well as commercially available 
Tat-FITC. 
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Figure 28 UPLC chromatograms of LB-01-AF647 and LB-01-FL at 226 nm wavelength, run with a linear gradient 
of 10 to 40% MeCN/H2O with additional 0.1% TFA on a C18 reverse-phase column. 
 
Table 9 Calculated mass and experimental m/z values of the two compounds measured by high-resolution ESI. 
Analogue Exact mass (calc.) m/z (HR-ESI) 
LB-01-AF647 521.0835 [M+5H]5+ 521.0825 [M+5H]5+ 
LB-01-FL 540.5423 [M+4H]4+ 540.5427 [M+4H]4+ 
 
 
Confocal fluorescence microscopy. HeLa cells were incubated with 10-20 µg/ml of the 
individual labelled compound, fixed by paraformaldehyde, mounted with DAPI (4',6-diamidino-
2-phenylindole)[94] containing mounting media, and analysed by fluorescence microscopy at 
the Center of Microscopy and Image Analysis (ZMB) at UZH. The blue dye DAPI used for DNA 
staining, distinctly highlighted the nucleus of each individual cell as expected. Both Tat-FITC 
and LB-01-FL at concentrations of 20 µg/ml led to an equal distribution of green fluorescence 
inside the cells (Figure 29 and Figure 30). Equally, LB-01-AF647 at a concentrations of 
10 µg/ml exhibited bright red fluorescence (Figure 31). All three fluorescence-labelled 
compounds were therefore efficiently taken up and distributed inside the cells under these 
experimental conditions. 
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Figure 29 HeLa cells treated with 20 µg/ml Tat-FITC (green) and nucleic acid stain DAPI (blue). 
 
 
 
Figure 30 HeLa cells treated with 20 µg/ml LB-01-FL (green) and nucleic acid stain DAPI (blue). 
 
 
 
Figure 31 HeLa cells treated with 10 µg/ml LB-01-AF647 (red) and nucleic acid stain DAPI (blue). 
 
  
Results and Discussion 
48 
Cell lysis assay. A cell lysis assay was performed to quantify the amount of fluorescence-
labelled compound LB-01-FL taken up by the cells in direct comparison to Tat-FITC. HeLa 
cells were grown and incubated with the individual compound in triplicate at a concentration of 
6.4 µM for 1 h. Cell lysis was performed, and the lysate was analysed on a fluorescence 
intensity plate reader to determine the concentration of fluorescence-labelled compounds 
inside the cells (Figure 32). The concentrations were 118 ± 25 nM for Tat-FITC and 69 ± 8 nM 
for LB-01-FL. Hence, Tat-FITC has an approximately 40% higher transduction rate than LB-
01 into HeLa cells. 
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Figure 32 Quantified uptake of Tat-FITC compared to LB-01-FL into HeLa cells. 
 
These results confirm the uptake of LB-01-FL into HeLa cells. Although Tat-FITC exhibits a 
significantly higher transduction rate than LB-01-FL, the LB-01 scaffold could be potentially 
used as a non-toxic delivery vehicle into eukaryotic cells. 
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3.1.11 Conclusion 
A reliable synthetic strategy has been applied to synthesize mono and multiple N-methylated 
LB-01 analogues in high purity of > 95% and yields of 3-15% (Scheme 2). The dipeptide Fmoc-
Pro-N-Me-Thr(OtBu)-OH was successfully synthesized in a good overall yield of 59% over 
three steps (Scheme 4) and incorporated into the sequence of analogue LB-01-ThrNMe. A 
wide range of MIC values were obtained for the twelve analogues in a complete N-methyl scan 
(Figure 17). The antimicrobial activity was correlated to the ability to fold a stable β-hairpin by 
utilising NMR analysis and CD spectroscopy data. However, not only the correct fold of the β-
hairpin was shown to be important for high antimicrobial activity, as previously anticipated. 
Several outward facing NH groups were also crucial. Since they were sensitive to N-
methylation, they likely participate in H-bonding interaction with the target protein LptD. A 
model was proposed, in which LB-01 interacts by antiparallel strand-strand interaction with a 
β-rich sequence in LptD (Figure 18). Additional modifications were introduced at position 4 and 
5 of the scaffold in form of ethyl and benzyl groups, and the regular side-chains were 
substituted by peptoids. Also, a double and a triple N-methylated analogue was synthesized. 
However, a clear trend could not be concluded from this, since most of the analogues retained 
high or moderate activity. During the course of this work, progress has been made by Gloria 
Andolina in localizing the binding site in LptD, which is now believed to be at the approximately 
90 residue insert domain found in P. aeruginosa spp. This insert domain is unique for the 
Pseudomonas family, but not found in other Gram-negative bacteria, possibly explaining its 
selective activity towards this family. A crystal structure of the full Pseudomonas LptD 
sequence and a co-crystal together with L27-11/LB-01 is still highly desirable, but proved to 
be exceptionally difficult to obtain. Binding studies of this interaction are currently ongoing. The 
cellular uptake of a fluorescence-labelled LB-01 analogue into mammalian HeLa cells has 
been confirmed by confocal fluorescence microscopy and a quantitative lysis assay (Figure 30 
and Figure 32). Although the transduction rate was lower than the reference compound Tat-
FITC, the LB-01 scaffold displays all the characteristics previously described for cell 
penetrating peptides. However, the influence of N-methylation on the transduction rate remains 
to be investigated. 
 
  
Results and Discussion 
50 
3.2 Thanatin 
3.2.1 Synthesis and Analysis of Thanatin 
Thanatin (GSKKPVPIIYCNRRTGKCQRM, Figure 33) was synthesized following the 
procedure of Fehlbaum et al.[71]. The enantiomeric D-thanatin was synthesized analogously 
with D-amino acids. The purity of the two compounds was confirmed by UPLC analysis (Figure 
34) and the identity by HR-ESI (Table 10). A 1H NMR spectrum was recorded for thanatin 
(Figure 35). 
 
Figure 33 Thanatin drawn in a hairpin structure. 
 
 
Figure 34 UPLC chromatograms of thanatin and D-thanatin at 226 nm wavelength, run with a linear gradient of 
10 to 40% MeCN/H2O with additional 0.1% TFA on a C18 reverse-phase column.  
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Table 10 Calculated mass and experimental m/z values of thanatin and D-thanatin measured by high resolution 
ESI. 
Analogue Exact mass (calc.) m/z (HR-ESI) 
Thanatin 487.4621 [M+5H]5+ 487.4620 [M+5H]5+ 
D-thanatin 487.4621 [M+5H]5+ 487.4635 [M+5H]5+ 
 
 
 
Figure 35 1H-NMR spectrum of thanatin. 
 
3.2.2 Design of a Stabilized Thanatin β-Hairpin 
In an attempt to improve the antimicrobial activity and the metabolic stability towards 
proteases, the β-hairpin moiety and the flexible N-terminal domain of thanatin were 
transformed into a more rigid, backbone circular molecule by introduction of the well-
established DPro-LPro template. Since the N-terminal truncated isoforms of thanatin retained 
activity as demonstrated by Fehlbaum et al.[71] (cf. Introduction 1.10), the idea was to use Pro5 
as an anchor to introduce the DPro-LPro template at this position, and move the two Lys 
residues at position 3 and 4 to the other side of the hairpin (Figure 36). The compound was 
synthesized according to the method of Srinivas et al.[46]. The purity of the compound was 
confirmed by UPLC analysis (Figure 37) and the identity was verified by HR-ESI with a 
calculated mass of 592.8229 [M+4H]4+ and a measured m/z value of 592.8224 [M+4H]4+. 
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Figure 36 Design of a fully circular thanatin β-hairpin. A DPro-LPro template is introduced and the two Lys residues 
(red) moved to the other side of the molecule. 
 
 
 
Figure 37 UPLC chromatogram of the circular thanatin hairpin at 226 nm wavelength, run with a linear gradient of 
10 to 40% MeCN/H2O with additional 0.1% TFA on a C18 reverse-phase column. 
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3.2.3 Antimicrobial Activity 
Antimicrobial activity of thanatin on E. coli ATCC25922 was determined by the MIC 
microdilution method, yielding an MIC value of 0.5 µg/ml. Enantiomeric D-thanatin was 
confirmed inactive (> 64 µg/ml). Native thanatin and the newly designed hairpin were tested 
on a series of Gram-positive and Gram-negative bacteria available in our lab. With the 
exception of Bacillus subtilis DMSZ with a mediocre MIC of 8 μg/ml, none of the treated 
bacteria in Table 11 showed any response to these two compounds. 
 
Table 11 MIC values of native thanatin compared to the designed circular hairpin. Values were determined by 
microdilution in MH-II with addition of 0.002% Tween80. 
MIC [μg/ml] Native thanatin Thanatin hairpin 
A. baumanii >64 >64 
S. aureus >64 >64 
P. aeruginosa PAO1 >64 >64 
P. aeruginosa ATCC27853 >64 >64 
Burkholderia cenocepacia >64 >64 
Bacillus subtilis DSMZ 8 >64 
 
The two compounds were further tested on a series of clinical E. coli isolates with broad 
antimicrobial resistance.[29] Although native thanatin exhibits good activity against all of them 
except E. coli 2144E/2155 (colistin resistant), the hairpin remained completely inactive (Table 
12). Unfortunately this particular hairpin design did not lead to improved antimicrobial 
properties and was therefore abandoned. Studies were continued with native thanatin. 
 
Table 12 MIC values of native thanatin and the designed hairpin compared against clinical E. coli isolates (adapted 
from Urfer et al.)[29]. Values were determined by microdilution in MH-II with addition of 0.002% Tween80. 
Strain/antibiotic 
E. coli 
ATCC 
25922 
E. coli 
2138E/ 
2151 
E. coli 
2139E/ 
2152 
E. coli 
2140E/ 
2153 
E. coli 
2143E/ 
2154 
E. coli 
2144E/ 
2155 
E. coli 
3459E/ 
2150 
Thanatin 0.5 0.5 0.5 0.5 1 >32 0.5 
Thanatin hairpin >32 >32 >32 >32 >32 >32 >32 
Colistin 0.12 0.12 0.03 0.06 0.06 16 0.06 
Gentamycin 0.5 1 0.5 8 1 0.06 1 
Ceftriaxone 0.06 0.06 0.06 0.06 0.12 1 >64 
Ampicillin 16 >64 >64 >64 >64 0.12 >64 
Rifampicin 32 64 64 64 >64 0.12 8 
Erythromycin >64 >64 64 64 64 0.12 >64 
Azithromycin 8 8 4 8 4 1 4 
Ciprofloxacin 0.008 0.12 0.02 0.01 0.02 0.25 0.12 
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3.2.4 Sytox® Green Assay in MH-I 
Sytox® Green is a dye commonly used to measure cell viability and susceptibility to certain 
antibiotics.[95] The fluorescent dye does not penetrate living cells. However, cells with 
compromised plasma membranes allow access of the dye to the cytoplasm, which then 
fluoresces bright green upon interaction with nucleic acids. Polymyxin B is a known membrane 
permeabilizer and served as a positive control in the following experiments. Although its 
mechanism of action is still under investigation, it has been shown that cationic polymyxin B 
interacts with the negatively charged lipid A component of LPS, displacing divalent cations 
such as Ca2+ and Mg2+, leading to a destabilization of the outer membrane.[96] The effect of 
thanatin on E. coli ATCC25922 cells was measured at a high concentration of 100 μg/ml, which 
is significantly above the MIC. Every spectrum is the mean value of three measurements 
performed under the same conditions with different cultures over the course of 1 h (Figure 38). 
The three graphs were normalized to the baseline signal at 440 s. This was done to account 
for the variations in background signal, stemming from the MH-I media and its residual DNA. 
 
Figure 38 Fluorescence increase of E. coli ATCC25922 cells in MH-I treated with polymyxin B and thanatin in 
presence of Sytox® Green. Control with cells and Sytox® Green but no addition of antibiotics. Signal intensity is 
normalized to the baseline signal at 440 s. 
E. coli cells were mixed with Sytox® Green in MH-I medium and fluorescence intensity was 
monitored until a stable signal was obtained. Then, addition of polymyxin B at a concentration 
of 1 μg/ml led to a fast increase of fluorescence by interaction of Sytox® Green with nucleic 
acid, indicating a strong permeabilization of the inner and outer membrane. As expected, no 
fluorescence increase was monitored for the negative control, which contained no antibiotic. 
Even though thanatin was added at a high concentration of 100 μg/ml, it did not lead to any 
increase in fluorescence, showing that the dye is unable to access the cytoplasm of the cell.  
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3.2.5 Sytox® Green Assay in HEPES Buffer 
In order to repeat the assay in a medium-free environment with a low nucleic acid background, 
5 mM HEPES ((4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid)[97] at pH 7.2 was chosen. 
Under these conditions, cells are not able to grow, while remaining intact over the course of a 
number of hours. Ciprofloxacin is an inhibitor of DNA replication and served as a negative 
control. Its mechanism of action comprises binding to topoisomerase II (DNA-gyrase) and 
topoisomerase IV resulting in strong antimicrobial activity against a wide range of Gram-
negative and certain Gram-positive bacteria.[98,99] The effect of thanatin and D-thanatin on 
E. coli ATCC25922 cells was measured at concentrations of 10 μg/ml and 100 μg/ml. Every 
spectrum is the mean value of three measurements performed under the same conditions with 
different cultures (Figure 39). 
 
 
Figure 39 Fluorescence increase of E. coli ATCC25922 cells in HEPES (5 mM, pH 7.2) treated with polymyxin B, 
thanatin and D-thanatin in presence of Sytox® Green. 
 
Addition of polymyxin (1 μg/ml) led to a fast increase in fluorescence similar to the experiment 
performed in MH-I (cf. Figure 38), though the plateau was reached later. Addition of 
ciprofloxacin (0.08 μg/ml) or H2O (control) did not lead to any increase of fluorescence, 
confirming the assumption that the membrane stayed intact over the 1 h measurement. 
Thanatin and D-thanatin both led to a similar, small increase in fluorescence with an 
approximately two-fold higher signal for the 100 μg/ml concentration compared to 10 μg/ml. 
Since the D-enantiomer of thanatin is completely inactive against E. coli ATCC25922, it is 
apparent that the observed effect was not caused by a stereospecific interaction with a target. 
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To test whether this observed fluorescence increase is caused by an inherently weakened 
membrane, the HEPES buffer (5 mM, pH 7.2) was supplemented with MgCl2 (0.5 mM) and 
CaCl2 (1 mM). This was done in order to strengthen the outer membrane by introducing 
divalent cations (i.e. Mg2+ and Ca2+), which are known to bridge and stabilize the LPS outer 
membrane monolayer.[96] The effects of polymyxin B (1 μg/ml), thanatin, and D-thanatin (both 
100 μg/ml) treatment were determined under the same experimental conditions as described 
above. 
 
Figure 40 Fluorescence increase of E. coli ATCC25922 cells in HEPES (5 mM, pH 7.2) supplemented with MgCl2 
(0.5 mM) and CaCl2 (1 mM) treated with polymyxin B, thanatin and D-thanatin in presence of Sytox® Green. 
 
The addition of polymyxin (1 μg/ml) led to an initially slower increase in fluorescence compared 
to the experiment described above (cf. Figure 39), although a similar intensity of approximately 
400 units was reached after 1 h. For thanatin and D-thanatin (both 100 μg/ml), no fluorescence 
increase was observed.  
These results lead to the conclusion, that the mechanism of action of thanatin does not involve 
full membrane permeabilization under physiological conditions. 
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3.2.6 β-Galactosidase Assay 
An assay that gives additional information on membrane permeabilization is the measurement 
of β-galactosidase activity towards ONPG (o-nitrophenyl-β-galactoside), a glycoside which can 
be used in colorimetric assays.[100] The E. coli ML-35::pET3a clone used in this experiment 
exhibits a constitutive (chromosomal) β-galactosidase expression in the cell cytoplasm and is 
permease deficient.[101] Release of β-galactosidase into the culture media, due to 
permeabilization of the membrane, can be detected by hydrolysation of the OPNG substrate 
into yellow coloured ortho-nitrophenol and D-galactose. The effect of protegrin-1 – a known 
lytic peptide – and thanatin were determined at different concentrations. Ciprofloxacin – an 
inhibitor of DNA replication – served as a negative control. Data points were averaged from 
three independent experiments (Figure 41). 
 
Figure 41 β-Galactosidase assay with ONPG (o-nitrophenyl-β-galactoside) as substrate on E. coli ML-35::pET3a 
grown in MH-II media. Light absorption is measured at 420 nm. The green dashed line represent the 100% cell 
permeabilization (lysed cells). 
 
Protegrin-1 led to a strong release of intracellular β-galactosidase, reaching the 100% plateau 
achieved by sonication of a control sample, at concentrations higher than 2.5 μg/ml. As 
expected, ciprofloxacin, with its non-lytic mechanism of action, showed no β-galactosidase 
activity. Thanatin had no effect on the β-galactosidase release, indicating no permeabilization 
of the inner and outer membrane.  
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3.2.7 β-Lactamase Assay 
Selective permeabilization of the outer membrane was measured by periplasmatic β-
lactamase activity towards CENTA, a chromogenic β-lactamase substrate.[102] The E. coli ML-
35::pET3a clone described above was also used for this experiment, since the pET3a plasmid 
carries the necessary bla gene coding for β-lactamase. Using this clone, β-lactamase is 
produced and excreted into the periplasm. Hence, any antibiotic that permeabilizes the outer 
membrane will lead to a release of the enzyme into the culture medium, where its activity can 
be detected using CENTA. Data points were averaged from three independent experiments 
with protegrin-1, thanatin, and ciprofloxacin (Figure 42). 
 
Figure 42 β-Lactamase assay with CENTA as a substrate on E. coli ML35::pET3a grown in MH-II media. Light 
absorption is measured at 405 nm. The green dashed line represents 100% cell permeabilization (lysed cells). 
 
Similar to the β-galactosidase assay (cf. Figure 41), protegrin-1 showed a strong release of 
periplasmatic β-lactamase at concentrations higher than 2.5 μg/ml, with a stable plateau equal 
to the 100% maximum. As expected, ciprofloxacin exhibited non-lytic behaviour and therefore 
no effect on β-lactamase release. Thanatin also has no effect on the β-lactamase release. 
Taken together, thanatin does not seem to have any perturbation effect on the outer nor the 
inner membrane. 
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3.2.8 Macromolecular Synthesis Assay 
The following study was carried out in collaboration with Matthias Urfer. Potential inhibition on 
macromolecular synthesis (i.e. DNA, RNA, proteins, cell wall) was monitored by incorporation 
of [3H]-labelled precursors in a defined medium (DM) in E. coli ATCC25922 using [3H]-
thymidine, [3H]-uridine, [3H]-leucine, and [3H]-N-acetylglucosamine. Control experiments were 
performed with known inhibitors of DNA-synthesis (tobramycin[103]), RNA-polymerase 
(rifampicin[104]), cell wall biosynthesis (ceftriaxone[105]), and protein biosynthesis 
(ciprofloxacin[98]). The observed effects are shown in Figure 43. 
 
Figure 43 The effect of reference antibiotics tobramycin (A), rifampicin (B), ceftriaxone (C), and ciprofloxacin (D) 
targeting macromolecular synthesis in E. coli ATCC25922. Incorporation of [3H]-precursors of DNA (circles), RNA 
(triangles), protein (squares), and cell wall (diamonds) were examined. The MIC value for each compound is 
indicated by a vertical red dashed line. 
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In the case of thanatin, no effects upon the incorporation of labelled precursors into DNA, RNA, 
and proteins were observed in three individual experiments (Figure 44). However, the 
incorporation of [3H]-N-acetylglucosamine was significantly higher than in the control 
experiments, suggesting a stimulation of the incorporation of this precursor, possibly into 
components of the polysaccharide coat at the cell surface, or into precursors for LPS 
biosynthesis. 
 
 
Figure 44 The effect of thanatin on the macromolecular synthesis in E. coli ATCC25922 of three individual 
experiments. Incorporation of [3H]-precursors of DNA (circles), RNA (triangles), protein (squares), and cell wall 
(diamonds) were examined. An MIC value of 0.25 μg/ml is indicated by a vertical red dashed line. 
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3.2.9 Live Cell Fluorescence Microscopy 
The effect of thanatin on live E. coli ATCC25922 cells was studied by confocal fluorescence 
microscopy. Images were recorded at the Center of Microscopy and Image Analysis (ZMB) 
UZH by Matthias Urfer. The red dye FM4-64[106] was used to highlight membranes and the blue 
dye DAPI was used for DNA staining. Sytox® Green was used to identify dead cells. An 
untreated sample is shown in Figure 45. The cells exhibit a well-rounded shape of single cells 
or paired cells with a distinct membrane. No detection in the Sytox® Green channel indicated, 
that all cells were alive during imaging. 
 
 
Figure 45 Untreated sample of E. coli ATCC25922 with FM4-64 membrane staining (red), DAPI staining of DNA 
(blue) and Sytox® Green for dead cells staining. 
 
Thanatin was added in a concentration of 5 μg/ml and the cells were incubated for 1 h at 30°C 
before imaging. Two obvious differences could be observed compared to the untreated 
sample: An accumulation of unusual membrane-like material highlighted by bright red knobs 
stained with FM4-64 and an assembly of multiple cells in elongated structures (Figure 46). This 
assembly can likely be explained by a general stress response and/or difficulties to separate 
after cell division. However, no permeabilization of the membrane was observed due to lack 
of a signal in the Sytox® Green channel. 
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Figure 46 Two sets of images with thanatin (5 μg/ml) treated sample of E. coli ATCC25922 with FM4-64 membrane 
staining (red), DAPI staining of DNA (blue), and Sytox® Green for dead cells staining. Arrows highlight multiple cells 
in elongated structures and difficulties to separate after cell division. 
 
With higher concentrations of thanatin (10 μg/ml), the elongation effect became even more 
apparent. A weak signal in the Sytox® Green channel in the bottom left picture was detected 
(Figure 47), indicating dead cells. 
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Figure 47 Thanatin (10 μg/ml) treated sample of E. coli ATCC25922 with FM4-64 membrane staining (red), DAPI 
staining of DNA (blue) and Sytox® Green for dead cells staining. Arrow highlights multiple cells in elongated 
structure and difficulties to separate after cell division. 
 
 
3.2.10 Fluorescence Microscopy with Probe Thanatin-BDP-FL 
A fluorescent probe of thanatin was synthesized by coupling a BODIPY[107] fluorophore at the 
N-terminus (thanatin-BDP-FL, Scheme 6). This probe was used for confocal fluorescence 
imaging of paraformaldehyde fixed E. coli ATCC25922 cells. The spectral properties of BDP-
FL are similar to fluorescein with higher photostability and good water solubility. The linear 
thanatin sequence was synthesized as described earlier and then a commercially available 
PEG (polyethylene glycol) spacer carrying an alkyne group (propargyl-PEG4-acid, 
Broadpharm) was coupled on-resin under standard conditions with HATU/HOAt. After 
cleavage from the resin, oxidation, and purification of the intermediate by preparative HPLC, 
BDP-FL-azide (Lumiprobe) was coupled by Click Chemistry as described later (Experimental 
Part 4.4). The purity of thanatin-BDP-FL was confirmed by UPLC (Figure 48) and its identity 
by HR-ESI with a calculated mass of 763.1505 [M+4H]4+ and an experimental m/z value of 
763.1500 [M+4H]4+. The molecule also showed good antimicrobial activity with an MIC of 
0.5 - 2 μg/ml on E. coli ATCC25922. 
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Scheme 6 Synthesis of fluorescent probe thanatin-BDP-FL: a) Piperidine:DMF (1:3), then propargyl-PEG4-acid, 
HATU, HOAt, DIPEA, DMF. b) TFA:EDT:thioanisole:H2O:TIS (75:10:10:4:1), then oxidation by air in 0.1 M 
ammonium acetate pH 8.5. c) BDP-FL-azide, CuSO4, sodium ascorbate, DMSO:H2O (1:5). 
 
Figure 48 UPLC chromatogram of thanatin-BDP-FL at 226 nm wavelength, run with a linear gradient of 10 to 
40% MeCN/H2O with additional 0.1% TFA on a C18 reverse-phase column. 
Results and Discussion 
65 
E. coli ATCC25922 cells were incubated with thanatin-BDP-FL at a concentration of 4 - 8 μg/ml 
and an incubation time of 2 h. The cells were fixated with paraformaldehyde before imaging. 
The conjugate was taken up efficiently and with a good distribution inside the cells. Similar to 
the images described above, elongation of multiple cells was observed along with an 
accumulation of membrane-like material in green knobs. Additionally, a distinct accumulation 
of thanatin-BDP-FL at the cell poles and junctions in certain cells was observed (Figure 49). 
 
 
Figure 49 E. coli ATCC25922 cells treated with thanatin-BDP-FL (4 and 8 μg/ml) were fixed by paraformaldehyde 
before imaging. 
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3.2.11 Photoaffinity Labelling 
Photoaffinity labelling (PAL) was applied here to identify possible interaction partners of 
thanatin. PAL is a technique developed in the 1960’s by Westheimer et al.[108] to covalently link 
a photo-reactive label to a larger molecule (e.g. a protein) with UV-light. A recent review by 
Ewan Smith and Ian Collins describes the broad application range of PAL in studying ligand-
protein interactions. In order to facilitate the isolation and detection of a crosslinked binding 
partner, the incorporation of a reporter group becomes necessary. The most popular affinity 
tag in use today is biotin, due to its extremely high affinity towards streptavidin. Different photo-
reactive groups can be incorporated such as benzophenones, phenylazides, and diazirines to 
form highly reactive diradicals, nitrenes, and carbenes, respectively. However, diazirines have 
a number of advantages when applied in a biological system. They are chemically stable and 
irradiation with a wavelength of 350 nm reduces potential damage to the cellular environment. 
The reactive singlet-carbene (Figure 50), formed upon irradiation has a short half-live, rapidly 
forming a covalent crosslink to its target molecule, which leads to fewer side reactions.[109] 
 
Figure 50 Formation of a highly reactive singlet-carbene upon UV irradiation. 
 
Suchanek et al.[110] demonstrated the incorporation of the radioactively labelled diazirine 
containing amino acids photo-methionine and photo-leucine into proteins by the unmodified 
mammalian translation machinery, in order to study protein-protein interactions of membrane 
proteins involved in cellular lipid homeostasis. An efficient synthesis of photo-phenylalanine 
was described by Nakashima et al.[111] and used to specifically label the protein calmodulin 
(CaM) in a calcium-dependent manner by photo-reactive calmodulin-binding peptide 
(CaMBP), containing this amino acid together with a biotin linker. Our group previously showed 
that the incorporation of photo-proline[112] and photo-leucine[113], with a biotin linker, can be 
used for mechanism of action studies of antibiotics. 
PAL probe thanatin-PAL5 was designed with an N-terminal biotin linker and a reactive diazirine 
group at position Pro5. The synthesis and incorporation of Fmoc-L-photoPro was performed 
according to the procedure described by van der Meijden and Robinson.[112] The linear thanatin 
sequence was synthesized as described earlier and the commercially available biotin-PEG4-
acid building block (Broadpharm) was coupled on-resin under standard conditions with 
HATU/HOAt (Scheme 7). After coupling, the peptide was cleaved from the resin, oxidized, and 
purified by preparative HPLC. The purity of thanatin-PAL5 was confirmed by UPLC (Figure 51) 
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and its identity by HR-ESI with a calculated mass of 587.3041 [M+5H]5+ and an experimental 
m/z value of 587.3041 [M+5H]5+. The diazirine group at position Pro5 is supposed to form a 
covalent cross-link to any interaction partner upon irradiation, whereas the biotin group is used 
for detection in a Western blot by chemiluminescence via a horseradish peroxidase 
NeutrAvidin conjugate (NeutrAvidin-HRP, Pierce). 
 
Scheme 7 Synthesis of PAL probe thanatin-PAL5: a) Piperidine:DMF (1:3), then Biotin-PEG4-acid, HATU, HOAt, 
DIPEA, DMF. b) TFA:EDT:thioanisole:H2O:TIS (75:10:10:4:1), then oxidation by air in 0.1 M ammonium acetate 
pH 8.5. 
 
Figure 51 UPLC chromatogram of thanatin-PAL5 at 226 nm wavelength, run with a linear gradient of 10 to 40% 
MeCN/H2O with additional 0.1% TFA on a C18 reverse-phase column. 
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Thanatin-PAL5 showed a 4-8 times higher MIC against E. coli ATCC25922 compared to the 
parent compound (2 - 4 μg/ml versus 0.5 μg/ml). Photolabelling of whole E. coli cells was 
performed at a concentration of 10 μg/ml and 2 μg/ml thanatin-PAL5. Additionally, a 
competition experiment was performed, in which a 20-fold excess of native thanatin 
(200 μg/ml) was preincubated with the cells before adding the photoprobe (10 μg/ml). For the 
control experiment, cells were treated in the same manner as described below, but without 
addition of the photoprobe. The cells were preincubated for 30 min with the photoprobe and 
then irradiated at 350 nm wavelength in a Rayonet reactor for 30 min. After cell lysis, the 
insoluble fractions, containing mainly membrane proteins, were isolated by differential 
ultracentrifugation and analysed by polyacrylamide gel electrophoresis (SDS-PAGE). Proteins 
were transferred onto a PVDF (polyvinylidene difluoride) membrane by the Western blotting 
technique[114] for subsequent biotin detection. The gel was blotted under conditions optimized 
for larger membrane proteins to ensure optimal transfer.[115] Biotin detection of the sample 
treated with 10 μg/ml thanatin-PAL5 (lane 2) showed at least four distinct bands in the Western 
blot around 100 kDa, 45 kDa, 40 kDa, and 20 kDa, plus a faint band below 75 kDa (Figure 52). 
For the sample treated with 2 μg/ml thanatin-PAL5 (lane 3), the same labelling pattern was 
observed, when the blot was exposed for a longer period of time. However, the competition 
with native thanatin led to a disappearance of the 100 kDa band, whereas the other bands 
remained visible when exposed for a longer time, suggesting a displacement of the photoprobe 
at the potential binding site within the 100 kDa protein. No signal could be detected for the 
control sample (lane 1). The Coomassie staining confirmed the loading of approximately equal 
amounts of protein for all samples. 
 
Figure 52 Western blots (A+B) and SDS-PAGE (C) of E. coli ATCC25922 membrane fractions from 10% self-
casted polyacrylamide gels. Lanes: M) molecular-weight marker, 1) control, 2) thanatin-PAL5 (10 μg/ml), 3) 
thanatin-PAL5 (2 μg/ml), 4) thanatin-PAL5 (10 μg/ml) + native thanatin (200 μg/ml). Blotting for 2 h (10 V, 0.5 A) 
with urea transfer buffer. Biotin detection by chemiluminescence with NeutrAvidin-HRP 1:30’000 and 
WesternBright™ Sirius™ HRP substrate. Exposure times: 92 s (blot A), 536 s (blot B). 
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Gel electrophoresis of the membrane protein extract treated with 2 μg/ml thanatin-PAL5 was 
repeated under non-reducing conditions (without DTT) before Western blotting. A distinct mass 
shift of the band at 100 kDa to approximately 130 kDa was observed (Figure 53). This mass 
shift was previously described in the literature as a characteristic feature of the outer 
membrane protein LptD.[40] The effect is caused by a difference in mobility upon reduction of 
the two disulfide bonds in E. coli LptD, in comparison to the unreduced form. 
 
Figure 53 Western blot (A) and SDS-PAGE (B) of E. coli ATCC25922 membrane fractions from 10% self-casted 
polyacrylamide gels. Lanes: M) molecular-weight marker, 1) control, 2) control (non-reducing conditions), 3) 
thanatin-PAL5 (2 μg/ml), 4) thanatin-PAL5 (2 μg/ml, non-reducing conditions). Blotting for 2 h (10 V, 0.5 A) with 
urea transfer buffer. Biotin detection by chemiluminescence with NeutrAvidin-HRP 1:30’000 and WesternBright™ 
Sirius™ HRP substrate. The arrow indicates a mass shift characteristic for LptD. Exposure time: 304 s (blot A). 
 
The photolabelling experiment was repeated with two different E. coli strains: E. coli K-12 and 
clinically isolated, multi resistant E. coli 926415. The MIC value against E. coli K-12 remained 
unchanged with 0.5 µg/ml. It was, however, 2 - 8 times higher (i.e. 1 - 4 µg/ml) against E. coli 
926415. A commercially available 4-20% gradient gel (Bio-Rad) was used for SDS-PAGE with 
blotting under the recommended conditions from the supplier for high molecular weight 
proteins. Those conditions also allowed the investigation of smaller proteins (< 30 kDa). The 
labelling pattern at a concentration of 2 μg/ml thanatin-PAL5 looked very similar between these 
two strains (Figure 54) with distinct bands at 100 kDa, 40 kDa, and 20 kDa in both strains, with 
several additional faint bands for E. coli K-12. In comparison to the E. coli ATCC25922 strain 
(cf. Figure 52), only one band was highlighted in the 40-45 kDa region. 
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Figure 54 Western blot (A) and SDS-PAGE (B) of E. coli K-12 and 926415 membrane fractions from 4-20% gradient 
polyacrylamide gels. Lanes: M) molecular-weight marker, 1) E. coli K-12 with thanatin-PAL5 (2 μg/ml), 2) E. coli 
926415 with thanatin-PAL5 (2 μg/ml). Blotting for 2x10 min (25 V, 1.3 A). Biotin detection by chemiluminescence 
with NeutrAvidin-HRP 1:30’000 and WesternBright™ Sirius™ HRP substrate. Exposure time: 193 s (blot A). 
 
Thanatin exhibited no activity against P. aeruginosa PAO1 and P. aeruginosa ATCC27853 
(MIC > 64 μg/ml). However, it has previously been claimed that thanatin shows low activity 
against P. aeruginosa ATCC27853 (MIC = 16 μg/ml) and good activity against a multi-drug 
resistant, clinical isolate P. aeruginosa XJ75297 (MIC = 1 μg/ml).[116] Further, a derivative 
named S-thanatin, in which residue Thr15 has been substituted by a serine, was used in a co-
treatment together with colistin in an in vivo study against P. aeruginosa ATCC27853 and 
colistin resistant clinical isolate P. aeruginosa AN-09.[117] Photoaffinity labelling of 
P. aeruginosa PAO1 with thanatin-PAL5 (10 μg/ml) revealed a band above 100 kDa (likely 
LptD), a band at 75 kDa, which was also present in the control and likely stems from the biotin 
carrying enzymes methyl crotonyl-CoA-carboxylase (MCCase) or geranyl-CoA-carboxylase 
(GCCase) with respective masses of 78 kDa and 74 kDa[118], a faint band around 60 kDa, and 
a large band at 50 kDa (Figure 55). It seems therefore, that thanatin interacts with several 
membrane proteins also in P. aeruginosa. 
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Figure 55 Western blot (A) and SDS-PAGE (B) of membrane fraction of P. aeruginosa PAO1 from 10% 
polyacrylamide gels. Lanes: M) molecular-weight marker, 1) control, 2) thanatin-PAL5 (10 μg/ml). Blotting for 2 h 
(10 V, 0.5 A) with urea transfer buffer. Biotin detection by chemiluminescence with NeutrAvidin-HRP 1:30’000 and 
WesternBright™ Sirius™ HRP substrate. Exposure time: 415 s (blot A). 
 
Two dimensional gel electrophoresis was applied in an attempt to identify the labelled proteins. 
Membrane protein extract from a photolabelling experiment performed with 10 μg/ml thanatin-
PAL5 on E. coli ATCC25922 was used. The proteins were first separated by isoelectric 
focusing from pH 4 – 7 by immobilization on pH gradient strips, and then by their molecular 
weight in the second dimension on a 10% polyacrylamide gel. The crosslinking of thanatin-
PAL5 to the individual proteins results in a pI shift corresponding to seven additional positive 
charges and an increase in molecular weight of +2.9 kDa. The observed labelling pattern 
(Figure 56) resembles the one from the 1D experiment (cf. Figure 52) with a number of 
differences: The band around 100 kDa actually stems from two proteins that could not be 
separated on a 1D gel. The previously observed faint band below 75 kDa was vastly more 
abundant in this experiment, whereas the 40 kDa band was fainter. Several membrane 
proteins in E. coli ATCC25922 were previously identified by Dr. Fabio Lo Monte by 2D SDS-
PAGE and mass spectrometry analysis in collaboration with the Functional Genomics Center 
Zurich at UZH (FGCZ) (Figure 57). The region around 100 kDa, where the two proteins LptD 
and BamA were assigned, was further investigated. The other signals in the Western blot could 
not be correlated to the protein map, since they appeared in a more crowded region with 
several possible interaction partners. 
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Figure 56 2D Western blot of membrane fractions of E. coli ATCC25922, from a 10% polyacrylamide gel. 
Photolabelling was performed with 10 μg/ml thanatin-PAL5. Blotting for 2 h (10 V, 0.5 A) with urea transfer buffer. 
Biotin detection by chemiluminescence with NeutrAvidin-HRP 1:30’000 and WesternBright™ Sirius™ HRP 
substrate. Exposure time: 122 s. 
 
Figure 57 2D SDS-PAGE (10% polyacrylamide) of membrane fractions of E. coli ATCC25922 with Coomassie 
staining. Proteins were assigned by mass spectrometry analysis. Results were obtained by Dr. Fabio Lo Monte.  
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Gel electrophoresis of the same membrane protein extract of E. coli ATCC25922 cells treated 
with 10 µg/ml thanatin-PAL5 was repeated under non-reducing conditions (i.e. without DTT) to 
investigate the previously described mass shift of LptD in two dimensions. Indeed, the upper 
band showed a clear difference in mobility, whereas the lower band remained at the previous 
position (Figure 58). Compared to the assigned protein map, this signal could be BamA. The 
calculated pI shift of LptD is 4.98 to 5.22 for the crosslinked product and matched the 
observation in the Western blot. The calculated pI shift of BamA is 4.87 to 5.08 and appears 
higher than expected in the Western blot. This provides evidence of a binding of thanatin to 
LptD and at least four other membrane proteins that remain to be identified. 
 
Figure 58 2D Western blot of membrane fractions of E. coli ATCC25922, from a 10% polyacrylamide gel. 
Photolabelling with 10 μg/ml thanatin-PAL5. Reducing conditions (left) and non-reducing conditions (right). Blotting 
for 2 h (10 V, 0.5 A) with urea transfer buffer. Biotin detection by chemiluminescence with NeutrAvidin-HRP 1:30’000 
and WesternBright™ Sirius™ HRP substrate. Exposure times: 75 s (left), 23 s (right). 
 
3.2.12 Protein Identification by Mass Spectrometry 
In order to unambiguously identify proteins labelled in the photoaffinity labelling experiments, 
mass spectrometry based methods were applied in a collaboration with Maik Müller and Prof. 
Bernd Wollscheid at ETH Zurich. In a first experiment, samples of E. coli ATCC25922 cells 
photolabelled with 10 µg/ml thanatin-PAL5 together with control samples of a photolabelling 
experiment as described above were analysed in triplicate by MS-methods. The cells were 
lysed and biotinylated (crosslinked) proteins were collected by streptavidin beads. After on-
bead proteolytic digestion with trypsin, data acquisition of protein fragments was performed by 
HPLC-MS/MS methodology. Peptide quantification and identification were based on the 
UNIPROT database for E. coli K-12[119]. A statistical analysis of cells treated with 10 μg/ml 
thanatin-PAL5 compared to untreated control samples identified 550 proteins in total, from 
which 230 proteins could be quantified in both samples, under the prerequisite that at least 
two peptide fragments derive from the same protein. Three proteins that were enriched in the 
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labelled sample could be identified with statistical significance above the threshold. LptA and 
LptD both exhibit high significance, whereas BamB lies just above the threshold (Figure 59). 
The labelling of LptD was already anticipated from the photoaffinity labelling experiments 
described above. LptA is directly associated with LptD in the periplasmic space, and both are 
part of the LPS transport machinery. BamB, however, is part of the outer membrane protein 
assembly complex (BAM complex), which is involved in assembly and insertion of β-barrel 
proteins into the outer membrane (cf. Introduction 1.4). 
 
Figure 59 Volcano plot comparing protein abundance of an unlabelled control sample and a sample treated with 
10 µg/ml thanatin-PAL5 in a photoaffinity labelling experiment, by quantitation using relative precursor ion signals 
and significance testing based on the UNIPROT database for E. coli K-12[119]. Significantly enriched (i.e. photo-
crosslinked) proteins are LptD, LptA, and BamB (cf. Appendix 6.3 for full protein sequence). 
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In a second experiment a different approach using a proximity based photo-oxidation method 
where methylene blue-labelled probe thanatin-PAL5-MB (Scheme 8) was applied. The 
previously described thanatin-PAL5 precursor (cf. Results and Discussion 3.2.11) was Fmoc 
deprotected and a propargy-PEG4 spacer coupled under standard conditions. After resin 
cleavage, oxidation, and purification by preparative HPLC, commercially available methylene 
blue azide (Atto-MB2 azide, Atto-Tec) was coupled by Click Chemistry as described later 
(Experimental Part 4.4). The purity of the compound was confirmed by UPLC analysis (Figure 
60) and the identity was verified by HR-ESI with a calculated mass of 652.1353 [M+6H]6+ and 
a measured m/z value of 652.1360 [M+6H]6+. 
 
 
Scheme 8 a) Piperidine:DMF (1:3), then propargyl-PEG4-acid, HATU, HOAt, DIPEA, DMF. b) 
TFA:EDT:thioanisole:H2O:TIS (75:10:10:4:1), then oxidation by air in 0.1 M ammonium acetate pH 8.5. c) Atto-MB2 
azide, CuSO4, sodium ascorbate, DMSO:H2O (1:5). 
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Figure 60 UPLC chromatogram of thanatin-PAL5-MB at 226 nm wavelength, run with a linear gradient of 10 to 40% 
MeCN/H2O with additional 0.1% TFA on a C18 reverse-phase column. 
 
Methylene blue is a photosensitizer that upon irradiation creates highly reactive singlet oxygen 
(1O2). The reaction of 1O2 with amino acid side chains such as Trp, Cys, His, Tyr and Met has 
been shown to give rise to further reactive species via radical and ring opening reactions.[120] 
Trp and Tyr residues can form ketones, which can then be captured by reacting them with a 
hydrazide-biotin probe via hydrazone formation. If the thanatin-PAL5-MB probe binds to a 
receptor such as a membrane protein, this method should allow the identification of proteins 
in the direct vicinity of the binding site. Samples of E. coli ATCC25922 cells treated with 3 µM 
thanatin-PAL5-MB and a control sample (3 µM thanatin-PAL5-MB preincubated with 30 µM 
native thanatin) were analysed in triplicate. Isolation of the biotinylated proteins and their 
quantification and analysis by MS-methods was then achieved as described above. An 
enrichment of protein clusters primarily consisting of periplasmic and membrane proteins was 
observed, as well as a slight depletion of primarily cytosolic proteins (Figure 61). The two 
previously identified proteins LptD and LptA were also confirmed with this method as top 
enriched hits, making it likely that the other enriched proteins are direct neighbors of LptD and 
LptA. The previously observed BamB signal could also be detected with this method, however, 
as a non-significantly enriched protein, possibly due to the pre-incubation treatment with native 
thanatin, blocking most of the unspecific binding sites. Other proteins of the Lpt and Bam family 
have been detected as enriched hits (LptF, BamA, BamC), and non-significantly enriched 
(LptB, LptE, LptG). These findings provide strong evidence for a direct interaction of thanatin 
with components of the LPS transport pathway, and likely an inhibition of LPS transport as the 
mechanism of action of thanatin in E. coli.  
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Figure 61 Volcano plot comparing protein abundance of a sample treated with 3 µM thanatin-PAL5-MB and a 
competition control sample (3 µM thanatin-PAL5-MB preincubated with 30 µM native thanatin) in a light induced 
proximity based photo-oxidation experiment, by quantitation using relative precursor ion signals and significance 
testing based on the UNIPROT database for E. coli K-12[119]. Significantly enriched proteins are depicted in green 
with LptA and LptD as top enriched hits. Depleted proteins are depicted in red. 
 
3.2.13 Production of Recombinant E.coli LptA-His6 
To study the interaction of thanatin with LptA in an in-vitro assay, the protein needed to be 
produced recombinantly. LptA is part of the lipopolysaccharide transport machinery in Gram-
negative bacteria (cf. Introduction 1.5). It is a soluble periplasmic protein consisting of 16 
consecutive antiparallel β-strands, folded to resemble a slightly twisted and semi-closed β-
jellyroll with two clefts at the ends of each LptA molecule.[121] Its main function is the binding of 
the Lipid A domain of LPS and the LPS transport along the hydrophobic interior of the β-jellyroll 
from the homologous domains of LptC to LptD.[122] LptA is assumed to form an oligomeric 
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channel where LptA molecules are assembled head-to-tail, to form a bridge-like structure 
through the periplasm. The N-terminal end of LptA has been confirmed by an in-vivo photo-
crosslinking experiment to make contact with LptC, whereas the C-terminal end interacted with 
the periplasmic domain of LptD (Figure 62).[123] The oligomerization effect of LptA to form a 
continuous array of end-to-end structures was also confirmed in solution, as a function of 
increasing protein concentration.[124] A recent study conducted by Schultz et al.[125], focusing 
on the LPS binding mechanism using site-directed electron paramagnetic resonance (EPR) 
spin-labelling methods, suggested a 1:1 ratio for the LptA-LPS complex. Binding of thanatin to 
LptA could therefore either inhibit the build-up of the channel at the interface or LPS transport 
itself, by occupying the LPS binding site. 
 
Figure 62 A channel formed of structurally homologous domains of LptC (PDB 3MY2), several monomers of LptA 
(PDB 2R19), and a model structure of the N-terminal domain of LptD in E. coli. Positions where photo-crosslinking 
of incorporated p-benzoylphenylalanine (pBPA) was observed are highlighted. (Reprinted from Freinkman et al.)[123] 
Chromosomal DNA was isolated from E. coli ATCC25922 and amplified by PCR (polymerase 
chain reaction) with primers for the lptA gene. The PCR product was then purified on a 
1% agarose gel and cloned into a pET-22b vector. Transformation of the plasmid into E. coli 
XL1 Blue was achieved by heat shock transformation, for the production of LptA with a C-
terminal His6 tag. An efficient procedure for the production of LptA-His6 was previously 
described by Santambrogio et al.[126] and was applied as described in the following. The 
plasmid was transformed into E. coli BL21 and protein expression induced by addition of IPTG 
(isopropyl β-D-1-thiogalactopyranoside). After cell harvesting and disruption by French press, 
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the soluble protein fractions were purified by Ni-NTA affinity chromatography with a yield of 
2.5 mg LptA-His6 per liter culture media. SDS-PAGE confirmed the purity of the protein (Figure 
63). The identity of the fully processed sequence (i.e. without the 27 N-terminal residues of the 
signal sequence M1–A27) was confirmed by ESI-MS with a calculated molecular weight of 
18’360.55 Da and a measured molecular weight of 18’360.5 Da. 
 
Figure 63 Coomassie stained 4-20% polyacrylamide gradient gel of purified LptA-His6. M: molecular-weight marker. 
 
With the purified LptA-His6 in hand, it was decided to study the interaction with thanatin by a 
fluorescence polarization based binding assay. 
 
3.2.14 Fluorescence Polarization 
The binding interaction of labelled thanatin-BDP-FL (cf. Results and Discussion 3.2.10) with 
LptA-His6 was studied by fluorescence polarization. Studying the association between 
biomolecules is crucial in understanding their biological function and activity. Fluorescence 
polarization provides a non-destructive method to determine the binding affinity of a fluorescent 
ligand to a macromolecule (i.e. a protein). The theory of fluorescence polarization was first 
described by Perrin[127] in 1926, as a physical phenomenon in which fluorescent molecules 
excited with linear polarized light will emit light back in the same (linear) polarization if the 
molecule remains stationary during excitation. If, however, the molecules move and tumble in 
solution, the degree of polarization of the emitted light of a fluorophore is inversely related to 
its molecular rotation. Quantitatively, fluorescence polarization is defined as the difference of 
the emission light intensity parallel (I||) and perpendicular (I⊥) to the excitation light plane 
normalized by the total fluorescence emission intensity (equation E 1), whereas fluorescence 
anisotropy is defined as equation E 2.[128] 
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 Fluorescence polarization = (I|| - I⊥) / (I|| + I⊥) E 1 
 
 Fluorescence anisotropy = (I|| - I⊥) / (I|| + 2 I⊥) E 2 
 
Since a fluorescent ligand bound to a protein exhibits a higher polarization than in free solution, 
a concentration dependent assay can be applied to determine a dissociation constant (Kd 
value) for this specific interaction. Further, with the established Kd, the Kd of any competing 
unlabelled ligand can also be determined accordingly.[129] In a direct assay, a constant 
concentration of 100 nM thanatin-BDP-FL was titrated with varying concentrations of LptA-His6 
(30.8 µM - 3.7 pM) and fluorescence anisotropy recorded. A distinct lower plateau was 
apparent at low concentrations of LptA-His6, whereas at higher LptA-His6 concentrations, 
higher anisotropy was detected in a typical sigmoidal behaviour. The upper plateau however, 
is not entirely flat, probably due to an oligomerization effect of LptA at higher concentrations 
as described by Merten et al.[124] A curve fitting yielded a Kd value of 12 ± 3 nM for this 
interaction (Figure 64). 
 
Figure 64 Fluorescence anisotropy of thanatin-BDP-FL interacting with LptA-His6. 
 
To prove that the binding affinity is caused by a specific interaction with the peptide and not 
the attached fluorophore, a competition experiment was performed with a constant 
concentration of thanatin-BDP-FL complexed with LptA-His6 (both 500 nM), titrated with 
varying concentrations of native thanatin (2’054 µM - 0.24 nM) as a competitor. Indeed, the 
free thanatin was able to compete for the binding site occupied by thanatin-BDP-FL at higher 
concentrations, whereas at lower concentrations of free thanatin, the complex stayed intact, 
exhibiting higher anisotropy. A curve fitting yielded a competitor Kd value of 10 ± 2 nM, 
suggesting the same binding affinity for the native thanatin (Figure 65). 
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Figure 65 Fluorescence anisotropy of a free thanatin (competitor) against a thanatin-BDP-FL LptA-His6 complex 
 
The competition experiment was repeated with D-thanatin, the enantiomer consisting of all D-
amino acids, within the same concentration range (2054 µM – 0.24 nM) against the thanatin-
BDP-FL LptA-His6 complex (both 500 nM). Although, the enantiomer displays the same 
molecular weight and charge density, it was not able to compete for the LptA binding site, 
strongly indicating a stereospecific interaction with LptA-His6 for the native thanatin (Figure 
66). 
 
Figure 66 Fluorescence anisotropy of D-thanatin against a thanatin-BDP-FL LptA-His6 complex. 
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3.2.15 Isolation and Gene Sequencing of Thanatin-Resistant Mutants 
Additional studies were conducted by Dr. Katja Zerbe in order to generate mutants resistant 
against thanatin (unpublished work). E. coli ATCC25922 cells were grown on MH-II agar 
containing 10 - 50 μg/ml thanatin. It had previously been claimed that the emergence of 
resistance against thanatin is very low.[130] To our surprise, however, resistant mutants could 
already be isolated after the first passage with a mutation frequency of approximately 10-8. In 
two independent experiments, a total of ten thanatin resistant mutants could be isolated, from 
which five remained stable over at least five subsequent passages on thanatin-free agar, all 
deriving from conditions where 50 μg/ml thanatin was used for selection. Sequencing of the 
lptA gene revealed two different point mutations, Q62L and D31N, with the Q62L obtained in 
both independent experiments (Table 13). These two residues (Q62 and D31) are highly 
conserved in LptA between other Gram-negative bacteria and lie in close proximity to each 
other on one side of the protein (Figure 67). The thanatin treatment apparently leads to a 
mutation of these residues to reduce binding affinity, escaping the toxic effect thanatin has on 
the cells. This might be due to the disruption of crucial H-bonds in the contact region (Q62L) 
and loss of a salt bridge in the case of D31N. 
 
Table 13 Analysis of thanatin resistant isolates of E. coli ATCC25922 and their respective mutations in LptA. 
ThanRes1 – ThanRes7 and ThanRes8 – ThanRes10 were identified in independent experiments. MIC Values were 
determined by microdilution in MH-II with addition of 0.002% Tween80. 
Mutants 
Thanatin conc. 
on original 
plate used for 
selection 
[μg/ml] 
MIC against 
thanatin 
[μg/ml] 
MIC against 
thanatin after 
four passages 
[μg/ml] 
Mutation in 
LptA sequence 
Wild type  1-2 1-2  
ThanRes1 10 2-4 2 - 
ThanRes2 50 >64 >64 Q62L 
ThanRes3 50 >64 1 - 
ThanRes4 50 32 64 D31N 
ThanRes5 20 16 4 - 
ThanRes6 20 16 4 - 
ThanRes7 20 16-32 1 n.d. 
ThanRes8 50 >64 >64 Q62L 
ThanRes9 50 >64 >64 Q62L 
ThanRes10 50 >64 >64 Q62L 
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Figure 67 Ribbon diagram of a single E. coli LptA molecule (PDB 2R19) and sequence alignment of LptA from 
various Gram-negative bacterial homologues. The backbone of non-conserved (green), similar (blue), and 
conserved (red) residues are depicted. Mutation sites are highlighted in magenta. (Adapted from Suits et al.)[121] 
 
The three thanatin resistant mutants ThanRes2, ThanRes4, and ThanRes8 were further 
analysed, and no difference in their growth behaviour (i.e. lag-time, doubling time, and final 
OD600) in MH-II media compared to the wild type was observed. They did not show an 
increased sensitivity in the presence of 0.5% SDS and 1 mM EDTA in MH-II media, indicating 
that the outer membrane remained unaffected. Susceptibility towards a series of standard 
antibiotics also remained unchanged as shown in the antibiogram in Table 14.  
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Table 14 Antibiogram of thanatin resistant mutants ThanRes2, ThanRes4, and ThanRes8 compared to the parent 
strain E. coli ATCC25922. Values were determined by microdilution in MH-II with addition of 0.002% P80. 
MIC (µg/ml)  
E. coli 
ATCC25922 
ThanRes2 
(LptA-Q62L) 
ThanRes4 
(LptA-D31N) 
ThanRes8 
(LptA-Q62L) 
Colistin 0.06 0.03 0.06 0.015 
Erythromycin >64 >64 64 64 
Gentamycin 0.5 0.5 0.5 0.5 
Vancomycin >64 >64 >64 n.d. 
Rifampicin 8 8 8 16-64 
Ampicillin 16 8 16 16 
Ciprofloxacin 0.002 0.002 0.002 0.015 
Thanatin 1 >64 >64 >64 
 
 
Sequencing of whole genomes was carried out in collaboration with Alessandra Vitale, Dr. 
Gabriella Pessi, and Prof. Leo Eberl at the Department of Plant and Microbial Biology UZH. 
Genomic DNA was extracted from thanatin resistant E. coli mutants ThanRes2, ThanRes4, 
and ThanRes8, as well as from the wild type E. coli ATCC25922 for comparison. Sequence 
analysis of the chromosome as well as the two plasmids revealed only a few changes (point 
mutations, deletions, insertions) which cause modifications on the amino acid level. The genes 
containing mutations are listed in Table 15. In all mutant genomes a point mutation in lptA was 
confirmed. In ThanRes2 and ThanRes4 additional changes in a small number of proteins were 
observed, some of them with unknown functions. Interestingly the ThanRes8 mutant showed 
only a single point mutation compared to the wild type sequence, causing the Q62L mutation 
in LptA, which further confirms LptA as a main target for thanatin. LptA is an essential gene for 
E.coli, which means that this mutation is not completely inhibiting the essential LPS transport. 
The protein is still functional, but seems to prevent thanatin binding. LptD as a target cannot 
be ruled out, even though no mutations in lptD were observed in this screening. This could be 
explained by the fact that mutations in LptD are lethal and no mutant colonies might have 
survived. 
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Table 15 Observed mutations (+ : mutation found, - : no mutation) in different genes of thanatin-resistant E.coli 
ATCC25922 mutants ThanRes2, ThanRes4, and ThanRes8, compared to the wild type genome, detected by whole 
genome sequencing. (Results were obtained by Alessandra Vitale and Dr. Gabriella Pessi) 
gene Protein/function ThanRes2 ThanRes4 ThanRes8 
lptA LPS transport + + + 
rpmB 50S ribosomal protein 28L + - - 
pckA 
Phosphoenolpyruvate-
carboxykinase 
+ - - 
rplE 50S ribosomal protein L5 + - - 
thiK Thiamine kinase + + - 
acnB Aconitate hydratase B - + - 
DR76_2839 unknown + + - 
DR76_4251 unknown + + - 
DR76_2319 unknown + - - 
DR76_3425 unknown - + - 
 
 
The point mutations Q62L and D31N were shown to be dominant resistance markers. If the 
proteins were expressed from plasmids which were transformed into a wild type E. coli strain 
(ATCC25922 or K-12), they conferred full resistance against thanatin. Higher levels of wild 
type LptA, when expressed from a plasmid additionally to the chromosomal gene (E. coli K-
12 + pOCI1548), had no significant effect and thanatin activity was largely retained (MIC 
approximately two-fold higher) (Table 16). 
 
Table 16 MIC of strains containing plasmid-borne copies of the wild type or mutant LptA genes. MIC Values were 
determined by microdilution in MH-II with addition of 0.002% Tween80. (pOCI1548: LptA-His6, pOCI1551: 
LptA_Q62L-His6, pOCI1552: LptA_D31N-His6) 
Strain 
(+ plasmid) 
MIC against 
thanatin [µg/ml] 
 
Strain  
(+ plasmid) 
MIC against 
thanatin [µg/ml] 
E. coli ATCC25922 0.5 - 1  E. coli K-12 0.5 - 2 
E. coli ATCC25922 
+ pET22b 
0.25 - 0.5  
E. coli K-12  
+ pET22b 
0.5 - 2 
E. coli ATCC25922 
+ pOCI1551 
32  
E. coli K-12 
+pOCI1551 
32 - >64 
E. coli ATCC25922 
+ pOCI1552 
8 - 16  
E. coli K-12 
+ pOCI1552 
16 - 64 
   
E. coli K-12 
+pOCI1548 
1 - 4 
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3.2.16 Electron Microscopy 
Scanning electron microscopy (SEM) and transmission electron microscopy (TEM) were 
performed on thanatin treated E. coli ATCC25922 by Dr. Katja Zerbe and Dr. Andres Käch 
from the Center of Microscopy and Image Analysis (ZMB) at UZH (unpublished work). Cells 
were grown in LB media at a thanatin concentration causing 50% growth inhibition. In 
comparison to a control sample, assemblies of multiple cells in elongated structures were 
observed in SEM (Figure 68), possibly due to difficulties to divide and to separate from each 
other during cell division. Similar results were obtained in fluorescence microscopy 
experiments described above (cf. Figure 46). 
 
Figure 68 SEM images of E. coli ATCC25922 cells grown in LB, untreated (left) and treated with 2.5 µg/ml thanatin 
(50% growth inhibition) (right). 
 
TEM images of thin sections of E. coli ATCC25922 cells grown in MH-II and treated with 
2 µg/ml thanatin (74% growth inhibition) showed a lot of modifications compared to untreated 
cells, predominantly defects in the membrane architecture and unusual accumulations of 
membrane-like material inside cells and at cell junctions, but also brighter vacuoles at the cell 
poles, detachment of outer membranes, and black spots/aggregates inside the cytoplasm 
(Figure 69). 
 
Figure 69 TEM images of E. coli ATCC25922 cells grown in MH-II, untreated (left) and treated with 2 µg/ml thanatin 
(74% growth inhibition) (right). Arrows indicate unusual membrane defects and accumulations. 
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A representative structure of an interesting multi-layered membrane fold inside the cell is 
shown in Figure 70. Such modifications are typically observed in cells where LPS transport is 
inhibited, as previously described for LptA/B, LptC, LptD, and LptE depleted E. coli mutants 
(Figure 71).[131,132] As a consequence, membranous material is accumulated and cell division 
is arrested. These findings indicate a direct effect of thanatin on the membrane, without 
causing actual permeabilization, likely by interfering with the biosynthesis or transport of 
membrane components such as LPS. 
 
Figure 70 TEM thin section image of an E. coli ATCC25922 cell grown in MH-II and treated with 2 µg/ml thanatin 
(74% growth inhibition) shows a high accumulation of membrane-like material inside the cell. 
 
 
 
Figure 71 Cell morphology upon depletion of LptA-LptB, LptE, LptD, and LptC. E. coli cells were grown in the 
presence (+) or in the absence (-) of arabinose (arabinose-dependent, conditional mutants). Scale bars indicate 0.5 
µm length. (Reprinted from Sperandeo et al.)[132] 
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3.2.17 Conclusion 
The antimicrobial activity of thanatin against E. coli ATCC25922 and a series of clinical, multi-
resistant E. coli isolates was confirmed. It was proven that thanatin does not act by a 
membranolytic mechanism of action by a series of assays. In the Sytox® Green assay 
performed in MH-I media, no membrane permeability was observed with thanatin 
concentrations up to 100 µg/ml (Figure 38). Although a signal could be detected when the 
Sytox® Green assay was performed in HEPES buffer, it was shown that the enantiomeric D-
thanatin, which has no antimicrobial activity, exhibited the same effect (Figure 39). This 
suggests an unspecific permeabilization, likely caused by the positive charge density of the 
molecule on weakened cells. If the HEPES media was supplemented with Ca2+ and Mg2+, 
again, no effect was observed with thanatin concentrations up to 100 µg/ml (Figure 40). These 
results were further reinforced by the β-lactamase and β-galactosidase assays, neither of 
which showed any perturbative effect of the inner or outer membrane (Figure 41 and Figure 
42). The effect of thanatin on the macromolecular pathways of DNA, RNA, protein, and cell 
wall biosynthesis was studied by monitoring the incorporation of radioactive precursors. No 
inhibition of any pathway was observed, however, an increase of N-acetylglucosamine 
incorporation was apparent, suggesting a stimulation of its incorporation into components of 
the polysaccharide coat or into precursors used for LPS biosynthesis (Figure 44). Confocal 
fluorescence microscopy and scanning and transmission electron microscopy images 
indicated that the membrane morphology was affected by thanatin. Accumulations of 
membranous material inside of cells were observed (Figure 70), resembling previously 
described structures in E. coli mutants, where LPS transport was inhibited. The fluorescence-
labelled probe thanatin-BDP-FL (Scheme 6) was used to confirm the uptake of the compound 
into cells (Figure 49). Additionally, elongated assemblies of multiple cells were observed, likely 
as a general stress response and/or failure to divide (Figure 47). Photoprobe thanatin-PAL5 
was synthesized (Scheme 7), carrying an N-terminal biotin tag and a photo-reactive diazirine 
group at position Pro5 for the use in photoaffinity labelling experiments. SDS-PAGE and 
Western blotting with subsequent biotin detection of photolabelled membrane proteins 
identified LptD as a potential interaction partner of thanatin. Mass spectrometry based methods 
were carried out in a collaboration with the Wollscheid group at ETH Zurich confirming LptD 
and identifying LptA with high significance as targets of thanatin (Figure 58). Since these 
proteins are both associated and involved in the LPS transport, it is highly likely that the LPS 
transport is disturbed by thanatin and is the reason for its antimicrobial activity in Gram-
negative bacteria. Thanatin resistant mutants were isolated, and the whole genome 
sequenced. A key point mutation in LptA (Q62L) was identified, rendering the bacteria 
completely resistant against thanatin. LptA-His6 was recombinantly expressed and the purified 
protein subjected to fluorescence polarization measurements with labelled probe thanatin-
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BDP-FL. A Kd value of 12 ± 3 nM was calculated for the specific interaction between thanatin-
BDP-FL and LptA-His6 (Figure 64). In an ongoing collaboration with Peer Mittl from the 
Department of Biochemistry at UZH a thanatin-LptA co-crystal is being produced for x-ray 
diffraction analysis. The results of which are expected in the near future to help understand 
the interaction on a residue-to-residue basis. Taken together, these studies provide an 
important advance in revealing the mechanism of action of thanatin. So far, no other molecules 
are known that bind to LptA and so target the LPS transport bridge across the periplasm. The 
results described in this thesis might therefore be used to develop new classes of antibiotics 
against this important new target in Gram-negative bacteria. Although E. coli LptA displays a 
high sequence identity among other Gram-negative bacteria (Figure 67), the binding affinity of 
thanatin to LptA needs to be confirmed for these species. It also remains to be identified how 
LptD makes contact to thanatin and how the maturation of LPS is affected. It would also be 
interesting to study the mechanism of action in Gram-positive bacteria and fungi, as they both 
lack the Lpt system. 
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4 Experimental Part 
4.1 General Procedures and Analytics 
All solvents used for reactions were purchased from Sigma-Aldrich, Merck, or Acros (puriss. 
or p.a.). Solvents for extractions, flash column chromatography and thin layer chromatography 
(TLC) were purchased as commercial grade and distilled prior to use. High purity H2O (18 MΩ) 
was supplied by a Purelab Flex 02 (Elga Laboratories) dispenser system. Commercially 
available reagents and amino acids (GL Biochem Ltd) were used without further purification, 
unless otherwise noted. In general, reactions were magnetically stirred and monitored by TLC 
performed on Merck TLC aluminium sheets (silica gel 60 F254). Spots were visualized with 
UV light (λ = 254 nm) and through staining with vanillin/H2SO4 or anisaldehyde/H2SO4. 
Chromatographic purification of products was performed using silica gel 60 (Fluka) for 
preparative column chromatography (particle size 40-63 μm). 1H, 13C-NMR were recorded in 
CDCl3, DMSO-d6, or D2O on Bruker AV-300, AV-400 MHz and AV-500 MHz instruments at 
RT. Chemical shifts (δ) are reported in ppm and are referenced to TMS and TSP (0 ppm) as 
an internal standard. Data for NMR spectra are reported as follows: s = singlet, d = doublet, 
t = triplet, q = quartet, m = multiplet, br = broad signal, J = coupling constant in Hz. Routine 
low resolution mass spectra were recorded on a Dionex MSQ Plus spectrometer coupled to 
an automated Gilson liquid handler system 215, a Dionex P580 Pump, and a Dionex UVD170U 
detector with an Agilent ZORBAX SB-C8/C18 column (3.5 μm, 2.1×150 mm). High resolution 
mass spectra were recorded by the MS-service of the University of Zurich on a Bruker maXis 
HR-MS instrument. 
 
4.2 Solid Phase Peptide Synthesis 
Resin loading. 2-Chlorotrityl chloride resin (GL Biochem Ltd) was washed three times with 
DMF and three times with DCM without prior activation (an additional step of resin activation 
using acetyl chloride in toluene can be performed if necessary). A loading of 0.75 mmol amino 
acid per gram of resin was applied. The resin was swelled in DCM for 15 min by bubbling N2 
through the reaction vessel. In a round bottom flask the amino acid was dissolved in DCM 
(5 ml) and DIPEA (4 eq.) was added. The reaction vessel was drained and the amino acid 
mixture transferred to the reaction vessel. After a reaction time of 3 h, liquids were drained and 
the resin washed three times with DCM. Then, the resin was blocked by treatment with a 
solution of DCM/MeOH/DIPEA (17:2:1; 20 ml) for 2 min. Blocking was repeated five times and 
the resin finally washed with DCM and dried in vacuo. 
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Determination of the resin loading. Completely dry resin (1-2 mg) was treated with a 25% 
piperidine/DMF (3 ml) solution for 30 min. The solution was transferred into a quartz UV-
cuvette with 10 mm path length. UV absorption was measured at a wavelength of 290 nm 
against a blank background (25% piperidine/DMF). The resin loading can be calculated by 
using equation E 3. 
 
 Loading (mmol/g) = (A290 nm (sample) – A290 nm (blank)) / (1.75 * mdry resin) E 3 
 
There is also the possibility of determining the resin loading gravimetrically using equation E 
4, where mtotal = the mass of the loaded resin, mresin = the mass of the unloaded resin and MW,AA 
= molecular weight of the immobilized amino acid. 
 
 Loading (mmol/g) = ((mtotal – mresin) × 103) / ((Mw,AA – 36.46) * mtotal) E 4 
 
Fmoc deprotection. The resin was washed three times with DMF and swelled for 15 min. 
DMF was drained and 25% piperidine/DMF was added to fully cover the resin. The resin was 
agitated by bubbling N2 through the reaction vessel for 8 min. This procedure was repeated 
three times and the resin finally washed three times with DMF and DCM. 
 
Coupling of the next amino acid. The respective amino acid (4 eq.) HBTU (4 eq.), HOBt 
(4 eq.) and DIPEA (10 eq.) were dissolved in DMF (5 ml) and activated for 2 min. The mixture 
was then added to the Fmoc deprotected resin and agitated under N2 for 2 h. The resin was 
then washed three times with DMF and DCM. The last two steps (deprotection and coupling) 
were repeated for each subsequent amino acid. 
 
Automated peptide synthesis. Linear peptides were synthesized on a 0.25 mmol scale by 
an ABI433A automated peptide synthesizer (Applied Biosystems) coupled to a Perkin-Elmer 
785A UV/VIS detector. Cartridges filled with the corresponding amino acids (1 mmol, 4 eq.) 
were activated with 0.9 mmol of an HBTU/HOBt (0.45 M) stock solution in DMF and transferred 
to the resin containing reaction vessel, which was vortexed for 20 min in a standard coupling 
reaction cycle. Fmoc deprotection was achieved by addition of 20% piperidine in NMP for 7 min 
under vortexing. Complete deprotection was ensured by monitoring the formation of the 
dibenzofulvene and its piperidine adduct at 301 nm wavelength or by changes in conductivity 
of the drained solvent. Intermediate and final washing steps with NMP and DCM were 
performed by vortexing and subsequent draining of the solvents. 
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Selective cleavage from 2-chlorotrityl chloride resin. The final linear peptide was cleaved 
from its solid support by repeated treatment with a 0.8% TFA in DCM solution for two min. This 
procedure was repeated ten times and the TFA immediately quenched by draining the aliquots 
into a two molar excess of DIPEA. Excess DCM was evaporated in vacuo yielding a thick oil 
that was transferred into a 50 ml falcon tube with as little DMF as possible. Ice cold H2O was 
then added causing precipitation of the peptide. The suspension was centrifuged (15 min at 
4’000 rpm), the supernatant discarded, and the pellet resuspended with ice cold diethyl ether. 
This procedure was repeated for two times and the pellet dried overnight in vacuo. An improved 
cleavage method first described by Bollhagen et al.[133] was used alternatively: The resin was 
treated with hexafluoroisopropanol (HFIP), DCM, and trifluoroethanol (65:25:10, 5 ml) three 
times for 5 min. The combined fractions were dried in vacuo and co-evaporated with toluene 
to obtain a crystalline solid. 
 
Cyclization. HBTU (4 eq.), HOBt (4 eq.) and DIPEA (15 eq.) were dissolved in DMF (10 ml). 
This mixture was then added dropwise to a solution of the crude linear side-chain protected 
peptide in DMF at a concentration of approximately 0.01 M. The reaction mixture was stirred 
for 3 h and excess DMF was then removed under high vacuum. 
 
Global deprotection. A solution of TFA/TIS/H2O (95:2.5:2.5, 10 ml) was added to the crude 
cyclized peptide under cooling. The mixture was then allowed to reach room temperature (RT) 
und stirred for 3 h. Excess TFA was removed in vacuo resulting in a thick oil. The oil was then 
transferred dropwise to a 50 ml falcon tube filled with ice cold diethyl ether to precipitate. The 
suspension was centrifuged (15 min at 2’400 rpm), the supernatant discarded, and the pellet 
resuspended in ice cold diethyl ether. This procedure was repeated twice and the pellet finally 
air-dried yielding a pale solid powder. Cys and Met containing peptides were deprotected 
under reducing conditions by a solution of TFA:1,2-ethandithiol:thioanisole:H2O:TIS 
(75:10:10:4:1, 10 ml), and directly precipitated by dropwise addition into cold diisopropyl ether. 
Peptides that additionally contain azide groups can suffer from reduction of azides to amines 
under these conditions, and the use of DTT instead of 1,2-ethandithiol as thioscavenger is 
advised.[134] 
 
Oxidation. Formation of disulfide bonds was achieved at a concentration of approximately 
0.1 mg/ml peptide in 0.1 M ammonium acetate pH 8.5. The solution was stirred at RT overnight 
in the presence of atmospheric oxygen.[71] 
 
Purification and analysis. Crude cyclic peptides were purified by reverse phase HPLC using 
a binary gradient from 10 to 60% MeCN in H2O with additional 0.1% TFA on an ÄKTA purifier 
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100 system (Amersham Biosciences). Columns for analytical chromatography were of the type 
C18 4.6 × 250 mm with 5 μm particle size and C18 21.2 × 250 mm 7 μm particle size (Agilent 
Technologies) for preparative chromatography. UPLC was performed on an ACQUITY UPLC® 
system (Waters) equipped with a BEH130 C18 column, 2.1 x 100 mm, and 1.7 μm particle 
size. 
 
4.3 Minimal Inhibitory Concentration 
Bacterial strains to be tested were inoculated in water supplemented with 0.9% NaCl from a 
fresh agar plate. According to the McFarland standard[135], the turbidity of the bacterial 
suspension was adjusted to 0.5. An aliquot of 100 μl of this suspension was transferred into 
10 ml MH-I with 0.02% BSA or MH-II with 0.002% Tween80. The peptide was dissolved in H2O 
with 0.01% acetic acid at a concentration of 1 mg/ml, which was determined accurately by 
UV/VIS spectroscopy at 280 nm. A two-fold dilution series was prepared in a 96 well plate in 
a range of 64 μg/ml down to 0.0005 μg/ml. 50 μl of the bacterial suspension was then used to 
inoculate each well for a total volume of 100 μl, corresponding to 5 x 105 CFU/ml (colony 
forming units per ml). The plate was incubated overnight at 37°C and 200 rpm. The minimal 
inhibitory concentration was assessed visually as the lowest concentration of the antimicrobial 
agent that inhibits visible growth.[136] 
 
4.4 Coupling of Fluorophores via Click Chemistry 
PEG spacer with azide and acid functionality were obtained from Broadpharm (propargyl-
PEG4-acid and azido-PEG4-acid) and coupled on-resin by standard Fmoc chemistry. Amino 
acid building block Fmoc-Glu(PEG3-N3)-OH was synthesized according to Come et al.[137]. 
Different fluorophores obtained from Lumiprobe (BDP-FL-azide), Atto-Tec (ATTO-MB2), and 
Thermo Fisher (Alexa Fluor® 488 and 647) were coupled according to an adapted protocol 
from Clavé et al.[138] via Click Chemistry. Fluorescein-alkyne for the LB-01-FL synthesis was 
kindly provided by former group member Jessica Steinmann. As a representative example 
reaction the coupling of thanatin to BDP-FL-azide (Lumiprobe) is described: Intermediate 
thanatin-PEG4-azide (8.94 mg, 0.00334 mmol) was dissolved in H2O (500 µl). Sodium 
ascorbate (30 µl, 0.1 M, 0.0035 mmol), BDP-FL-azide (0.00134 mmol, 0.25 mg) dissolved in 
DMSO (100 µl) and CuSO4 (35 µl, 0.1 M, 0.0035 mmol) were sequentially added under stirring. 
After 15 min the mixture was injected on an LC-MS for reaction control. After another 15 min, 
the reaction mixture was directly purified by preparative HPLC in a single run with a gradient 
of 10-50% MeCN/H2O (0.1% TFA) and a retention time of 19.8 min. The isolated fraction was 
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lyophilized yielding 4 mg (98%) of red lyophilisate. HRMS (ESI): calculated for 
C132H220BF2N41O33S3 [M+4H]4+ 763.1505, found 763.1500. 
 
4.5 LB-01 
4.5.1 Introduction of N-Methyl Groups 
Introduction of N-methyl amino acids. Commercially available N-methylated amino acid 
building blocks were coupled according to the protocol described above. Fmoc-N-Me-Ala-OH, 
Fmoc-N-Me-Leu-OH, and Fmoc-N-Me-Trp(Boc)-OH were acquired from Sigma-Aldrich or 
Bachem. Subsequent peptide couplings onto an N-methylated terminus proved to be difficult 
under regular conditions. Higher yields were achieved by double coupling with the use of amino 
acid (4 eq.), HATU (4 eq.), HOAt (4 eq.), and DIPEA (8 eq.). 
 
On resin methylation (Kessler protocol). The resin was washed three times and swelled in 
DMF for 15 min by bubbling N2 through the reaction vessel. 2-Nitrobenzenesulfonyl chloride 
(4 eq.) and sym-collidine (10 eq.) were dissolved in DMF (7 ml) and the resin treated for 15 min 
with this mixture. This procedure was repeated once. The resin was washed thoroughly with 
anhydrous THF. In a round bottom flask, triphenylphosphine (5 eq.) was dissolved in 
anhydrous THF (4 ml) and anhydrous MeOH (10 eq.) was added to the solution and mixed 
well. The resin was treated with this mixture for 2 min. Diisopropyl azodicarboxylate (DIAD, 
5 eq.) was dissolved in THF (4 ml) and added to the reaction mixture in a portion wise manner, 
taking 1 ml aliquots each time with a reaction time of 10 min. This procedure was repeated 
once. The resin was washed three times with DMF. Mercaptoethanol (10 eq.) and DBU (5 eq.) 
were dissolved in DMF (7 ml) and added to the resin with a reaction time of 5 min. This 
procedure was also repeated once, and the resin was finally washed three times with DCM 
and dried in vacuo.[81] 
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4.5.2 Synthesis of Dipeptide Fmoc-Pro-N-Me-Thr(OtBu)-OH 
(2S,3R)-methyl 2-(((benzyloxy)carbonyl)(methyl)amino)-3-(tert-butoxy)butanoate 
 
 
Z-Thr(tBu)-OH dicylohexylamine salt (1.00 g, 2.04 mmol) was converted to the free acid by 
treatment with aq citric acid 5% and extraction into Et2O (3 x 20 ml). Ag2O (1.89 g, 8.16 mmol) 
was added to a solution of Z-Thr(tBu)-OH free acid and MeI (1.91 ml, 30.6 mmol) in DMF (7 ml) 
and stirred overnight at RT. DCM (15 ml) was then added and the solution was filtered through 
celite. The filter cake was washed with DCM (3 x 20 mL), and the combined organic phases 
were washed with 15% aq Na2S2O3 (2 x 30 ml), H2O (3 x 30 mL) and brine (30 ml). After drying 
(MgSO4), the combined organic phases were concentrated in vacuo and the oily residue was 
purified by flash column chromatography (4:1 cyclohexane/EtOAc) yielding 647 mg of colorless 
oil (94% yield). 
 
TLC: Rf 0.50 (cyclohexane/EtOAc 4:1, UV, vanillin) 
[α]D24: +3.5° (c 0.65, MeOH) 
 
Two rotamers with an approximate ratio of 2:1 are present. 
1H-NMR (500 MHz, CDCl3):  
Major: δ =7.39 - 7.27 (m, 5H), 5.21 - 5.04 (m, 2H), 4.82 (d, J=4.3 Hz, 1H), 4.41 - 4.35 (m, 1H), 
3.70 (s, 3H) 3.14 (s, 3H), 1.19 (d, J = 6.2 Hz, 3H), 1.13 (s, 9H). 
Minor: δ =7.39 - 7.27 (m, 5H), 5.21 - 5.04 (m, 2H), 4.59 (d, J= 5.1 Hz, 1H), 4.30 - 4.24 (m, 1H), 
3.65 (s, 3H), 3.11 (s, 3H), 1.16 (d, J = 6.2 Hz, 3H), 1.12 (s, 9H). 
13C-NMR (100 MHz, CDCl3): 
Major: δ = 170.7, 157.6, 136.8, 128.5, 128.0, 127.9, 127.6, 74.0, 68.4, 67.4, 64.1, 51.7, 33.6, 
28.7, 20.5. 
Minor: δ = 170.5, 156.4, 136.6, 128.5, 128.0, 127.9, 127.6, 74.1, 67.9, 67.4, 64.4, 51.7, 34.1, 
28.7, 20.7. 
 
HRMS (ESI): calculated for C22H25NNaO4 [M+Na]+ 390.1676, found 390.1672.[39]  
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(R)-(9H-fluoren-9-yl)methyl 2-(((2S,3R)-3-(tert-butoxy)-1-methoxy-1-oxobutan-2-yl) 
(methyl)carbamoyl)pyrrolidine-1-carboxylate 
 
 
To the foregoing dipeptide (294 mg, 0.87 mmol) in THF (9 mL) was added Pd/C (10%, 93 mg, 
0.09 mmol), and stirred for 30 min under H2. The solution was then filtered through celite, 
washed with THF, and dried under vacuo. COMU (746 mg, 1.74 mmol) was added to a mixture 
of Fmoc-Pro-OH (588 mg, 1.74 mmol), the dipeptide, and DIPEA (445 μl, 2.61 mmol) in DMF 
(9 ml) at 0°C. The reaction mixture was warmed to RT and stirred for 2 h. The mixture was 
then diluted with EtOAc (25 ml) and washed with aq citric 5% (2 x 15 ml), 1 M NaHCO3 
(2 x 15 ml), and saturated NaCl (2 x 15 ml). The organic layer was then dried over MgSO4 and 
the solvent removed in vacuo. The residue was purified by flash column chromatography 
(2:1 cyclohexane/ EtOAc then 1:1 cyclohexane/EtOAc) yielding 327 mg reddish foam that 
solidified overnight (72% yield). 
 
Mp 64 - 68°C 
TLC: Rf 0.47 (cyclohexane/EtOAc 1:1, KMnO4) 
[α]D24: -42.3 ° (c 0.22, MeOH) 
 
Two rotamers with an approximate ratio of 2:1 (Fmoc-amide rotation) are apparent by NMR, 
each with a low abundance rotamer deriving from the N-methyl-amide (not assigned). 
 
1H-NMR (500 MHz, CDCl3): 
Major: δ = 7.78 - 7.73 (m, 2H), 7.67 - 7.55 (m, 2H), 7.42 - 7.35 (m, 2H), 7.34 - 7.27 (m, 2H), 
5.35 (s, J = 3.5 Hz, 1H), 4.86 (dd, J = 8.4 Hz, 1H), 4.47 - 4.41 (m, 1H), 4.41 - 4.37 (m, 1H), 
4.33 - 4.26 (m, 1H), 4.30 - 4.24 (m, 1H), 3.70 (s, 3H), 3.80 - 3.72 (m, 1H), 3.62 - 3.56 (m, 1H), 
3.34 (s, 3H), 2.30 - 2.21 (m, 1H), 2.05 - 1.96 (m, 1H), 2.20 - 2.09 (m, 1H), 2.03 - 1.92 (m, 1H), 
1.20 (d, J = 6.3 Hz, 3H), 1.14 (s, 9H). 
Minor: δ = 7.78 - 7.73 (m, 2H), 7.67 - 7.55 (m, 2H), 7.42 - 7.35 (m, 2H), 7.34 - 7.27 (m, 2H), 
5.29 (s, J = 3.5 Hz, 1H), 4.65 (dd, J = 8.4 Hz, 1H), 4,71 - 4.65 (m, 1H), 4.41 - 4.35 (m, 1H), 
4.23 - 4.16 (m, 1H), 4.21 - 4.16 (m, 1H), 3.68 (s, 3H), 3.69 - 3.63 (m, 1H), 3.56 - 3.47 (m, 1H), 
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3.15 (s, 3H), 2.30 - 2.21 (m, 1H), 2.02 - 1.95 (m, 1H), 2.04 - 1.96 (m, 1H), 2.91 - 1.82 (m, 
1H),1.09 (s, 9H), 0.93 (d, J = 6.3 Hz, 3H). 
13C-NMR (100 MHz, CDCl3): 
Major: δ = 174.1, 170.7, 154.8, 144.3, 144.0, 141.3, 127.6, 127.0, 125.4, 125.2, 119.9, 74.0, 
68.8, 67.4, 61.5, 57.0, 51.7, 47.2, 47.6, 34.4, 29.2, 28.7, 24.3, 20.3. 
Minor: δ = 173.9, 170.5, 154.3, 144.4, 143.9, 141.3, 127.6, 127.1, 127.0, 125.3, 125.1, 119.9, 
119.8, 74.1, 68.5, 66.9, 61.4, 56.8, 51.7, 47.4, 46.9, 34.0, 30.2, 28.7, 23.0, 20.2. 
 
HRMS (ESI): calculated for C22H25NNaO4 [M+Na]+ 390.1676, found 390.1672.[39] 
 
(2S,3R)-2-((R)-1-(((9H-fluoren-9-yl)methoxy)carbonyl)-N-methylpyrrolidine-2-
carboxamido)-3-(tert-butoxy)butanoic acid 
 
 
To the foregoing methyl ester (265 mg, 0.51 mmol) in EtOAc (5 mL) was added LiI (679 mg, 
5.07 mmol). The mixture was refluxed for 16 h. After cooling, water was added and the solution 
acidified with aq citric acid 5% to pH 3, and extracted with EtOAc (3 x 20 ml). The combined 
organic phases were dried over MgSO4 and concentrated in vacuo. The product was purified 
by flash column chromatography (19:1 to 4:1 DCM/MeOH) yielding 203 mg of a white solid 
(79% yield). 
 
Mp 96 - 99°C 
TLC: Rf : 0.51 (9:1 DCM/MeOH, KMnO4) 
[α]D24: -34.8° (c 0.23, MeOH) 
 
Two rotamers with an approximate ratio of 1:1 (Fmoc-amide rotation) are apparent by NMR, 
each with a low abundance rotamer deriving from the N-methyl-amide (not assigned). 
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1H-NMR (500 MHz, DMSO-d6):  
Rotamer 1: δ = 12.80 - 12.62 (br, 1H), 7.92 - 7.85 (m, 2H), 7.70 - 7.53 (m, 2H), 7.45- 7.39 (m, 
2H), 7.37 - 7.26 (m, 2H), 4.79 (d, J=3.7 Hz, 1H), 4.75 - 4.68 (m, 1H), 4.38 - 4.34 (m, 1H), 4.27 
- 4.21 (m, 2H), 4.17 - 4.11 (m, 1H), 3.49-3.39 (m, 2H), 3.16 (s, 3H), 2.32 - 2.18 (m, 1H), 1.83 - 
1.76 (m, 2H), 1.79 - 1.73 (m, 1H), 1.12 (s, 9H), 1.04 (d, J = 6.3 Hz, 3H),  
 
Rotamer 2: δ = 12.80 - 12.62 (br, 1H), 7.92 - 7.85 (m, 2H), 7.70 - 7.53 (m, 2H), 7.45 - 7.39 (m, 
2H), 7.37 - 7.26 (m, 2H), 5.01 (d, J = 3.7Hz, 1H), 4.75 - 4.68 (m, 1H), 4.44 - 4.38 (m, 1H), 4.34 
- 4.29 (m, 1H), 4.28 - 4.23 (m, 1H), 4.14 - 4.07 (m, 1H), 3.49 - 3.39 (m, 2H), 3.08 (s, 3H), 2.32 
- 2.18 (m, 1H), 1.91 - 1.83 (m, 2H), 1.75 - 1.69 (m, 1H), 1.06 (s, 9H), 0.88 (d, J = 6.3 Hz, 3H),  
 
13C-NMR (100 MHz, DMSO-d6): 
Rotamer 1: δ =172.9, 171.5, 153.6, 143.9, 143.8, 140.7, 127.6, 127.1, 125.2, 120.1, 73.2, 67.9, 
66.4, 61.2, 56.6, 47.1, 46.9, 33.7, 29.6, 28.5, 23.7, 20.5. 
Rotamer 2: δ = 172.8, 171.3, 153.6, 143.8, 143.4, 140.7, 127.6, 127.1, 125.1, 120.0, 73.2, 
67.8, 66.2, 60.9, 56.4, 46.6, 46.4, 33.6, 28.6, 28.5, 23.7, 20.3. 
 
HRMS (ESI): calculated for C29H36N2NaO6 [M+Na]+ 531.24715, found 531.24656.[39] 
 
4.5.3 Solution NMR of N-methylated Analogues 
1H NMR measurements were performed in H2O/D2O (9:1) or pure D2O at pH 2-3, at 10-
15 mg/ml. Spectra were acquired on a Bruker AV-600 spectrometer at 300K. Water 
suppression was performed by presaturation. Spectral assignments were made by using 
2D DQF-COSY, TOCSY and NOESY spectra. 3JHNHα coupling constants were determined from 
1D spectra or, in the case of signal overlap from 2D NOESY spectra, by inverse Fourier 
transformation of in-phase multiplets. Distance restraints were obtained from NOESY spectra 
with a mixing time of 250 ms. Spectra were typically collected with 1024 x 256 complex data 
points zero-filled prior to Fourier transformation to 2048 x 1024, and transformed with a cosine-
bell weighting function. Data processing was carried out with TOPSPIN (Bruker) and 
XEASY[139]. Temperature coefficients were obtained by measuring the chemical shifts of the 
amide protons, and calculating their relative change over that temperature range. For the 
H/D exchange experiments, the lyophilized peptides were dissolved in 99% D2O, and one-
dimensional spectra were acquired every 10 min for 2 h at 300K. The amide region of the 
spectrum was analysed to determine slow exchanging amide protons. The structure 
calculations were performed by restrained molecular dynamics in torsion angle space by 
applying the simulated annealing protocol implemented in the program CYANA[89]. Starting 
from 100 randomized conformations, a bundle of 20 conformations incurring the lowest 
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CYANA target energy function were selected. MOE (Molecular Operating Environment, 
Chemical Computing Group Montreal, Canada) was used for structure analysis and 
visualization of the molecular models.[39] 
 
4.5.4 Circular Dichroism 
Circular dichroism spectra were recorded on a J-175 spectropolarimeter (Jasco) using a quartz 
cell of 1 cm path length at RT. The measurement range was 195 to 250 nm with a scan rate 
of 20 nm/min and standard sensitivity. Two scans were accumulated, corrected for background 
signal, averaged, and smoothed for each spectra. Concentrations of all compounds were 
10 µM in PBS (phosphate buffered saline) pH 7.4. Values are expressed as molar ellipticity 
(deg*cm2/dmol). 
 
4.5.5 Cellular Uptake Studies 
Cell culture. HeLa cells were kindly provided by the Wang group at the Institute of 
Experimental Immunology UZH. Cells were cultivated in DMEM with the addition of 10% FBS 
(fetal bovine serum, Sigma-Aldrich) and 1x streptomycin/penicillin (100x stock Gibco®, Thermo 
Fisher). 1x trypsin-EDTA 0.5% (10x stock Gibco®, Thermo Fisher) was used for cell 
dissociation in routine cell culture passaging. 
 
Confocal microscopy. 100’000 HeLa cells, counted with a Neubauer chamber, were seeded 
on round cover slips in a 12 well plate and grown for 24 h. Media was exchanged with addition 
of fluorescence-labelled peptides Tat-FITC (20 µg/ml), LB-01-FL (10 µg/ml), or LB-01-AF647 
(20 µg/ml). The cells were washed three times with PBS and then incubated in 2% 
paraformaldehyde in PBS for 10 min. Cells were then aspirated and mounted with mounting 
media containing DAPI (ProLong® Gold Antifade, Thermo Fisher) on microscope slides 
(Menzel-Gläser, 76x26 mm, Thermo Fisher). Fluorescence microscopy was performed on a 
Leica CLSM SP8 inverted microscope, using a 100x oil objective (HC PL APO, Leica). 
 
Cell lysis assay. 7 x 100’000 cells were seeded in 12 well plates the day before. Cells were 
washed three times with PBS (500 µl) and incubated in triplicate with 6.4 µM Tat-FITC, 6.4 µM 
LB-01-FL, and one control, for 1 h in serum free DMEM (500 µl). Cells were then carefully 
washed three times with PBS (500 µl). Cell lysis was performed with 100 µl DISC lysis buffer 
(30 mM Tris-HCl (pH 7.5), 150 mM NaCl, 10% glycerol, 1% Triton X-100, cOmplete™ mini 
protease inhibitor cocktail (Roche)) for 20 min on ice. The lysate was transferred to Eppendorf 
tubes and centrifuged (5’000 rpm, 5 min). 50 µl of the supernatant was transferred to a white, 
flat-bottom 96 well plate (Corning) and diluted with 50 µl PBS. Fluorescence intensity was then 
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recorded on a Tecan infinite 200 Pro plate reader (Ex. 485 nm / Im. 535 nm). A dilution series 
of Tat-FITC was used to calculate the concentrations of fluorescence-labelled compound taken 
up by the cells. 
 
4.6 Thanatin 
4.6.1 Sytox® Green Assay in MH-I 
20 mL of MH-I were inoculated with 2% (400 μl) of an E. coli ATCC25922 overnight culture. 
The bacteria were grown at 37°C and 200 rpm, to an OD600 of 0.3-0.4. The cells were then 
centrifuged (5 min at 4’000 rpm) and the pellet was resuspended in the right amount of MH-I 
to obtain an OD600 of 0.1. 3 ml of this suspension were transferred into a cuvette containing a 
magnetic stir bar and 0.002% Polyoxethylene80 (P80 or Tween80). The fluorescence was then 
recorded using an LS55 Fluorescence Spectrometer (PerkinElmer). Excitation and emission 
wavelengths for Sytox® Green dye were 488 nm and 525 nm respectively. A slit width of 2.5 nm 
was used to record the spectrum. A blank was first measured for 100 s. After this, Sytox® 
Green dye from a 500 μM stock solution in DMSO was added to reach a concentration of 
0.5 μM, and the signal was observed during 400 s. At this point, the antibiotic was added and 
the fluorescence intensity was recorded for 1 h. 
 
4.6.2 Sytox® Green Assay in HEPES Buffer 
20 mL of MH-I were inoculated with 2% (400 μl) of an E. coli ATCC25922 overnight culture. 
The bacteria were grown at 37°C and 200 rpm, to an OD600 of 0.3-0.4. The cells were then 
centrifuged (5 min at 4’000 rpm) and the pellet was washed a single time and then 
resuspended in 5 mM HEPES buffer pH 7.2 with or without MgCl2 (0.5 mM) and CaCl2 (1 mM) 
supplementation to obtain an OD600 of 0.1. 3 ml of this suspension were taken into a cuvette 
containing a magnetic stir bar, 0.002% of Tween80, and the antibiotic. The fluorescence 
intensity was then recorded as stated above. 
 
4.6.3 β-Galactosidase Assay 
MH-II was inoculated with 2% of an overnight culture of E. coli ML-35[140] (ATCC43827) in LB 
(lysogeny broth). The bacteria were grown at 37°C and 200 rpm, to an OD600 of 0.4 - 0.6. 
During this time a 24-well plate was prepared containing the right amount of antibiotic, 0.02% 
BSA and a solution of H2O/DMSO (80:20%) to fill up to 50 µl. At an OD600 of around 0.6, the 
cells were centrifuged (5 min at 4’000 rpm), washed in LB media and centrifuged again (5 min 
at 4’000 rpm). Finally, the cell pellet was resuspended in PBS (containing 1 mM CaCl2 and 
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0.5 mM MgCl2) to obtain an OD600 of 0.5. From this culture, 950 µl were added to each well 
(except the wells containing PBS only for the controls and the wells containing the supernatant 
of lysed cells for the 100% β-galactosidase release control). The plate was incubated at 37°C 
and 200 rpm for 1 h. The content of each well was transferred to Eppendorf tubes and 
centrifuged (45 s at 11’000 rpm). The supernatant (900 µl) was placed back in a fresh 24-well 
plate and OPNG (o-nitrophenyl-β-galactoside) was added to a final concentration of 0.25 mM 
(100 µl of a 0.25 mM a stock solution). After 30 min at RT, the absorbance was measured at 
420 nm. H2O:DMSO (80:20) treated bacteria were used as “zero intensity” controls and 
sonicated, lysed cell were used as 100% β-galactosidase release controls.[29] 
 
4.6.4 β-Lactamase Assay 
For periplasmic β-lactamase expression, E. coli ML-35 cells were grown in MH-II containing 
ampicillin (100 µg/ml) to an OD600 of 0.4 - 0.6. During this time, a 24-well plate was prepared 
containing the right amount antibiotic, 0.02% BSA, and a solution of H2O:DMSO (80:20%) to 
fill up to 50 µl. The cells were then collected, washed twice with fresh MH-II, and resuspended 
in PBS supplemented with CaCl2 (1 mM) and MgCl2 (0.5 mM) to an OD600 of 0.3. The cell 
suspension (950 µl) was distributed to the previously prepared 24-well plate. The plate was 
incubated at 37°C and 200 rpm for 1 h. The content of each well was transferred to Eppendorf 
tubes and centrifuged (45 s, 11’000 rpm). The supernatant (900 µl) was placed back in a fresh 
24-wells plate, to which CENTA (Merck-Millipore) substrate was added to a final concentration 
of 100 μg/ml. After 30 min at RT, the absorbance was measured at 405 nm. H2O:DMSO (80:20) 
treated bacteria were used as “zero intensity” controls and sonicated, lysed cell were used as 
100% β-lactamase release.[29] 
 
4.6.5 Macromolecular Synthesis Assay 
The radioisotope precursors (10x final concentration, in 2x DM) and an 8-point, two-fold serial 
dilution of antibiotics (10x final concentration, in H2O:DMSO (80:20) were prepared (Table 17 
and Table 18). The experiments were carried out in 96-well round bottomed polypropylene 
plates (Thermo Fisher). For each [3H]-precursor, a background (without cells), a maximal 
incorporation (cells without antibiotic), and a duplicate of cells treated with antibiotic dilutions 
were made. For the background and the maximal incorporation, 10 μl of the 10x radioisotope 
stock + 10 μl of H2O:DMSO (80:20) were added. For the antibiotic treated samples, 10 μl of 
the 10x radioisotope stock and 10 μl of the antibiotic dilution were added. Once prepared, the 
plates were prewarmed to 37°C. 
 
Experimental Part 
102 
Table 17 Concentrations and specific activities of precursors used for the macromolecular synthesis assay in E. 
coli ATCC25922. 
 Final conc. 
[μCi/ml] 
Final conc. 
[μM] 
Specific activity 
[Ci/mmol] 
[3H]-Leucine 10 0.16 60 
[3H]-Uridine 10 0.16 60 
[3H]-Thymidine 10 0.14 71 
[3H]-NAG 1 0.016 60 
 
 
Table 18 Concentrations of the 10x antibiotic stock solutions in H2O:DMSO (80:20). 
 Tobramycin 
[μg/ml] 
Rifampicin 
[μg/ml] 
Ciprofloxacin 
[μg/ml] 
Ceftriaxone 
[μg/ml] 
Thanatin 
[μg/ml] 
1 320 2560 5.12 80 160 
2 160 1280 2.56 40 80 
3 80 640 1.28 20 40 
4 40 320 0.64 10 20 
5 20 160 0.32 5 10 
6 10 80 0.16 2.5 5 
7 5 40 0.08 1.25 2.5 
8 2.5 20 0.04 0.625 1.25 
 
 
1x DM (defined growth media) was inoculated with 2% of an overnight culture of E. coli 
ATCC25922 in MH-I (2%) and grown at 37°C and 200 rpm. When the mid-log phase was 
reached (OD600=0.3), 80 μl of 1x DM was added to the background wells (cell-free blank) and 
80 μl of mid-log phase cells were added to the maximum incorporation and the antibiotic 
treated incorporation wells. Plates were incubated at 37°C and 200 rpm for 20 min, which is 
approximately half the generation time for E. coli ATCC25922 in 1x DM. At this point, the 
incorporation was terminated by addition of 50 μl of 30% TCA (trichloroacetic acid) to each 
well. Plates were cooled down for 1 h at 4°C, incubated at 37°C and 200 rpm for 30 min, and 
cooled again for 15 min at 4°C. During this time, 96-well filter plates (Merck-Millipore) were 
prepared by washing with 200 μl of 5% TCA, according to the manufacturer’s instructions. Test 
aliquots of 120 μl (of a total 150 μl) were transferred to the filter plates, filtered, and washed 
four times with 5% TCA and one time with 95% EtOH. The filter plates were dried (50°C for 
1 h) and the underdrain removed. The filters were punched and transferred to a 96-well 
isoplate (Perkin Elmer). 200 μl of OptiPhase Supermix (Perkin Elmer) was added to each well 
and the top of each plate was sealed with transparent film (Merck-Millipore). After one night 
shaking at 150 rpm, the plates were counted on a Wallac MicroBeta 1’450 scintillation counter 
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(PerkinElmer), with top and bottom PMT counting for a better signal-to-noise ratio (each well 
2 min). 
 
Defined growth media (DM). The defined medium used for macromolecular synthesis assays 
comprised the following: 1xM9 salts; 0.5% glucose (w/v); 1 mM MgCl2; 20 μg/ml CaCl2; 2 μg/ml 
thiamine; 2 μg/ml nicotinic acid; 100 μM L-alanine, L-asparagine, L-aspartate, L-glutamate, L-
glycine, L-proline, and L-serine; and 200 μM L-arginine, L-cysteine, L-histidine, L-isoleucine, 
L-lysine, L-methionine, L-phenylalanine, L-threonine, L-tryptophan, L-tyrosine, and L-valine; 1 
μM L-leucine. 
 
4.6.6 Photoaffinity Labelling 
200 ml MH-I medium was inoculated with 2% of an E. coli ATCC25922 overnight culture and 
incubated at 37°C and 200 rpm. After reaching an OD600 of 1, 50 ml of this culture were spin 
down (20 min at 4’000 rpm). The cells were washed once, then taken up in 50 ml PBS and 
incubated for 30 min at 37°C and 200 rpm in the dark with 2-10 μg/ml thanatin-PAL5 (MIC = 
2-4 µg/ml), followed by UV irradiation at 350 nm wavelength in a Rayonet Reactor (16 x 8W 
Sylvania blacklight lamps) for 30 min at 30°C. A control sample was treated in the same 
manner, without addition of the photoprobe. Cells were harvested by centrifugation (30 min at 
4’000 rpm) and washed two times with PBS. Pellets can be stored at -20°C. 
 
Membrane isolation. The cell pellets described above were resuspended in 50 mM Tris-HCl, 
pH 7.3, with addition of one tablet cOmplete™ mini protease inhibitor cocktail (Roche) per 
30 ml and lysed by three cycles of sonication using a Branson digital sonifier equipped with a 
microtip (80 W, 30% intensity, 20 sec on with 20 sec off for 2 min) under cooling on ice. To 
remove unbroken cells and cell debris, the lysate was centrifuged (30 min at 4’000 rpm, 4°C). 
The supernatant was then carefully decanted and subjected to ultracentrifugation (200’000 g, 
45’000 rpm in a Sorvall T-875 rotor, 1 h, 4°C). The supernatant, containing the soluble 
cytoplasmic protein fraction, was kept. The pellet was resuspended in 50 mM Tris-HCl, pH 7.3 
and again, subjected to ultracentrifugation (1 h at 45’000 rpm, 4°C). The pellets (isolated 
membrane fraction) can be stored at -20°C. 
 
Determination of protein concentration. Protein concentrations were determination by the 
Bradford method[141]. H2O (500 µl) and Bradford reagent (500 µl) (Sigma-Aldrich) and 5 µl of 
the protein suspension were mixed and the absorption was measured at 595 nm. A standard 
curve was generated using BSA, to determine the sample concentration by linear regression. 
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1D gel electrophoresis. Aliquots of 1-10 μg of protein from membrane or cytoplasmic 
fractions were loaded on SDS-polyacrylamide gels in SDS loading buffer containing 100 mM 
DTT as a final concentration. After 5 min heating at 100°C in a heating block, each sample 
was loaded onto the gel twice, resulting in 2 half gels, one for Coomassie brilliant blue staining 
and the other half for Western blotting and biotin detection. 
 
Investigation of proteins with low molecular weight. Precasted 4-20% TGX gradient gels 
(Bio-Rad) were run at 200 V in electrophoresis buffer (25 mM Tris, pH 8.8, 192 mM glycine, 
0.1% SDS). Blotting was achieved using the Trans-Blot® Turbo blotter (Bio-Rad) with 
commercially available membrane stacks (PVDF, 0.2 µm pore size, Bio-Rad) for 2 x 8 min at 
1.3 A, 25 V. 
 
Investigation of proteins with high molecular weight. Self-casted gels with 10% acrylamide 
(4% acrylamide in stacking gel) according to Laemmli[142] were run in electrophoresis buffer 
(25 mM Tris-HCl, pH 8.3, 192 mM glycine, 0.1% SDS) with initially 90 V for the stacking and 
then 130 V for the separating gel. For blotting, a properly sized piece of PVDF membrane 
(0.45 μm pore size, Immobilon®-P, Merck) was activated with MeOH (30 s), then rinsed two 
times for 2 min with H2O and pre-equilibrated 5 min with transfer buffer (buffer 1: 12 mM Tris, 
96 mM glycine, 0.1 % SDS and buffer 2: 10 mM Na2HPO4, 1 % SDS, 6 M Urea. Mix 1:1 and 
filter (0.22 µm pore size, Whatman)). Six filter papers (3 mm, Whatman) were cut out in the 
same size as the gel and the membrane. Filters, membrane and gel were placed on the 
graphite plate in the following order: i) three filter papers soaked in transfer buffer, ii) pre-
equilibrated membrane, iii) gel, iv) three filter papers soaked in transfer buffer. Electrophoretic 
transfer of proteins from gel onto the membrane was achieved by a Pierce G2 Fast Blotter 
(Thermo Fisher) for 2 h at 0.5 A and 10 V. After transfer, the membrane was blocked with 
blocking buffer (3% BSA, 0.2% Tween20 in PBS) for 1 h at RT or overnight at 4°C. After 
blocking, the membrane can be stored at -20°C. For detection, the blocked membrane was 
incubated with Streptavidin-HRP or NeutrAvidin-HRP conjugate (Pierce, 1:30'000 from stock, 
1% BSA, 0.2% Tween20 in PBS) for 1 h. The membrane was washed 4 x 5 min with PBS. 
Then, the membrane was covered with WesternBright™ Sirius™ (Advansta) HRP substrate 
(1 - 3x dilution with H2O) on the tray and covered with plastic foil. Chemiluminescence was 
detected on a ChemiDoc™ MP Imaging System (Bio-Rad) over the course of 1-20 min. The 
washed (PBS) membrane can be stored at -20°C. 
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4.6.7 2D Gel Electrophoresis 
The protein concentration was determined by the Bradford method after the first 
ultracentrifugation and resuspension in 50 mM Tris-HCl, pH 7.3 buffer. After the second 
ultracentrifugation step the samples were resuspended to a concentration of 1.33 mg/ml in 
rehydration buffer (1% w/v tetradecanoylamido-propyl-dimethylammonio-propane-sulfonate 
(ASB-14, Sigma-Aldrich), 2 mM tributyl phosphine, 7 M urea, 2 M thiourea and 0.5% w/v carrier 
ampholytes 3-10 (Biolytes pH 3-10, Bio-Rad, and a small spatula of bromophenol blue). For 
Coomassie staining 600 µg protein/gel (450 µl), for biotin detection 200 µg protein/gel (150 µl 
diluted to 450 µl) were required. Samples were centrifuged (3 min, 13’000 rpm) and loaded by 
in-gel rehydration onto immobilized pH gradient strips (IPG-strips, pH 4-7, 18 cm, Bio-Rad) 
overnight at RT. Isoelectric focussing was performed using an Ettan IPGphor isoelectric 
focussing system (Amersham) for 3 h at 150 V, 3 h at 300 V, and finally 8’000 V for a total of 
50 kVh. Subsequently, the IPG-strips were equilibrated in 6 M urea, 20% glycerol, 2% w/v 
SDS, 5 mM tributyl phosphine and 375 mM Tris (3 ml/strip) for 30 min at RT. The strips were 
then placed on top of a 10% SDS-PAGE gel (acrylamide/bisacrylamide Roti Gel 40, 375 mM 
Tris-HCl pH 8.8, 5% glycerol, 0.1% SDS, 1.1 µM TEMED, 0.05% ammonium persulfate) and 
sealed using 1.5 ml of a 0.5% agarose solution in running buffer, containing a small amount of 
bromophenol-blue. Precision Plus Protein standard plugs (Bio-Rad) or filter papers soaked 
with pre-stained protein ladder (Fermentas Page Ruler™) were added and gels were 
electrophoresed using an Ettan DALT II system (Amersham) with 2 W/gel for 45 min and 
17 W/gel for 3 h, with electrophoresis buffer (25 mM Tris-HCl, pH 8.3, 192 mM glycine, 0.1% 
SDS). For Coomassie staining, gels were incubated in fixing solution (20% methanol, 1% 
phosphoric acid (80%)) for 30 min and stained overnight in 20% RotiBlueTM (Roth) 
concentrate, 20% methanol, and 60% water. Gels were destained for 5 min in 25% 
methanol/water and stored in MilliQ-water. For Biotin detection the proteins from an unstained 
gel were blotted onto an PVDF membrane (0.45 μm pore size, Immobilon®-P, Merck) in a 
Pierce G2 Fast Blotter (Thermo Fisher) for 2 h at 0.5 A and 10 V. After transfer, the membrane 
was blocked with blocking buffer (3% BSA, 0.2% Tween20 in PBS) for 1 h at RT or overnight 
at 4°C. After blocking, the membrane can be stored at -20°C. 
 
4.6.8 Fluorescence Microscopy 
20 ml of MH-II were inoculated with 400 μl of an overnight culture of E. coli ATCC25922 in LB. 
The bacteria were grown at 37°C and 200 rpm to exponential growth phase (OD600 of 0.5 - 
0.7). When the exponential phase was reached, 200 μl of the culture was taken and transferred 
to an Eppendorf tube. Antibiotics in the desired concentration were added. A negative control 
was done by adding the same amount of H2O:DMSO (80:20). The samples were incubated for 
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1 h at 30°C and 200 rpm. In case of thanatin-BDP-FL (BDP-FL-azide, Lumiprobe) labelling, 
the cells were incubated for 1-2 h, washed twice with PBS, and then fixated with 200 μl of 4% 
paraformaldehyde in PBS for 30 min at RT. After fixation, the cells were again washed in PBS 
and resuspended in H2O (20 μl). In the meantime, microscope patches were prepared by 
boiling 1% agarose solution in water until the agarose was completely dissolved. 800 μl were 
then poured onto a clean microscope slide (Menzel-Gläser, 76x26 mm, Thermo Fisher), 
covered with a second slide, and cooled down for 5 min. The agarose patches were kept wet. 
Different dyes were added to the samples and the bacteria were incubated on ice for 1 h. The 
samples were centrifuged (30 s at 3’300 g) and resuspended in 200 μl medium to wash the 
cells. The cells were then centrifuged again (30 s at 3’300 g) and concentrated in one tenth of 
the volume. 3 μl of the sample were added onto the microscope patch and imaged with a 
fluorescence microscope (CLSM SP8 inverted, Leica), using a 100x oil objective (HC PL APO, 
Leica). Fluorescent compounds were used in concentrations according to Table 19. 
 
Table 19 Concentrations of different fluorescent compounds used in the experiments. 
Compound Stock (in DMSO) 
Concentration 
Experiment 
Labelling time 
[min] 
FM4-64 100 μg/ml 1 μg/ml 45 - 60 
Sytox 50 μM  0.5 μM 10 - 15 
DAPI 200 μg/ml 0.2 μg/ml 10  
Thanatin-BDP-FL 500 μg/ml (20% H2O) 4 - 8 μg/ml 60 - 120 
 
 
4.6.9 Protein Identification by Mass Spectrometry 
Cell harvesting. For the photoaffinity labelling experiment, 2 x 200 ml MH-I were inoculated 
with 2% (4 ml) of an E. coli ATCC25922 overnight culture. The cells were harvested at an 
OD600 of 1 by centrifugation (20 min, 4’000 rpm). The cells were washed, and taken up in 
200 ml PBS and incubated for 30 min at 37°C with 10 μg/ml thanatin-PAL5 and 0.002% 
Tween80, followed by UV irradiation (350 nm) for 30 min at 30°C. A control sample was treated 
in the same manner. The cells from three different cultures of labelled and control samples 
were washed five times with PBS (50 ml), put on ice, and subjected to mass spectrometric 
analysis at ETH Zurich. For the proximity based photo-oxidation experiment, 200 ml MH-I were 
inoculated with 2% (4 ml) of an E. coli ATCC25922 overnight culture. The cells were harvested 
at an OD600 of 1.2 by centrifugation (20 min, 4’000 rpm) and washed once with PBS (50 ml) 
and delivered to ETH Zurich on ice. 
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Sample preparation photoaffinity labelling. Cell pellets of thanatin-PAL5 labelled (n=3) and 
unlabelled control samples (n=3) were resuspended in 50 mM ammonium bicarbonate 
containing protease inhibitor cocktail (cOmplete™ mini protease inhibitor cocktail, Roche) and 
1% RapiGest (Waters). Cells were lysed at 4°C by six intervals of 30 s ultrasound sonication 
in a vial tweeter (Hielscher Ultrasonics GmbH) at a power of 170 W and 80% cycle time. Protein 
concentration was measured by Nanodrop 2000 Spectrophotometer (Thermo Fisher) and 
10 mg protein incubated with 200 µl agarose based streptavidin resin (Thermo Fisher) for 
100 min at 4°C to bind biotinylated proteins. Beads were settled by centrifugation (5 min at 
2’000 g). The supernatant was collected and stored at -20°C. Beads were then resuspended 
in 50 mM ammonium bicarbonate and transferred to Mobicol columns equipped with a 30 μm 
pore size filter (MoBiTec GmbH). On a Vac-Man Laboratory Vacuum Manifold (Promega), the 
beads were extensively washed with 20 times 500 µl aliquots of 5 M NaCl, StimLys buffer 
(50 mM Tris pH 7.8, 137 mM NaCl, 150 mM Glycerol, 0.5 mM EDTA, 0,1 % Triton X-100), 
100 mM NaHCO3 and a final 50 mM ammonium bicarbonate wash to remove non-biotinylated 
proteins. Beads were transferred to fresh Mobicol columns and proteins reduced with 5 mM 
Tris(2-carboxyethyl)phosphine (TCEP) in 50 mM ammonium bicarbonate for 40 min at 37°C. 
Then, proteins were alkylated on-beads by adding iodoacetamide to a final concentration of 
10 mM for 30 min at 37°C. Purified biotinylated proteins were proteolytically digested by 
sequencing grade modified trypsin (Promega) for 20 h at 37°C. Peptide containing solution 
was collected by quick spinning of Mobicols in Eppendorf tubes. Beads were further washed 
with 50 mM ammonium bicarbonate and the flow-through pooled with peptide solution. 
Samples were acidified to pH < 3 by addition of formic acid and subjected to C18 purification 
using 3–30 μg UltraMicroSpin Columns (The Nest Group) according to the manufacturer's 
instructions. 
 
Sample preparation proximity based photo-oxidation. Cell pellets were resuspended in 
PBS containing 3 μM thanatin-PAL5-MB (n=3) or 3 μM thanatin-PAL5-MB with 30 μM native 
thanatin (n=3, competition control). Cells were incubated for 30 min at 37°C and then 
resuspended in ice cold PBS containing 5 mM biocytin-hydrazide (Pitsch Nucleic Acids) at 
pH 6.5. Subsequently, cells were illuminated for 5 min with monochromatic light at a 
wavelength of 656 nm and an intensity of 58 mW/cm2 at 4°C, using precision LED spotlights 
(Micro Control Instruments Ltd.). After the photo-oxidation, cells were incubated in the dark for 
25 min at 4°C to ensure thorough biotinylation of oxidized proteins. Samples were 
resuspended in 50 mM ammonium bicarbonate, containing protease inhibitor cocktail 
(cOmplete™ mini protease inhibitor cocktail, Roche) and 0.1% RapiGest (Waters). Cells were 
lysed at 4°C by six intervals of 30 s ultrasound sonication in a vial tweeter (Hielscher 
Ultrasonics GmbH) at a power of 170 W and 80% cycle time. Protein concentration was 
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measured by a Nanodrop 2’000 spectrophotometer (Thermo Fisher) and 8 mg protein per 
sample was subjected to automated purification and processing of biotinylated proteins. For 
this, in-house packed tips containing 80 µl streptavidin plus ultraLink resin (Thermo Fisher) 
were coupled to a Versette liquid handling robotic system (Thermo Fisher) and incubated with 
the cell lysate for 1 h at room temperature while pipetting up-and-down. In an automated 
fashion, bead-bound proteins were subsequently washed with 5 M NaCl, StimLys Buffer 
(described above), 100 mM NaHCO3 and 50 mM ammonium bicarbonate, reduced with 5 mM 
TCEP, 3 M urea, 50 mM ammonium bicarbonate for 30 min at 37°C, alkylated with 10 mM 
iodoacetamide in 3 M urea and 50 mM ammonium bicarbonate for 30 min at 37°C and 
proteolytically digested with sequencing grade modified trypsin (Promega) in 1.5 M urea and 
50 mM ammonium bicarbonate for 17 h at 37°C. Eluted peptides were acidified to pH < 3 by 
addition of formic acid and subjected to C18 purification using 3–30 μg UltraMicroSpin 
Columns (The Nest Group) according to the manufacturer's instructions. 
 
Mass spectrometry acquisition. Peptide samples were separated by reversed-phase 
chromatography on a HPLC column (75 μm inner diameter, New Objective) that was packed 
in-house with a 15 cm stationary phase (ReproSil-Pur C18-AQ, 1.9 µm) and connected to a 
nano-flow HPLC combined with an autosampler (EASY-nLC II, Thermo Fisher). The HPLC 
was coupled to a Q-Exactive Plus mass spectrometer (Thermo Fisher) equipped with a nano 
electrospray ion source (Thermo Fisher). Peptides were loaded onto the column with 100% 
buffer A (99.9% H2O, 0.1% formic acid) and eluted at a constant flow rate of 300 nl/min with a 
30 min linear gradient from 6–20% buffer B (99.9% ACN, 0.1% FA) and 15 min 20-32% 
followed by a 3 min transition from 32% to 50% buffer B. After the gradient, the column was 
washed 5 min with 98%, 4 min with 50%, and again 5 min with 98% buffer B. In between runs, 
the column was further cleaned for 18 min with two steep consecutive gradients of acetonitrile 
(10% - 98%). Electrospray voltage was set to 2 kV, sheath and auxiliary gas flow to zero, and 
capillary temperature to 250°C. In data-dependent acquisition (DDA) mode, the mass 
spectrometer automatically switched between MS and MS/MS detection. Following a high-
resolution survey MS spectrum (from 300 to 1’500 m/z) acquired in the Orbitrap with resolution 
R = 70’000 at m/z 200 (automatic gain control target value 3*106), the 15 most abundant 
peptide ions with a minimum intensity of 2.5*104 were selected for subsequent HCD 
fragmentation with an isolation window of 1.4 Da and fragments were detected by MS/MS 
acquisition at resolution R = 35’000 (automatic gain control target value: 1*106). Target ions 
already selected for fragmentation were dynamically excluded for 30 s. 
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Data analysis. Acquired raw files were subjected to peptide and protein identification using 
Trans Proteomic Pipeline v.4.7 (SPC/ISB Seattle). First, fragment ion spectra acquired in DDA 
mode were matched against a database of SwissProt (UniProt consortium) reviewed E. coli 
protein sequences and common contaminants.[119] Peptides were required to be fully tryptic 
with a maximum of 2 missed cleavage sites, carbamidomethylation as fixed modification, and 
methionine oxidation as a dynamic modification. The precursor and fragment mass tolerance 
were set to 20 ppm and 0.02 Da, respectively. Identified proteins were quantified by integration 
of chromatographic traces on MS1 level using Progenesis QI v.2.0 (Nonlinear Dynamics UK). 
Contaminant hits were removed and proteins filtered to obtain a false discovery rate of < 1%. 
Raw protein abundances based on non-conflicting peptides were exported and differential 
abundance testing was performed using R-package MSstats v3.5.3[143]. Bacterial proteins with 
an abundance fold change of +/- 1.5 and adjusted p-value < 0.05 were considered as 
significantly regulated by photoaffinity labelling or proximity based photo-oxidation. 
 
4.6.10 Production of Recombinant E. coli LptA-His6 
Gene cloning. Primers for NdeI and XhoI restriction site were ordered from Sigma-Life 
Science (Ndefor: ATCTACATATGAAATTCAAAAACAAAC and Xhorev: 
TACGTCTCGAGATTACCCTTCTTCTGTGC). Chromosomal DNA from E. coli ATCC25922 
was isolated (Bacterial Genomic DNA Kit, GenElute™) and loaded for PCR (polymerase chain 
reaction) amplification according to Table 20. The temperature program was run on a 
GeneAmp® PCR System 2700 (Applied Biosystems) with 25 amplification cycles (45 min/95°C, 
45 min/45°C, 1 min/72°C). The PCR product was purified on a 1% agarose gel with addition 
of ethidium bromide (approximately 0.5 μg/ml). Bands were highlighted around 500 bp and cut 
out under UV light for digestion with restriction enzymes. The pET-22b vector was isolated 
(QIAprep Spin Miniprep Kit, Qiagen) from an overnight culture of a pET-22b containing strain, 
digested by restriction enzymes NdeI and XhoI, and purified on a 1% agarose gel. One third 
of the vector band and the whole band of lptA were cut out, pooled, and purified using the 
QIAquick gel extraction Kit (Qiagen). Ligation was performed overnight at 16°C.  
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Table 20 Components used for PCR amplification. 
 MgSO4 3 mM MgSO4 4 mM 
 control  control  
template genomic 'DNA 0 1 0 1 
ddH2O 41 40 39 38 
10xPfu/20 mM MgSO4 5 5 5 5 
MgSO4 25 mM 2 2 4 4 
LptA NdeI for 50 μM 0.5 0.5 0.5 0.5 
LptA XhoI rev 50 μM 0.5 0.5 0.5 0.5 
dNTPs 25 μM 0.5 0.5 0.5 0.5 
Pfu Taq Pol (3 U/μl) 0.5 0.5 0.5 0.5 
Total volume [μl] 50 50 50 50 
 
 
Transformation. E. coli XL1 Blue were taken from a -80°C stock and put on ice for 30 min 
with the addition of an aliquot of the vector. Then, the cells were put in a water bath at 45°C 
for 45 min (heat shock transformation) and again put on ice for 2 min. After that, 600 μl of 
S.O.C. medium (Thermo Fisher) was added and the cells incubated for 1 h at 37°C and 
200 rpm. Cells were plated out on solid agar supplemented with ampicillin and incubated 
overnight. Four single colonies were isolated and grown in LB overnight. 1.5 ml of each 
overnight culture were subjected to DNA extraction (QIAprep Spin Miniprep Kit, Qiagen). Then, 
the plasmid DNA was incubated with restriction enzymes NdeI and XhoI for 1.5 h. Colonies 
were sent to sequencing analysis (Microsynth) and the correct sequence was confirmed. 
 
Protein expression. LptA-His6 was overexpressed and purified according to the method of 
Santambrogio et al.[126] 4 x 500 ml cultures of transformed E. coli BL21 were grown in 
TB/phosphate buffer (terrific broth Table 21) with 5x glycerol and ampicillin (100 μg/ml) to an 
OD of 0.80 at 37°C and 200 rpm. The flasks were cooled down to 16°C for 30 min, then IPTG 
induced (0.1 mM) and grown overnight. Cells were harvested by centrifugation (20 min, 
5’000 rpm) and resuspended in buffer A (50 mM sodium phosphate, pH 8.0, 300 mM NaCl, 
10 mM imidazole, 10% glycerol) containing lysozyme (1 mg/ml), DNase (100 μg/ml), MgCl2 
(10 mM), phenylmethylsulfonyl fluoride (PMSF, 1 mM). Cells were disrupted in three cycles of 
French press (SLM Aminco) at 14’000 psi. Unbroken cells were removed by centrifugation 
(30 min at 20’000 rpm). The supernatant was loaded on a 1 ml Ni NTA column (Qiagen) and 
eluted stepwise by 5% increments of buffer B (buffer A with 500 mM imidazole) on an ÄKTA 
start FPLC system (GE Healthcare). The 40% and 45% fraction contained the desired protein 
in high purity. The fractions were combined and dialyzed against 50 mM sodium phosphate 
(150 mM NaCl, pH 8.0) in 2 l for 3 h and then overnight into 2 l fresh buffer. A sample of LptA-
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His6 was desalted using a C4 ZipTip® (Merck-Millipore) and analysed with ESI-MS (FGCZ) 
confirming the calculated molecular weight of 18’360.55 Da (found 18’360.5 Da). 
 
Table 21 Terrific broth with 5x glycerol: 900 ml A and 100 ml B were mixed after autoclaving. 
Part A (900 ml) Per liter 
Tryptone (casein digest) 12 g 
Yeast extract 24 g 
Glycerol 20 ml 
  
Part B (100 ml)  
KH2PO4 (170 mM) 23.14 g 
K2HPO4 (720 mM) 125.41 g 
 
 
4.6.11 Fluorescence Polarization 
Fluorescence polarization measurements were recorded on a safire2 plate reader (Tecan) in 
black, flat-bottom, non-binding 96 well plates (Greiner). Instrument settings were optimized for 
BDP-FL (Ex. 470 nm, Im. 508 nm) with a bandwidth of 10 nm and a G-factor of 1.21. 
 
Direct assay. In the direct assay a constant concentration of the fluorescence-labelled reporter 
(thanatin-BDP-FL) was titrated with the analyte protein LptA-His6. A 24 fold titration series of 
LptA-His6 was prepared starting from a 61.6 μM stock solution in buffer (sodium phosphate 
50 mM, NaCl 150 mM, pH 8.0). 100 μl was pipetted in triplicate in a 96 well plate in the first 
wells, 50 μl was taken and then diluted in a 1:1 fashion with buffer. The concentration of the 
thanatin-BDP-FL conjugate was kept constant by adding 50 μl of a 200 nM stock solution in 
buffer supplemented with 0.1% Tween20 to each dilution resulting in an end concentration of 
100 nM thanatin-BDP-FL and 0.05% Tween20. After an incubation time of 30 min, 
fluorescence polarization was recorded. Data were averaged from triplicate and normalized 
from the concentration point with the lowest anisotropy value. Data were fitted by a one-to-one 
binding model using GraphPad Prism by implementing equation E 5, where a = -1, b = Kd + x 
+ Atot and c = -x * Atot. m is the amplitude of maximal anisotropy increase, Kd is the dissociation 
constant and Atot is the total ligand concentration.[144] 
 
 y = m*((- b + sqrt(b2 - 4*a*c)) / 2*a) / Atot E 5 
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Competition assay. In the competition experiments, a constant concentration of thanatin-
BDP-FL and LptA-His6 was titrated with free thanatin and enantiomeric D-thanatin 
(competitors). A 24 fold titration series of the of free thanatin or enantiomeric D-thanatin was 
prepared starting from a 2054 µM stock (10 mg/ml) solution in buffer (sodium phosphate 
50 mM, NaCl 150 mM, pH 8.0). 100 μl were pipetted in triplicate in a 96 well plate in the first 
wells, 50 μl were taken and then diluted in a 1:1 fashion with buffer. The concentration of 
thanatin-BDP-FL and LptA-His6 was kept constant by adding 50 μl of a 1 µM stock solution in 
buffer supplemented with 0.1% Tween20 to each dilution, resulting in an end concentration of 
0.5 µM thanatin-BDP-FL and LptA-His6 with 0.05% Tween20. After an incubation time of 
30 min, fluorescence polarization was recorded. Data were averaged from triplicate and 
normalized from the concentration point with the lowest anisotropy value. Data were fitted by 
a competition binding model using GraphPad Prism by implementing equation E 6, where 
a=Ka+Kb+Ao+x-Po, b=Kb*(Ao-Po)+Ka*(x-Po)+Ka*Kb, c=-Ka*Kb*Po, and d=arccos((-2*a^3+9*a*b-
27*c)/(2*sqrt((a^2-3*b)^3))).[145] Kb is the competitive Kd value for a certain competitor and Ka 
the Kd value for thanatin-BDP-FL obtained in the direct assay. 
 
y = m*((Ao*(2*sqrt(a^2-3*b)*cos(d/3)-a))/((3*Ka+(2*sqrt(a^2-3*b)*cos(d/3)-a)))/Po) E 6 
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6 Appendix 
6.1 Abbreviations 
AMPs Antimicrobial peptides 
Boc tert-Butyloxycarbonyl 
BSA Bovine serum albumin 
Cbz or Z Benzyloxycarbonyl 
CFU Colony-forming unit 
COMU (1-Cyano-2-ethoxy-2-oxoethylidenaminooxy)dimethylamino-
 morpholino-carbenium hexafluorophosphate 
CPP Cell-penetrating peptide 
CSDs Chemical shift deviations 
DAPI 4’,6-diamidino-2-phenylindole 
Dab 2,4-Diaminobutyric acid 
DBU 1,8-Diazabicyclo[5.4.0]undec-7-ene 
DCM Dichloromethane 
DIAD Diisopropyl azodicarboxylate 
DIPEA N,N-Diisopropylethylamine 
DM Defined growth media 
DMF Dimethylformamide 
DMSO Dimethyl sulfoxide 
DTT Dithiothreitol 
EDT 1,2-Ethanedithiol 
EDTA Ethylenediaminetetraacetic acid 
eq. Equivalents 
Fmoc N-9H-Fluoren-2-ylmethoxycarbonyl 
HATU 1-[Bis(dimethylamino)methylene]-1H-1,2,3-triazolo[4,5-b]pyridinium 
 3-oxid hexafluorophosphate 
HBTU  N,N,N’,N’-Tetramethyl-O-(1H-benzotriazol-1-yl)uronium 
hexafluorophosphate 
HEPES 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid 
HOAt  3-Hydroxytriazolo[4,5-b]pyridine 
HOBt N-Hydroxybenzotriazole 
HPLC High performance liquid chromatography 
HR-ESI High-resolution electron spray ionization 
HRP Horse radish peroxidise 
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IPTG Isopropyl β-D-1-thiogalactopyranoside 
LB Lysogeny broth 
LPS Lipopolysaccharides 
MH-I/II Müller-Hinton broth I/II 
MIC Minimal inhibitory concentration 
NOE Nuclear Overhauser effect 
OMPs Outer membrane proteins 
PAL Photoaffinity labelling 
Pbf 2,2,4,6,7-Pentamethyldihydrobenzofuran-5-sulfonyl 
PBS Phosphate-buffered saline 
PCR Polymerase chain reaction 
PDB Protein Data Bank 
PEG Polyethylene glycol 
PEM Protein epitope mimetic 
pI Isoelectric point 
PVDF Polyvinylidene difluoride 
rmsd Root mean square deviation 
rpm Revolutions per minute 
RT Room temperature 
SAR Structure activity relationship 
SDS-PAGE Sodium dodecyl sulfate polyacrylamide gel electrophoresis 
SPPS Solid phase peptide synthesis 
TCA Trichloroacetic acid 
TCEP Tris(2-carboxyethyl)phosphine 
TFA Trifluoroacetic acid 
THF Tetrahydrofuran 
TIS Triisopropylsilane 
TMS Tetramethylsilane 
Tris Tris(hydroxymethyl)aminomethane 
TSP Trimethylsilyl propanoic acid 
Trt Trityl 
UPLC Ultra performance liquid chromatography 
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6.2 NMR Spectra of LB-01 N-Methyl Analogues 
 
Figure 72 1H-NMR spectrum of Thr1NMe. 
 
 
 
 
Table 22 1H-NMR shift assignments of analogue Thr1NMe. 
 H HA HB HG HD HE HZ HH 
Thr1 2.12 3.96 4.93 1.28 - - - - 
Trp2 9.52 4.97 3.10,3.23 - 7.26 7.55,10.17 7.10,7.53 7.26 
Leu3 8.74 4.47 1.51,1.63 1.5 0.82 - - - 
Dab4 8.44 4.04 1.86,2.04 2.46,2.80 - - - - 
Orn5 8.06 4.36 1.74,1.87 1.66 - - - - 
DLys6 8.36 4.27 1.72,1.75 1.33,1.42 - - - - 
Arg7 8.24 4.36 1.65,1.74 1.47 - - - - 
Trp8 8.44 4.71 3.16,3.26 - 7.15 7.29,10.05 7.00,7.46 7.21 
Orn9 8.21 4.46 1.59,1.75 1.58 - - - - 
Dab10 8.49 4.22 1.84,2.02 2.71 - - - - 
Ala11 8.16 4.3 1.31 - - - - - 
Lys12 8.23 4.57 1.68,1.76 1.39,1.46 1.67 - - - 
DPro13 - 4.68 1.92,2.26 2.04 3.63,3.75 - - - 
Pro14 - 4.34 1.94,2.28 2.06,2.08 3.65,3.82 - - - 
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Figure 73 1H-NMR spectrum of Trp2NMe. 
 
 
 
 
 
 
Table 23 1H-NMR shift assignments of analogue Trp2NMe. 
 H HA HB HG HD HE HZ HH 
Thr1 7.78 4.82 4.2 1.2 - - - - 
Trp2 3.4 5.41 3.00,3.30 - 7.1 7.32,10.10 7.01,7.48 7.24 
Leu3 8.51 4.48 1.59,1.73 1.57 0.9 - - - 
Dab4 8.68 4.97 2.06,2.16 2.91,2.98 - - - - 
Orn5 8.42 4.48 1.79,1.89 1.58,1.63 2.95 - - - 
DLys6 8.87 4.26 1.72,1.78 1.37,1.49 1.7 2.99 - - 
Arg7 8.82 4.23 1.59,1.73 1.30,1.38 3.05 7.06 - - 
Trp8 8.16 4.71 3.29,3.46 - 7.34 7.57,10.12 7.03,7.47 7.2 
Orn9 8.2 4.94 1.72,1.82 1.6 2.62,2.73 - - - 
Dab10 8.38 4.42 1.80,1.98 2.80,2.98 - - - - 
Ala11 8.42 4.02 0.76 - - - - - 
Lys12 8.39 4.67 1.51,1.74 1.26,1.36 1.65 2.95 - - 
DPro13 - 4.72 1.84,2.27 1.96,2.04 3.38,3.72 - - - 
Pro14 - 4.44 2.06,2.16 1.93,2.05 3.66,3.94 - - - 
  
Appendix 
122 
 
Figure 74 1H-NMR spectrum of Leu3NMe. 
 
 
 
 
 
 
Table 24 1H-NMR shift assignments of analogue Leu3NMe. 
 H HA HB HG HD HE HZ HH 
Thr1 7.86 4.24 4.04 1.1 - - - - 
Trp2 8.49 5.03 3.07,3.22 - 7.17 7.57,10.08 7.09,7.48 7.23 
Leu3 2.76 4.48 1.45,1.51 1.12 0.72 - - - 
Dab4 7.87 4.29 1.92,2.13 2.87,2.95 - - - - 
Orn5 8.18 4.42 1.79,1.88 1.7 3 - - - 
DLys6 8.56 4.35 1.70,1.76 1.37,1.40 1.7 2.99 - - 
Arg7 8.39 4.28 1.60,1.66 1.38 3.06 7.07 - - 
Trp8 8.15 4.59 3.16,3.27 - 7.19 7.61,10.02 7.10,7.47 7.22 
Orn9 8.28 4.32 1.63,1.86 1.58 2.95 - - - 
Dab10 8.04 4.3 1.99,2.15 3.04 - - - - 
Ala11 8.15 4.04 1.15 - - - - - 
Lys12 8.14 4.71 1.54,1.74 1.28,1.34 1.59 2.91 - - 
DPro13 - 4.71 1.90,2.29 1.99,2.06 3.58,3.71 - - - 
Pro14 - 4.49 2.06,2.20 1.96,2.04 3.67,3.90 - - - 
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Figure 75 1H-NMR spectrum of Dab4NMe. 
 
 
 
 
 
 
Table 25 1H-NMR shift assignments of analogue Dab4Me. 
 H HA HB HG HD HE HZ HH 
Thr1 7.7 4.42 4.17 1.21 - - - - 
Trp2 8.64 4.88 2.97,3.03 - 7.27 7.38,10.15 7.08,7.54 7.26 
Leu3 9.01 4.92 1.59,1.71 1.56 0.9 - - - 
Dab4 3.09 4.55 1.96 2.07,2.48 - - - - 
Orn5 7.97 4.55 1.71,1.88 1.66 3 - - - 
DLys6 8.59 4.25 1.77 1.37,1.48 1.71 2.98 - - 
Arg7 8.62 4.21 1.57,1.61 1.29,1.35 3.04 7.04 - - 
Trp8 8.36 4.81 3.23,3.45 - 7.32 7.41,10.08 7.03,7.50 7.22 
Orn9 8.15 4.87 1.72,1.84 1.65 2.64,2.77 - - - 
Dab10 8.64 4.25 1.75,2.01 2.70,2.86 - - - - 
Ala11 8.52 4.21 1.07 - - - - - 
Lys12 7.93 4.6 1.59,1.73 1.28,1.40 1.65 2.94 - - 
DPro13 - 4.66 1.90,2.28 1.99,2.07 3.53,3.71 - - - 
Pro14 - 4.49 1.89,2.10 1.89,2.05 3.64,3.90 - - - 
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Figure 76 1H-NMR spectrum of Orn5NMe. 
 
 
 
 
 
Table 26 1H-NMR shift assignments of analogue Orn5NMe. 
 H HA HB HG HD HE HZ HH 
Thr1 7.84 4.38 4.18 1.21 - - - - 
Trp2 8.51 4.82 3.07,3.16 - 7.28 7.49,10.19 7.09,7.52 7.27 
Leu3 8.64 4.47 1.49,1.61 1.47 0.86 - - - 
Dab4 8.67 4.7 1.75,1.97 2.39,2.65 - - - - 
Orn5 2.73 5.06 1.69,1.93 1.57 2.99 - - - 
DLys6 8.02 4.4 1.69,1.73 1.33,1.44 1.68 2.98 - - 
Arg7 8.61 4.19 1.58,1.65 1.37 3.07 7.07 - - 
Trp8 8.13 4.85 3.20,3.35 - 7.33 7.43,10.09 7.00,7.45 7.17 
Orn9 8.41 4.69 1.75,1.84 1.69 2.81,2.87 - - - 
Dab10 8.56 4.25 1.81,2.04 2.78,2.89 - - - - 
Ala11 8.49 4.23 1.1 - - - - - 
Lys12 7.9 4.61 1.59,1.73 1.29,1.40 1.64 2.95 - - 
DPro13 - 4.67 1.88,2.28 1.98,2.06 3.58,3.69 - - - 
Pro14 - 4.46 1.94,2.07 1.87,2.03 3.65,3.87 - - - 
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Figure 77 1H-NMR spectrum of DLys6NMe. 
 
 
 
 
 
Table 27 1H-NMR shift assignments of analogue DLys6NMe. 
 H HA HB HG HD HE HZ HH 
Thr1 7.68 4.44 4.16 1.2 - - - - 
Trp2 8.59 4.94 3.04 - 7.23 7.28,10.13 6.98,7.48 7.26 
Leu3 8.7 4.6 1.68 1.55 0.90,0.93 - - - 
Dab4 8.71 4.97 2.07,2.13 2.88,2.94 7.71 - - - 
Orn5 8.59 4.93 1.77,1.90 1.68 2.88,3.02 7.56 - - 
DLys6 3.07 4.73 1.88 1.34,1.44 1.73 3.00 - - 
Arg7 8.68 4.23 1.60,1.75 1.42 3.08 7.09 - - 
Trp8 7.92 4.7 3.25,3.41 - 7.34 7.50,10.14 7.01,7.48 7.2 
Orn9 8.33 4.98 1.70,1.83 1.59 2.57,2.71 7.36 - - 
Dab10 8.41 4.43 1.77,1.98 2.74,2.94 7.74 - - - 
Ala11 8.55 3.96 0.85 - - - - - 
Lys12 8.21 4.6 1.47,1.69 1.24,1.35 1.65 2.95 7.54 - 
DPro13 - 4.69 1.88,2.27 1.97,2.07 3.38,3.69 - - - 
Pro14 - 4.46 2.05,2.13 1.90,2.06 3.66,3.93 - - - 
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Figure 78 1H-NMR spectrum of Arg7NMe. 
 
 
 
 
 
Table 28 1H-NMR shift assignments of analogue Arg7NMe. 
 H HA HB HG HD HE HZ HH 
Thr1 7.75 4.37 4.15 1.16 - - - - 
Trp2 8.4 4.74 3.08,3.08 - 7.22 7.34,10.15 7.03,7.50 7.23 
Leu3 8.52 4.5 1.61 1.48 0.86 - - - 
Dab4 8.51 4.82 2.02,2.12 2.87,2.94 7.65 - - - 
Orn5 8.21 4.47 1.82,1.87 1.62,1.70 2.93,3.01 7.63 - - 
DLys6 8.85 4.65 1.73 1.33,1.47 1.66 2.96 7.56 - 
Arg7 2.63 5.06 1.57,1.90 1.38 3.14 7.17 - - 
Trp8 7.94 4.94 3.29,3.41 - 7.25 7.57,10.07 7.05,7.48 7.22 
Orn9 8.49 4.92 1.73,1.82 1.60,1.61 2.61,2.73 7.37 - - 
Dab10 8.53 4.5 1.92,2.07 2.91,3.00 7.75 - - - 
Ala11 8.53 4 0.95 - - - - - 
Lys12 8.2 4.63 1.50,1.70 1.25,1.36 1.65 2.95 7.53 - 
DPro13 - 4.7 1.88,2.26 1.97,2.05 3.42,3.68 - - - 
Pro14 - 4.41 1.98,2.14 1.91,2.04 3.66,3.91 - - - 
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Figure 79 1H-NMR spectrum of Trp8NMe. 
 
 
 
 
 
Note: For analogue Trp8NMe complete assignments could not be determined, due to signal 
overlap and rotational isomers (cf. Structural Studies by NMR 3.1.7). 
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Figure 80 1H-NMR spectrum of Orn9NMe. 
 
 
 
 
 
Table 29 1H-NMR shift assignments of analogue Orn9NMe. 
 H HA HB HG HD HE HZ HH 
Thr1 7.92 4.24 4.18 1.2 - - - - 
Trp2 8.06 4.69 3.11,3.21 - 7.22 7.48,10.15 7.22,7.47 7.23 
Leu3 8.22 4.27 1.56,1.56 1.44 0.82 - - - 
Dab4 8.12 4.47 2.03,2.13 2.95,2.95 7.65 - - - 
Orn5 8.19 4.45 1.75,1.85 1.61,1.68 2.85 7.54 - - 
DLys6 8.59 4.29 1.61,1.61 1.33,1.39 1.66 2.94 7.52 - 
Arg7 8.53 4.19 1.57,1.65 1.33,1.33 3.05 7.06 - - 
Trp8 8.18 5.04 3.15,3.27 - 7.24 7.62,10.15 7.14,7.51 7.26 
Orn9 3.04 4.94 1.73,1.82 1.33,1.41 2.74 7.43 - - 
Dab10 8.03 4.38 1.99,2.15 2.99,2.99 7.71 - - - 
Ala11 8.2 4.19 1.19 - - - - - 
Lys12 8.21 4.67 1.57,1.75 1.31,1.40 1.66 2.96,2.96 - - 
DPro13 - 4.7 1.92,2.29 1.99,2.07 3.51,3.67 - - - 
Pro14 - 4.39 1.88,2.13 1.91,2.02 3.68,3.89 - - - 
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Figure 81 1H-NMR spectrum of Dab10NMe. 
 
 
 
 
 
Table 30 1H-NMR shift assignments of analogue Dab10NMe. 
 H HA HB HG HD HE HZ HH 
Thr1 8.02 4.16 4.14 1.15 - - - - 
Trp2 8 4.59 3.13,3.24 - 7.25 7.52,10.22 7.14,7.52 7.26 
Leu3 7.94 4.19 1.51 1.36 0.81,0.82 - - - 
Dab4 8.08 4.11 1.89,2.01 2.50,2.82 7.57 - - - 
Orn5 8.06 4.43 1.74,1.86 1.64,1.71 2.93 7.58 - - 
DLys6 8.47 4.27 1.66 1.36,1.42 1.66 2.97 7.53,7.53 - 
Arg7 8.39 4.28 1.64,1.74 1.43 3.09 7.07 - - 
Trp8 8.2 4.71 3.17,3.29 - 7.22 7.51,10.06 7.09,7.50 7.23 
Orn9 8.32 4.72 1.59,1.77 1.56 2.94 7.57 - - 
Dab10 2.97 4.38 1.87,2.18 2.76 7.59 - - - 
Ala11 7.9 4.25 1.25 - - - - - 
Lys12 7.93 4.66 1.65,1.77 1.35,1.41 1.66 2.96 - - 
DPro13 - 4.7 1.93,2.29 2.02,2.07 3.63 - - - 
Pro14 - 4.36 1.84,2.09 1.94,2.02 3.65,3.85 - - - 
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Figure 82 1H-NMR spectrum of Ala11NMe. 
 
 
 
 
 
Table 31 1H-NMR shift assignments of analogue Ala11NMe. 
 H HA HB HG HD HE HZ HH 
Thr1 7.66 4.39 4.13 1.19 - - - - 
Trp2 8.59 4.63 3.06,3.07 - 7.24 7.25,10.14 6.91,7.50 7.24 
Leu3 8.67 4.58 1.54,1.67 1.47 0.88 - - - 
Dab4 8.61 5.03 2.11,2.19 2.99,3.00 - - - - 
Orn5 8.48 4.48 1.80,1.91 1.66,1.73 2.99 - - - 
DLys6 8.86 4.26 1.70,1.76 1.37,1.50 1.70 2.97 - - 
Arg7 8.75 4.22 1.53,1.67 1.23,1.34 3.03 7.02 - - 
Trp8 8.11 4.72 3.30,3.46 - 7.34 7.63,10.14 7.07,7.49 7.21 
Orn9 8.34 5.09 1.75,1.86 1.64,1.64 2.58,2.71 - - - 
Dab10 8.54 5.05 1.80,2.12 2.73,2.98 - - - - 
Ala11 2.97 4.71 0.57 - - - - - 
Lys12 8.26 4.63 1.48,1.71 1.23,1.34 1.66 2.94,2.94 - - 
DPro13 - 4.68 1.85,2.26 1.97,2.06 3.40,3.70 - - - 
Pro14 - 4.42 2.04,2.16 1.93,2.03 3.66,3.92 - - - 
  
Appendix 
131 
 
Figure 83 1H-NMR spectrum of Lys12NMe. 
 
 
 
 
 
Table 32 1H-NMR shift assignments of analogue Lys12NMe. 
 H HA HB HG HD HE HZ HH 
Thr1 7.86 4.2 4.15 1.17 - - - - 
Trp2 8.07 4.64 3.21,3.28 - 7.25 7.59,10.12 7.13,7.48 7.23 
Leu3 7.88 4.19 1.38 1.26 0.69 - - - 
Dab4 8.11 4.17 1.96,2.09 2.85,2.91 7.63 - - - 
Orn5 8.07 4.37 1.73,1.84 1.66 2.95 7.59 - - 
DLys6 8.39 4.3 1.76 1.34,1.39 1.66 2.96 7.53,7.53 - 
Arg7 8.32 4.26 1.61,1.67 1.39 3.07 7.07 - - 
Trp8 8.14 4.66 3.18,3.29 - 7.2 7.54,10.03 7.07,7.43 7.2 
Orn9 8.4 4.28 1.73,1.90 1.67 2.98 7.59 - - 
Dab10 7.93 4.38 2.01,2.13 3.04 7.74 - - - 
Ala11 8.41 4.2 1.24 - - - - - 
Lys12 2.66 5.13 1.40,1.71 1.18 1.53 2.85 7.42 - 
DPro13 - - 1.81,2.31 1.92,2.00 3.22,3.59 - - - 
Pro14 - 4.45 1.98,2.07 1.95,2.03 3.64,3.87 - - - 
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6.3 Protein Identification by Mass Spectrometry 
 
 
Figure 84 Full LptA sequence and peptide fragments (blue), identified by protein mass spectrometry. The signal 
sequence is shown in grey. 
 
 
 
Figure 85 Full BamB sequence and peptide fragments (blue), identified by protein mass spectrometry. The signal 
sequence is shown in grey. 
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Figure 86 Full LptD sequence and peptide fragments (blue), identified by protein mass spectrometry. The signal sequence is shown in grey. 
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